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1. Introduction 
1.1 FKBPs and their versatile biological functions 
FK506-binding proteins (FKBPs) belong to the highly conserved group of immunophilins and 
display peptidyl-prolyl-cis-trans isomerase (PPIase) activity [1, 2]. After discovery of cyclo-
philins in the 1980s, which are named for their high affinity to Cyclosporine A [3, 4] another 
unrelated PPIase was found and named FKBP [1, 5]. Most peptide bonds in folded proteins 
are found in trans conformation, whereas 6% of all Xaa-Pro peptide bonds show a cis con-
formation [6]. FKBPs are involved in the energetically hindered isomerization of these Xaa-
Pro peptide bonds in order to fold proteins. Binding of a peptide substrate in the hydrophobic 
pocket of FKBP and stabilization of the transition state by hydrogen bonds accelerates the 
isomerization process [6]. Independent of their PPIase function some FKBPs act as chaper-
ones where they recognize non-native proteins, prevent unwanted inter- and intramolecular 
interactions and influence the partitioning between unproductive and productive folding steps 
[7]. In addition to their role in protein maturation, the diverse members of the FKBP protein 
family bind tightly to the natural compounds FK506 and rapamycin. In complex with FKBPs 
FK506 induces an inhibitory ternary complex with the Ca2+ - and calmodulin-dependent pro-
tein phosphatase calcineurin [8, 9]. Complex formation leads to inhibition of dephosphoryla-
tion of the transcription factor NF-AT, which normally induces IL-2 expression and thereby 
promotes T-cell activation [10]. Contrary, the complex formed by FKBP12 and rapamycin 
inhibits the mechanistic target of rapamycin (mTOR), a protein kinase that regulates growth 
and cell cycle progression [11-13]. Therefore both natural compounds are used as immuno-
suppressants.  
Recently it was shown that other FKBPs can substitute the effects of FKBP12 [14]. Since 
immunophilin ligands have been shown to have neuroprotective activities [15, 16] FKBPs 
were proposed as likely targets for mediating this neurotrophic activity, although there is dis-
agreement as to their specific mechanism [17-20]. 
FKBPs are named according to their molecular mass, which range from 12 to 135 kDa [21]. 
While FKBP12, as the archetype of the family only consists of one FK506 binding domain 
(FK1) [22], which harbors the described PPIase activity, others have additional domains, 
such as the TPR domain, which enables these FKBPs to interact with the co-chaperone 
Hsp90 [23, 24]. The overall structure of FK domains consists of an antiparallel five-stranded 
β-sheet wrapped around a central α-helix [22, 25]. FKBP13 contains an additional C terminal 
ER recognition sequence [26, 27]. The TPR domain of the higher molecular weight FKBPs is 
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a helical structure consisting of three units of 34 aa. A single TPR unit consists of two con-
secutive α-helices of 12-15 residues each crossing to an angle of approximately 20°. An ad-
ditional seventh helix that extends beyond the final TPR motif contains a putative calmodulin-
binding site in FKBP38, FKBP51 and FKBP52 [24, 28, 29]. 
 
 
 
Figure 1.1: Domain structure of important human FKBPs 
Gene names and the size of the unprocessed proteins are shown in brackets. In the second row, the accession numbers of 
UniProtKB/Swiss-Prot database and NCBI Reference Sequence are given. The third row shows alternative protein names. 
FK1=FK506 binding domain FK1, FK2=FK506 binding domain 2, TPR=Tetratricopeptide domain, HLH=Helix-Loop-Helix do-
main, modified after Schiene-Fischer [21] 
 
In the following sections the FKBPs, used throughout this thesis will be further characterized. 
1.1.1 FKBP12 and FKBP12.6 – small, but important 
FKBP12 is ubiquitous expressed in almost all human tissues [30]. Human FKBP12 was 
shown to bind rapamycin with a Kd of 0.2 nM [31] and FK506 with a Kd of 0.4 nM by forming 
a ternary complex with TOR or calcineurin [8, 32]. It was further identified as accessory pro-
tein of the skeletal muscle ryanodine receptor 1 (RyR1) calcium release channel and the ino-
sitol-1,4,5-triphosphate receptor (IP3R) suggesting a biological significance as regulator of 
Ca2+ signaling [33-35]. Also the receptor serine/threonine protein kinase TGF-β receptor 1 
[36] and the epidermal growth factor receptor (EGFR) form an FKBP12 target since FKBP12 
was shown to inhibit EGFR auto-phosphorylation [37].  
The deposition of the microtubule-associated tau proteins into neurofibrillary tangles and 
impaired processing of the Amyloid Precursor Protein (APP) to β-amyloid (Aβ) are hallmarks 
of Alzheimer’s disease. FKBP12 was found to associate with the tau [38] and the intracellular 
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domain of APP [39]. In a mouse model which brain specific lacks FKBP12 mTOR signaling 
was enhanced and this was connected to enhanced long-term potentiation (LTP) and long 
term memory formation (LTM) [40]. In contrast Aβ1-42 induced inhibition of mTOR signaling 
and LTP was prevented in FKBP12 knockout mice supporting an involvement of FKBP12 in 
the pathology of alzheimer’s disease [41]. Recently it was shown in a cellular assay that of all 
FKBPs abundant in the brain FKBP12 was the most prominent in accelerating α-synuclein 
fibril formation as a common feature in Parkinson’s disease [42].  
 
FKBP12.6 shares 85% sequence identity with FKBP12 and it is similar effective to enable 
FK506-dependent inhibition of calcineurin in vitro as FKBP12 [29, 43]. However, in contrast 
to FKBP12 FKBP12.6 was shown to regulate ryanodine receptor 2 (RyR2) function in the 
heart whereas FKBP12 is involved in regulating cardiac voltage-gated sodium channels [44]. 
1.1.2 FKBP51, FKBP52 – opposite effects 
FKBP51 was initially isolated from murine T cells [45] and murine adipocytes [46], where it is 
involved in adipocyte differentiation. In general it is expressed in many human tissues some-
times even in molar excess compared to FKBP12 [30]. FKBP51 is a multidomain protein with 
two FK506 binding domains (FKBD) of which only the FK1 domain shows PPIase activity 
and binding affinity to immunosuppressants [28].  
One of the best-characterized properties of FKBP51 is its function as a co-chaperone of 
Hsp90/Hsp70 mediated by the TPR domain of FKBP51 [23, 47]. FKBP51 is a negative regu-
lator of hormone binding affinity of the glucocorticoid receptor. The first indications pointing in 
this direction came from studies in new world primates, including squirrel monkeys which 
show markedly elevated FKBP51 levels of a highly potent isoform leading to reduced hor-
mone binding affinity [48-50]. As a compensation these species are marked by high levels of 
circulating cortisol [51, 52]. Although less potent than squirrel monkey FKBP51, human 
FKBP51 can also modify steroid receptor activity [48, 53]. In intact cells, FKBP51 was shown 
to slow down the nuclear translocation of the GR, possibly by blocking FKBP52-mediated 
recruitment to the dynactin motor complex [54]. Mechanistically it seems that the Hsp90-
binding but not PPIase activity of FKBP51 is necessary for its inhibitory effect on glucocorti-
coid receptor binding affinity [55]. The expression of FKBP51 is strongly increased by corti-
costeroids [56] indicating that FKBP51 attenuates cortisol responses in hormone-conditioned 
tissues as part of a negative feedback mechanism [53, 57]. This seems to be particularly 
important in the regulation of the HPA (hypothalamic-pituitary-adrenal) axis, one of the main 
regulators of stress response. Deregulation of the HPA axis caused by reduced glucocorti-
coid receptor sensitivity was found to be common in depressed patients leading to the corti-
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costeroid receptor hypothesis of depression [58]. Indeed, polymorphisms within the FKBP51 
encoding gene FKBP5 were found to be associated with increased recurrence of depressive 
episodes and improved patient’s response to antidepressive treatment [59-61]. Several re-
search groups have shown a protective effect of FKBP51 knockout or knockdown on stress 
endocrinology and stress-coping behavior [62-64]. Taken together the results of these stud-
ies implicate an important role of FKBP51 in HPA axis deregulation and suggest that drug 
targeting of this protein might be beneficial for treatment of patients suffering from depression 
and anxiety disorders. 
Beside their regulating role in steroid hormone receptor signaling a novel role for Hsp90 and 
associated co-chaperones in folding and aggregation disorders has emerged. FKBP51 was 
found to stabilize tau. In vitro FKBP51 stabilizes microtubules with tau in a reaction depend-
ing on the PPIase activity of FKBP51 which was shown with a PPIase deficient mutant 
(F130A) [65].  
 
The emerging role of FKBP51 in cancer is increasingly being recognized, both as a bi-
omarker for tumor progression and as a possible target for cancer therapy. Initially FKBP51 
was found to be overexpressed in idiopathic myelofibrosis (IMF) megakaryocytes where it 
prevented apoptosis of malignant cells possibly by a NF-κB driven mechanism [66]. By map-
ping the protein interaction network of the TNF-α/NF-κB pathway it was later demonstrated 
that FKBP51 co-purifies with IKKα, IKKε, TGF-β activated kinase (TAK1) and mitogen acti-
vated protein kinase kinase (MEKK1) pointing to an essential role for FKBP51 in the overall 
signaling process of NF-κB activation [67]. Several studies shared evidence for pro-apoptotic 
or apoptotic effects of the prototypic FKBP ligand rapamycin through regulation of signal 
transduction of the of NF-κB pathway [68-70]. FKBP51 down-modulation was shown to sen-
sitize melanoma cells to apoptosis caused by ionizing radiation, again revealing FKBP51 to 
counteract apoptotic processes [71]. It should be especially noted that FKBP51 is overex-
pressed in several prostate cancer cell lines and tissues where it promotes androgen recep-
tor activity [72-74]. In contrast to the elevated FKBP51 levels in the above studies, Pei et al. 
[75] found FKBP51 protein levels to be decreased in pancreatic cancer samples. Further-
more, FKBP51 was shown to act as a scaffold protein for the phosphatase PHLPP, thereby 
negatively regulating the kinase Akt [75]. In a pancreatic cancer xenograft model the positive 
correlation between the expression of FKBP51 and the response to chemotherapeutics was 
confirmed in vivo [76]. However, diverging results have been reported from several other 
tumor tissues [77]. Nevertheless, the enhancement of the PHLPP-mediated Akt dephosphor-
ylation, e.g. via FKBP51, could be an option to sensitize susceptible cancer cells to chemo-
therapy.  
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FKBP52 shares 55 % identity (alignment by PRALINE (see section 3.13) with FKBP51 and 
was originally characterized in 1992 as a protein with three clearly distinguishable domains 
that are arranged like in FKBP51 [78-80]. Again, one active PPIase pocket located within the 
FK1 domain and a TPR domain is present. The TPR domain enables FKBP52 to interact 
with Hsp90. In contrast to FKBP51 FKBP52 is a positive regulator of the glucocorticoid re-
ceptor [81], progesterone receptor [82] and androgen receptor [83], but not the estrogen re-
ceptor or mineralocorticoid receptor [81]. The specific ability of FKBP52 to promote steroid 
hormone receptor activity is dependent on a region called proline rich loop overhanging the 
PPIase pocket but independent of PPIase activity [84]. Biochemically FKBP52 was shown to 
replace FKBP51 in the Hsp90/GR complex after hormone-binding, indicating a preference for 
FKBP52 for activated steroid hormone receptors [85-87]. Furthermore, FKBP52 but not 
FKBP51 binds via its PPIase domain to the motor protein dynein that is connected to micro-
tubule and accelerates the translocation of activate steroid hormone receptors from the cyto-
plasm to the nucleus [88, 89]. The switch of bound FKBP51 with FKBP52 seems to be a cru-
cial step during receptor activation [85].  
The current model of steroid receptor translocation is depicted in Figure 1.2 (modified after 
[90] by Y. Wang, MPI of Psychiatry). 
 
 
Figure 1.2: Current model of steroid hormone receptor translocation 
FKBP51 enters the Hsp90-dimer-stereoid-hormone receptor complex (SHR) by binding to the C-terminus of Hsp90 via its TPR 
domain. The complex is stabilized by the p23 cochaperone, bringing the FKBP FK1 domain into contact with the receptor ligand 
binding domain to directly influence hormone binding affinity. Upon steroid binding, the SHR heterocomplex exchanges FKBP51 
for FKBP52, which is able to interact with dynein. The whole SHR–chaperone complex translocates through the nuclear pore 
complex followed by receptor transformation, binding of the steroid-activated receptor to hormone response elements and gene 
transcription regulation.  
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The physiological importance of FKBP52 on steroid receptor function is highlighted in FKBP4 
knockout mice. Male FKBP4 knockout mice display several developmental defects in repro-
ductive tissue consistent with androgen resistance [83, 91]. Female FKBP4  knockout mice 
are infertile due to failure of embryo implantation in the uterus caused by progesterone re-
sistance [82, 92, 93]. Furthermore these mice suffer from increased cell proliferation, inflam-
mation and angiogenesis leading to endometriotic lesions, consistent with the finding that 
woman suffering from endometriosis show reduced FKBP52 expression [94]. Finally, a state 
of glucocorticoid resistance was observed in mice heterozygous for FKBP52 ablation after 
four weeks of high fat diet combined with a higher susceptibility to hyperglycemia and hyper-
insulinemia [95]. 
Using RNAi to investigate possible causes of tau-induced neurodegeneration Kraemer et al. 
[96] found FKBP4 RNAi to worsen the phenotype in a Caenorhabditis elegans model of hu-
man tauopathies [96]. Indeed FKBP52 seems to have opposing effects to FKBP51: Microtu-
bule assembly formation of purified rat brain tubulin caused by addition of human recombi-
nant tau was prevented in the presence of purified recombinant FKBP52, indicating an “anti-
tau” activity of FKBP52 in vitro [97]. Moreover, FKBP52 expression levels were found to be 
abnormally low in post mortem analyzed frontal cortex of Alzheimer’s disease patients as 
compared to controls [98] and FKBP52 prevented tau-accumulation in cellular models [97]. 
Currently it is not known wheather the FKBP52 induced neuroprotection against tauopathies 
is linked to degradation processes of modified tau proteins or changes in tau accumulation 
and to which extend Hsp90 is involved [99]. Nevertheless, activating FKBP52 or inhibiting 
FKBP51 may be novel therapeutic strategies for tauopathies in the future. 
 
Another aspect should be mentioned: Gold et al. proposed FKBP inhibitors to promote neu-
rite outgrowth in an FKBP52/Hsp90 dependent mode of action [100]. Indeed, the balance 
between FKBP51 and FKBP52 seems to play a key role during the early mechanism of neu-
ronal differentiation [101]. 
1.1.3 FKBP25 – the mysterious 
FKBP25 has an FK1 binding domain in common with other FKBPs but it differs in its ligand 
binding characteristics: The FK1 domain shows PPIase activity which is preferentially 
blocked by rapamycin with a Kd of 0.9 nM compared to the inhibitory effect of FK506 with a 
Kd of 160 nM [102, 103]. Investigations by Liang et al. suggested structurally differences in 
the 50S loop region, flexibility of the 40S loop insertion and a substitution of one residue in 
the hydrophobic ligand-binding pocket as possible cause for rapamycin selectivity [104]. 
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Furthermore FKBP25 possesses a strongly hydrophilic N-terminal domain with no recog-
nizable homology to any known protein [102, 105]. This domain embodies a helix-loop-helix 
(HLH) motif. An exclusive feature in FKBP25 is its nuclear translocation sequence consisting 
of four lysines [103]. Indeed FKBP25 is abundant in the nucleus [106], where it was found to 
be phosphorylated by serine/threonine kinase casein kinase II. The tight interaction with ca-
sein kinase II implied that FKBP25 might play a role in ribosome biogenesis and cell replica-
tion [107]. Furthermore FKBP25 was demonstrated to bind to the N-terminus of histone 
deacetylases (HDAC1 and HDAC2) and to the transcription factor YY1 modifying its binding 
capability [108]. In extracts from porcine brains analyzed with native 2D electrophoresis fol-
lowed by MALDI-TOF FKBP25 was associated with the high-mobility group (HMG) protein II, 
which is also crucial for transcription of some genes and the GTP binding protein Rab 5. The 
latter interaction depends on FKBP25 phosphorylation [109]. It was demonstrated that 
FKBP25 is negatively regulated by the tumor suppressor protein p53 [110]. In turn FKBP25 
seems to induce p53 activation and proteasome dependent down-regulation of p53’s coun-
terpart MDM2 [111]. Weather the PPIase domain is necessary for the above mentioned pro-
tein-protein interactions has not been investigated so far. 
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1.2 FKBP ligands 
1.2.1 Immunosuppressive immunophilin ligands 
The natural occurring prototypic ligands of immunophilins are the clinically used immunosup-
pressants cyclosporine A (CsA), FK506 and rapamycin (Figure 1.3). 
Interestingly and most remarkably all three compounds impart a gain-of-function on their im-
munophilin partners but they affect different signaling pathways in T-lymphocytes. 
 
 
 
Figure 1.3: Immunosuppressive immunophilins [112] 
Highlighted are the immunophilin-binding domains (Cyp for CsA, FKBP for FK506 and rapamycin); Aminoacids 3-7 of CsA, 
atoms 19-22 and 27-33 of FK506: calcineurin binding domain; Atoms 15-27 and 34-46 of rapamycin: mTOR binding domain 
 
 
Cyclosporine A as the first immunophilin ligand to be discovered binds to the class of cyclo-
philins (Cyp). A ternary complex is formed with the phosphatase calcineurin (CN) [8]. In this 
heterocomplex calcineurin is unable to dephosphorylate its substrate nuclear factor of acti-
vated T-cells (NF-AT) which is necessary for T-cell activation and IL-2 expression [113]. In 
1983 Cyclosporine A was FDA approved as trade brand Sandimmune® being first drug used 
to prevent allograft rejections in humans. It was further shown to to be effective in a variety of 
human autoimmune diseases, including psoriasis, nephrotic syndrome, type I diabetes, and 
sight-threatening uveitis [114]. 
FK506 (also: Tacrolimus) was first isolated from Streptomyces tsucubaensis and its target, 
the FKBP protein family was termed thereafter. Just as Cyp-CsA the FKBP-FK506 complex 
binds to and allosterically inhibits calcineurin leading to the same immunosuppressive effect 
as described before [113]. The immunosuppressive action of FK506 is mainly thought to be 
mediated by FKBP12 and partially by FKBP12.6 and FKBP51 [115, 116]. FK506 was FDA 
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approved as medication after organ transplantation to prevent allograft rejections as Pro-
graf® in 1994. Additionally FK506 is used for treatment of various inflammatory diseases, 
such as contact eczema, hand dermatitis and psoriasis [117]. 
Rapamycin (also: Sirolimus) was isolated from Streptomyces hygroscopicus in the 1970s 
and was named after the location where this strain was isolated, the Easter Island (Rapa 
Nui) [118-120]. First, its fungicidal activity was discovered [121] later rapamycin was shown 
to be effective against transplanted tumors [122] and to have immunosuppressive action 
[123]. In organ transplantation experiments with animals it was demonstrated that rapamycin 
reduces allograft rejections [124]. In 1999 rapamycin was approved as Rapamune® for this 
indication. Furthermore the compounds anti-inflammatory and anti-proliferative effects are 
used in eluting stents to prevent restenosis in patients suffering from vascular obliterations 
[125]. 
Mechanistically rapamycin was thought to bind exclusively to FKBP12. The rapamy-
cin/FKBP12 heterocomplex inhibits the serine/threonine protein kinase mTOR (mechanistic 
target of rapamycin) and allosteric inhibition of the latter results in a blockade of various 
downstream signaling pathways involved in the control of translation of proteins crucial for 
cell cycle progression [126, 127]. Thus the alteration of mTOR signaling by rapamycin has 
commanded great interest in the oncologic field [128, 129].  
1.2.2 Unspecific non-immunosuppressive immunophilin ligands 
Chronic rapamycin treatment was shown to enhance life span from yeast to mice [130-134]. 
In addition it might also improve the quality of life in the elderly as it was shown to improve 
the cognitive and behavioral deficits in several animal models of neurodegenerative diseases 
such as Alzheimer’s, Parkinson’s and Huntington’s disease [135-139]. Another interesting 
observation was that FK506, rapamycin and CsA have additionally neuroprotective and neu-
rotrophic effects [16]. However, the chronic use of these agents for diverse indications is lim-
ited by the suppression of immune response, being an inacceptable side effect. Therefore 
especially the finding that the neuroprotective and neurotrophic effects were partially inde-
pendent of calcineurin or mTOR inhibition, lead to tremendous efforts to identify immunophil-
in ligands without immunosuppressive properties [112]. Compounds of this type used for ex-
periments throughout this thesis are introduced below: 
Antascomicin B was first isolated from a Micromonospora strain, which originated from a 
soil sample from china. Its ability to bind FKBP12 is in the same range as that of FK506 or 
rapamycin [140]. In 2005 Brittain et al. presented the total synthesis of Antascomicin B [141].  
FK1706 is a semi-synthetic derivative of FK506, where the effector domain required for cal-
cineurin binding was abolished. The compound shows significant neurotrophic effects, which 
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were shown to be putatively assigned to be mediated by FKBP52 and the Ras/Raf/mitogen-
activated protein kinase signaling pathway, suggesting the potential of this compound to be 
used to treat a variety of neurological disorders [142]. A small phase I clinical trial didn’t give 
any hints for drug induced discontinuations within the two-week time period. Thus the com-
pound seems to be tolerated for an extended time period in humans [143]. 
The compounds of the YW serie were synthesized by Y. Wang at the MPI of Psychiatry 
[144]. The small molecule compounds were designed to improve the pharmacokinetic pro-
file. 
 
 
 
Figure 1.4: Examples of unselective non-immunosuppressive immunophilins [112] 
Antascomicin B and FK1706 derived from natural products. Highlighted are modifications compared to rapamycin and FK506  
1.2.3 Selective non-immunosuppressive immunophilin ligands 
Due to strong off-target effects and lack of selectivity there is a high demand not only for non-
immunosuppressive but also for selective inhibitors for FKBPs, which can be used to investi-
gate the roles of individual FKBPs in mammalian systems and finally for development of 
medications targeting an FKBP subgroup in a certain tissue. 
1.2.3.1 FKBP12-selective immunophilin ligands 
Biricodar is a synthetic FKBP ligand still based on the dicarbonyl pipecolyl-scaffold derived 
from rapamycin and FK506. Biricodar binds to FKBP12 almost as tightly as to FK506 and 
FK1706 but discriminates more strongly against the larger FKBP51 and FKBP52 (> 500 fold 
selectivity for FKBP12) [145]. The compound also binds to p-glycoprotein (MDR1) [146] and 
has been investigated in several clinical trials as a chemo-sensitizing adjuvant, where it 
seemed to be well tolerated even with steady-state serum levels up to 10 µM [147]. 
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Compound 44 (cmpd44)/GR591 was synthesized by R. Gopalakrishnan at the MPI of Psy-
chiatry. The compound structurally differs from Biricodar by having a pipecolate sulfonamide 
moiety. Compound 44 is highly selective for FKBP12 as it binds to FKBP12 with an IC50 of 3 
nM but to FKBP51 and FKBP52 with an IC50 of 2 µM and 3.1 µM, respectively [148]. 
 
 
 
Figure 1.5: Examples of non-immunosuppressive immunophilins selective for FKBP12 [112, 148] 
Biricodar and compound 44 are synthetic FKBP ligands. The conserved pipecolyl moiety is shaded. 
 
1.2.3.2 FKBP51-selective immunophilin ligands 
Based on the corticosteroid receptor hypothesis of depression [58] as introduced in section 
1.1.2 our research group aimed to identify selective inhibitors for FKBP51. These compounds 
could be able to displace FKBP51 from the Hsp90/glucocorticoid-receptor-complex and 
thereby might restore physiologic glucocorticoid sensitivity leading to a reduction of circulat-
ing cortisol.  
The compound SG537, synthesized by S. Gaali at the MPI of Psychiatry has a >10 000 fold 
selectivity for FKBP51 compared to FKBP52, the antagonist of FKBP51 in steroid receptor 
signaling [149]. 
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1.3 The serine/threonine kinase Akt 
Akt (also called PKB) was first described as the cellular homolog of the product of the v-akt 
oncogene [150]. In 1991 evidence was growing that this act gene codes for a ser-
ine/threonine kinase [151-153] and classifies as a member of the AGC kinase superfamily, 
which share a highly conserved catalytic domain. Besides the three highly homologous Akt 
isoforms Akt1/PKBα, Akt2/PKBβ and Akt3/PKB this class includes among others the p70 
ribosomal S6 kinase (S6K) , the serum- and glucocorticoid-inducible kinase (SGK), the Pro-
tein kinase C related kinase (PRK) and finally the protein kinases A, G and C, where the 
name of the class derived from [154].  
Although the three isoforms show broad tissue distribution [155], Akt1 is the most ubiquitous-
ly expressed. Akt2 is expressed at a lower level than Akt1 except in insulin-responsive tis-
sues where it predominates [156, 157] and Akt3 expression is the lowest, except in testes 
and brain [158, 159].  
1.3.1 Structure of Akt and its regulation 
Each Akt isoform is characterized by an N-terminal pleckstrin homology (PH) domain, an 
kinase lobe and a carboxy-terminal lobe, which also includes the hydrophobic motif (HM). 
This motif is characteristic for most AGC kinase family members [160]. 
Akt is a major kinase downstream of phosphoinositol-3-kinase (PI3K). Upon activation of 
receptor tyrosine kinases by ligands such as growth factors or insulin, auto-phosphorylation 
of tyrosine residues on the intracellular portion of the receptor leads to recruitment of PI3K. 
PI3K converts phophatidylinositol-4,5-bisphosphate (PIP2) to phophatidylinositol-3,4,5-
triphosphate (PIP3), thereby affecting the structure of Akt and recruiting it via its PH domain 
from the cytosol to the plasma membrane [161]. Here, PDK1 phosphorylates the activation 
loop (T308) and thereby activates Akt [162]. In addition, phosphorylation of the hydrophobic 
motif (HM) at S473 by mTORC2 (mechanistic target of rapamycin complex 2) [163] is a cru-
cial step for maximal activation [164]. mTORC2 comprises six different proteins, several of 
which are common to mTORC1 as well (section 1.4): mTOR; rapamycin insensitive compan-
ion of mTOR (rictor); mammalian stress-activated protein kinase interacting protein (mSIN1); 
protein observed with Rictor-1 (Protor-1, also known as PRR5); mammalian lethal with 
Sec13 protein 8 (mLST8, also known as GβL) and DEP-domain-containing mTOR-interacting 
protein (DEPTOR) [165]. Constitutive Phosphorylation on T450 occurs during translation and 
is required for Akt integrity [166].  
Figure 1.6 shows the structure and important features of Akt.  
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Figure 1.6: Structure of Akt/PKB 
A 3D-structure of inactive (PDB code 1GZK) and active (PDB code 1O6K) recombinant Akt kinase domain □]])  . In activated Akt 
the αB- and αC helices of the N-lobe, together with the activation segment and the hydrophobic motif □) become ordered. 
Thereby catalytic residues become aligned leading to a conformational change in the DFG motif  □) , which is involved in nucle-
otide binding. B amino acid sequence of Akt2 (PH domain □) , kinase domain □) and hydrophobic motif □)  ) and the structure of 
all three Akt isoforms. Highlighted are the DFG motif  □) and important phosphorylation sites □)  . 
 
 
 
Akt is on one hand activated via phosphorylation but needs on the other hand tight regulation 
which is achieved by dephosphorylation. Protein phosphatase PP2A has been shown to 
dephosphorylate Akt at Thr308 [167, 168]. However, it should be noted that Akt, which is 
bound to the chaperone Hsp90 seems to be protected from dephosphorylation by PP2A 
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[169]. PHLPP (PH domain leucine-rich repeat protein phosphatase) is the phosphatase 
known to inactivate Akt (S473) [170]. Thereby PHLPP2 dephosphorylates Akt1 and Akt 3 
whereas the highly homologues PHLPP1 dephosphorylates Akt2 and also Akt 3 [171]. 
1.3.2 Akt in health and disease 
Akt constitutes an important node in diverse signaling cascades and plays an essential role 
in cell survival, growth, migration, proliferation, polarity, metabolism, cell cycle progression, 
muscle and cardiomyocyte contractility as well as angiogenesis [172]. 
1.3.2.1 Akt in protein synthesis, proliferation and cell survival 
Over 100 substrates [173] are phosphorylated by activated Akt independent of the cellular 
localization. By phosphorylating the protein BAD [174], the transcription factor FOXO [175] 
and the pro-caspase-9 [176], Akt inhibits proapoptotic processes and promotes cell survival. 
Akt also activates NF-κB via regulating IκB kinase (IKK), thus results in transcription of pro-
survival genes [177]. The same is achieved by Akt mediated activation of the E3 ubiquitin 
ligase MDM2, [178] which results in translocation of MDM2 to the nucleus where it degrades 
the tumor suppressor protein p53 thereby inhibiting its function.  
Phosphorylation of the tumor suppressor proteins TSC2 [179] and PRAS40 [180] leads to 
their inhibition thereby activating mTORC1 signaling and promoting cell growth via promotion 
of ribosomal protein biosynthesis. By Akt-mediated phosphorylation of the cyclin-dependent 
kinase inhibitors p27Kip1 [181], Myt 1 [182] and several others cell cycle progression is accel-
erated. Deregulation of these tightly regulated processes can be observed in several cancers 
[183]. The Akt transforming mutation (E17K), which leads to a constitutive attachment of Akt 
to the cell membrane was identified in 8% of human breast, 6% of colorectal, and 2% of ovar-
ian cancers [184]. 
The Akt signaling axis also actively engages with the migratory process in motile cells, in-
cluding metastatic cancer cells. Thus Akt is involved in cell migration and invasion, epithelial-
mesenchymal transition, and finally cancer metastasis [185]. Akt is involved in angiogenesis, 
which can further promote cancer development [186, 187].  
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Figure 1.7: Upstream effectors and downstream targets of Akt (picture adapted from Cell Signaling Technology, Inc. 
(www.cellsignal.com) 
 
1.3.2.2 Akt in metabolism 
Insulin rapidly and persistently activates Akt leading to a manifold cell type specific influence 
on metabolism [188]. 
The first target of Akt, that was discovered was the constitutively active glycogen synthase 3 
kinase (GSK-3), which is inhibited upon Akt phosphorylation [189, 190]. By inhibition of GSK-
3β Akt increases the activity of the eukaryotic initiation factor 2B (eIF2B), a multimeric gua-
nine-nucleotide exchange factor that facilitates the conversion of inactive eIF2-GDP to active 
eIF2-GTP, thus being a critical step for initiation of translation and thereby protein synthesis 
[191]. Akt mediated inhibition of GSK-3 leads to the activation of glycogen synthase [192], 
thereby promoting glycogen synthesis.  
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Besides effects mediated by GSK, Akt promotes increased cellular glucose metabolism by 
stimulating the localization of the glucose transporter Glut1 and Glu4 to the plasma mem-
brane, thus facilitating increased glucose uptake [193, 194]. 
In addition, Akt increases glycolytic metabolism by stimulating the activity of hexokinase 
[195, 196] and phosphofructokinase [197], both rate-limiting enzymes of the glycolytic path-
way.  
An important pathway, which has impact on several metabolic processes, is the mTOR 
pathway, which will be focused on in section 1.4. 
Finally, Akt activity is required for the antilipolytic action of insulin mediated by activation of 
phosphodiesterase-3B (PDE-3B) [198]. Mechanistically activation of PDE-3B leads to in-
creased hydrolysis of cAMP, resulting in reduced activity of protein kinase A (PKA) and 
thereby depletion of hormone-sensitive lipase (HSL) and other target enzymes involved in 
lipolysis. In addition to this antilipolytic action, it was shown in a murine adipocyte cell line 
that insulin also seems to promote lipid storage by activation of lipogenesis via regulation of 
the lipogenic enzyme acetyl-CoA-carboxylase (ACC) by AMP activated protein kinase 
(AMPK) [199].  
 
Akt’s impact on metabolism is inextricably linked to its effects on cell growth and survival and 
Akt hyperactivation is believed to be associated with altered glucose metabolism observed in 
tumor cells. It was shown that proliferating cancer cells preferentially use aerobic glycolysis 
to support growth, a metabolic alteration called “Warburg effect” [200-202]. 
1.3.2.3 Akt in neurobiology 
Akt controls different aspects of neuron function and neurodegeneration: First, it can regulate 
neurite outgrowth by several target proteins, such as GSK-3 and mTOR or NF-κB [203].  
Second, the ligand-gated chloride ion channel γ-aminobutyric acid A (GABAA) was identified 
as a direct Akt substrate in vitro and in vivo. The GABAA receptor mediates synaptic trans-
mission at most inhibitory synapses in the mammalian brain. Akt mediated phosphorylation 
increases the number of GABAA receptors on the plasma membrane surface, which increas-
es the efficacy of receptor mediated inhibition of GABAergic synapses [204].  
Third, Akt was shown to directly or indirectly phosphorylate substrates involved in neuro-
degenerative diseases such as Huntington’s disease [205], spinocerebellar ataxia type 1 
(SCA1) [206], Alzheimer’s disease [207] and schizophrenia [208, 209]. The phosphorylation 
of the protein huntingtin by Akt results in blockage of aggregation promoting neuroprotection. 
Most strikingly, an altered form of full length Akt was observed in patients suffering from Hun-
tington’s disease [205, 206]. In addition, Kaspar et al. found that stimulation of the Akt path-
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way by insulin growth factor 1 (IGF-1) prolongs the lifespan in a mouse model for amyo-
trophic lateral sclerosis (ALS) [210].  
Finally, Akt and GSK-3 have been associated with the action of psychiatric drugs. Specifical-
ly, the effects of lithium, valproate, olanzapine, clozapine but also haloperidol and fluoxetine  
are partially mediated by Akt and GSK-3 [211]. 
1.3.2.4 Severe limitations in mice lacking Akt 
The importance of Akt signaling was demonstrated very clearly by knockout experiments in 
mice: Akt2-/- mice have a normal body mass, but display a profound diabetic phenotype 
including insulin resistance and hyperglycemia. This phenotype is accompanied by the loss 
of pancreatic β-cells [212, 213].  
Akt1-/- mice experience defects in both fetal and postnatal growth, and these persisted into 
adulthood. Moreover, increased rates of apoptosis were observed. Generally these mice had 
increased neonatal mortality. However, in striking contrast to Akt2 null mice, Akt1 deficient 
mice are normal with regard to glucose tolerance and insulin-stimulated disposal of blood 
glucose [214, 215].  
Akt3 knockout mice are characterized by impairment in brain development but are otherwise 
healthy [216]. 
Double knockout experiments indicated that some Akt isoforms are redundant; others seem 
to fulfill specific tasks. Particularly Akt1 seems be indispensable since it is exclusively in-
volved in proliferation, differentiation, and early development [217]. 
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1.4 Focus on PI3K/Akt/mTOR pathway 
mTOR signaling mediated by mTORC1 is associated with cellular growth and proliferation in 
response to a variety of environmental cues, such as growth factors and nutrient availability 
(including aminoacids), as well as immune regulatory signals [218]. Of the numerous Akt 
targets reported, mTORC1 appears to be the master regulator of protein biosynthesis, which 
will be focused on in this section (Figure 1.8). 
 
 
Figure 1.8: Simplified representation of the PI3K/Akt/mTOR signaling pathway with focus on the downstream signals 
S6K and 4E-BP1 
 
 
Upon activation of the insulin receptor by hormone binding, Akt is phosphorylated as de-
scribed in section 1.3.1. Akt kinase then directly phosphorylates the tumor suppressor pro-
teins tuberous sclerosis protein 1 and 2 (TSC1/2) at several positions which lead to inhibition 
of TSC1/TSC2 [219, 220]. The proteins TSC1 (also known as Hamartin) and TSC2 (also 
known as Tuberin) form a functional complex in which TSC1 mainly fulfills stabilizing func-
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tions whereas TSC2 acts as GTPase activating protein (GAP) for the small regulatory 
GTPase Rheb (Ras-homolog enriched in brain). TSC2 activates the intrinsic GTPase of 
Rheb and converts it to its inactive GDP bound state [221, 222]. The loss of the inhibitory 
effects of TSC protein leads to excessive cell growth and tumor formation, phenotypes that 
can be observed in the disease Tuberous Sclerosis [223]. Upon de-activation of TSC by 
phosphorylation of Akt, the active, GTP bound Rheb interacts with mTORC1 to promote sig-
naling [224]. mTORC1 has four components (compare with mTORC2 – section 1.3.1): 
mTOR, which is the catalytic subunit of the complex; the regulatory associated protein of 
mTOR (Raptor); mLST8 (GβL) and DEPTOR [165]. Additionally, Akt activation by growth 
factors can activate mTORC1 in a TSC1/2-independent manner by promoting phosphoryla-
tion and thereby dissociation of the protein proline rich Akt substrate 40 kDa (PRAS40) from 
mTORC1 [180, 225, 226]. Physiologically, PRAS40 interacts with mTOR via Raptor and 
thereby competes with other substrates for binding to mTOR [227, 228].  
Activated mTORC1 stimulates biosynthesis of ribosomes and translation of proteins via its 
substrates 4E-BP1 and S6Kinase.  
The described processes entail significant energy consumption and the energy status of the 
cell is signaled to mTORC1 through AMP-activated protein kinase (AMPK), a master sensor 
of intracellular energy status [229]. By sensing energy depletion (low ATP:ADP) AMPK is 
activated and phosphorylates TSC2 thereby reducing mTORC1 activity via Rheb [230, 231]. 
Additionally, AMPK can reduce mTORC1 activity in response to energy depletion by direct 
phosphorylation of Raptor [232]. 
The active mTORC1 phosphorylates 4E-BP1 (PHAS-I) at its multiple phosphorylation sites 
resulting in its dissociation from eukaryotic initiation factor 4E (eIF4E), which in turn initiates 
cap-dependent translation [233]. For regulation via growth signals (especially insulin) four 
phosphorylation sites seem to be crucial (T37, T46, S65, T70) which are phosphorylated by 
mTORC1 in a strictly hierarchical manner: first the residues T37 and T46, creating the basis 
for phosphorylation of T70 [234] and finally S65 [235] resulting in total loss of eIF4E binding. 
The second well studied target of mTORC1 is the serine/threonine protein kinase S6Kinase. 
The AGC kinase family member S6K1 is present in mammalian cells in two isoforms, which 
are produced from the same transcript by differential translation and similar regulation [236]. 
S6K1L (p85 S6K) is characterized by an N-terminal extension that contains signals for nu-
clear localization, while the small isoform S6K1S (p70 S6K) is localized in the cytoplasm 
[237]. S6K2, a second S6K is highly identical to S6K1, especially within the catalytic and the 
autoinhibitory domain [238]. Both, S6K1 and S6K2, are expressed ubiquitously in mammali-
an tissues. S6K is activated by phosphorylation at multiple serine and threonine residues 
within the C-terminal regulatory domain and the kinase domain.  First T389 is phosphory-
lated by mTORC1. This phosphor-threonine serves as adapter for the kinase PDK1 leading 
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to phosphorylation at position T229 within the catalytic activation loop [239]. The nucleo-
cytoplasmatic shuttling of S6K seems to be mediated by phosphorylation events as well 
[240]. S6K regulates several effector proteins by direct phosphorylation, among them ribo-
somal proteins (S6, eIF-4B and eIF2k) [241, 242], transcription factors (CREB) and proteins 
involved in cell survival (BAD1, PDCD4, MDM2) [243].  
After successful activation of S6Kinase the Akt signaling pathway is dampened by S6K1 de-
pendent negative feedback inhibition [244]. S6K directly phosphorylates the insulin receptor 
substrate 1 (IRS-1), thereby hindering the scaffold function between the insulin receptor and 
PI3K, a process which is enhanced by degradation of IRS-1 [245]. This auto-regulatory pro-
cess within the PI3K/Akt/mTORC1 signaling pathway is crucial for the fine-tuning of insulin 
sensitivity. There are several other feedback loops such as mTORC1 induced stabilization of 
the IRS adapter protein Grb10, which inhibits productive interaction of IRS with a key phos-
photyrosine in the insulin receptor [246]; inhibition of mTORC2 by S6K1-mediated phosphor-
ylation of rictor and mTORC1 mediated transcriptional upregulation of the phosphatidylinosi-
tol phosphatase and tensin homologue (PTEN) by the transcription factor hypoxia inducible 
factor 1 (HIF1α) [247]. Furthermore, expression of the phosphatase PHLPP is regulated by 
mTORC1 [248]. 
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1.5 Pharmacological modulation of the PI3K/Akt/mTOR pathway  
Receptor tyrosine kinase amplifications, mutations or silencing of the tumor suppressor 
PTEN and/or mutations within PI3K are the most common alterations which lead to upregula-
tion of the PI3K/AKT signaling axis causing tumor genesis [249].  
With Imatinib (Gleevec®) the first tyrosine kinase inhibitor was approved by the EMA against 
chronic myelogenous leukemia followed by the rapamycin analogues (“Rapalogues”) 
temsirolimus (Torisel®) and everolimus (Afinitor®) for treatment of kidney cell carcinomas. 
However most of the PTEN- , PI3K-, Akt- and mTOR inhibitors are still in clinical trial phases 
I/II or III [250]. In addition, mTOR/PI3K dual specific inhibitors as well as combinatory thera-
pies are promising [250, 251]. In research, modulators of the PI3K/Akt/mTOR pathway serve 
as valuable tools to get further insights into the complex mechanism of regulation of this im-
portant pathway.  
1.5.1 Rapamycin – an “old acquaintance” connecting FKBPs, Akt and mTOR 
A general anti-proliferative effect of the immunosuppressive drug rapamycin (see section 
1.2.1) was first observed in a panel of different cancer lines under cell culture conditions 
[252], defining rapamycin as the first selective mTOR inhibitor [253]. To increase bio-
availability and compound concentration in the target organs the “Rapalogues” were devel-
oped. Temsirolimus was additionally EMA approved against mantle cell lymphoma, while 
everolimus was recently approved as medication for advanced breast cancer and pancreatic 
neuroendocrine tumors.  
 
The molecular mechanism of rapamycin was thought to be the induction of a ternary complex 
with mTOR and the obligatory accessory protein FKBP12. After acute treatment with ra-
pamycin mTORC1 binds directly to FKBP12/rapamycin leading to a reduction of the kinase 
activity of mTORC1 [253]. In contrast, mTORC2 does not bind the rapamycin/FKBP12 com-
plex, suggesting that the FRB domain is not accessible on mTORC2. However under condi-
tions of prolonged rapamycin treatment rapamycin/FKBP12 was shown to reduce intact 
mTORC2 in some cell types, presumably as newly synthesized or turned over free mTOR 
molecules are sequestered [254]. Theoretically, the inhibition of the assembly of mTORC2 
should lead to a decreased phosphorylation of Akt S473. This was not observed in every cell 
type and in some cell types phosphorylation was even shown to be increased [254]. This can 
be explained by a negative feedback loop from mTOR or p70S6K to Akt.  
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1.5.2 Akt inhibitors – more than one strategy 
The majority of the described Akt inhibitors are competitive with ATP. AT7867 as a member 
of this class inhibits Akt1/2/3 and p70 S6 kinase with an IC50 of 32 nM/17 nM/47 nM and 85 
nM, respectively [255, 256]. The compound binds and stabilizes the activated ‘PH out’ con-
formation of Akt (PDB code 2UW9) [255]. The occupation of the ATP binding site causes 
stabilization of a conformation in which the phosphorylated sites are protected from 
dephosphorylation by phosphatases, thus resulting in hyperphosphorylation and locking in a 
non-functional state [257, 258].  
Inhibitor VIII was the first commercialized PH domain dependent allosteric Akt1/Akt2 inhibitor 
binding to Akt1 with an IC50 of 58 nM and to Akt2 with an IC50 of 210 nM [259]. The com-
pound intercalates between the PH and the kinase domain of Akt and locks the latter in a 
closed inactive conformation (PDB code 3O96) with reduced phosphorylation at position 
S473 and T308 [260, 261]. The next generation allosteric compound derived from Akt inhibi-
tor VIII (MK-2206) is currently evaluated in phase III clinical studies. 
The most clinically advanced Akt inhibitor is the alkylphospholipid perifosine in phase III of 
clinical trials, where single agent activity was shown in sarcomas and Waldenström macro-
globulinemia [250]. Phase III combination clinical trials are ongoing in colorectal cancer and 
multiple myeloma [262]. Based on its structure perifosine is incorporated into the cell mem-
branes were it interferes with lipid-based signal transduction [263]. Additionally, the PH do-
main of all Akt isoforms seems to be a target, thereby preventing Akt activation [250]. Chem-
ical structures of some Akt inhibitors are depicted in Figure 1.9. 
 
 
 
Figure 1.9: Chemical structure of Akt inhibitors with different mechanisms of action 
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2. Aim of the project 
Recently it was shown that FKBP51 acts as a scaffold protein mediating the interaction be-
tween PHLPP and Akt1 or Akt2, respectively [75]. In a pancreatic cancer xenograft model the 
positive correlation between the expression of FKBP51 and the response to chemotherapeu-
tics was confirmed in vivo [76]. However, diverging results have been reported from several 
other tumor tissues [77]. Nevertheless, the enhancement of the PHLPP-mediated Akt 
dephosphorylation, e.g. via FKBP51, could be an option to sensitize susceptible cancer cells 
to chemotherapy. However, to implement this strategy pharmacologically, a much better bio-
chemical understanding of the Akt/FKBP51/PHLPP interaction is required. The aim of this 
study was thus to get an improved insight into the interaction of FKBP51 and Akt.  
Central questions were: Is there a direct FKBP51/Akt interaction? Which domains are in-
volved and what activation status of Akt is obligatory? Is the interaction restricted to human 
FKBP51? Can other AGC kinases bind to FKBPs as well? 
 
Further we aimed to investigate possible effects of different chemical modulators such as 
FKBP inhibitors and Akt inhibitors on Akt/FKBP interaction and downstream signaling. This is 
crucial in order to exclude and/or understand possible unwanted side effects of future medi-
cation.  
 
Additionally there were hints from previous studies [14] showing that the immunosuppressive 
compound rapamycin exerts its effects not only by binding to FKBP12 but also by interaction 
with larger paralogs like FKBP51. Therefore it was asked if FKBP12 could be replaced by 
larger FKBPs in functional assays. These alternative FKBP/rapamycin/mTOR complexes 
would contain additional functional domains that could be relevant for the complex, cell-type 
specific effects of rapamycin. New insights could provide additional data supporting a ra-
tionale for FKBP subtype-selective rapamycin analogues, which could specifically target tis-
sues that express a certain FKBP subtype. 
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3. Materials 
3.1 Oligonucleotide primers 
For amplification and cloning of the FKBP nucleotide sequences the following oligonucleotide 
primers Sigma-Aldrich (St. Louis, MO, USA) were used together with the indicated vectors: 
 
Name Sequence (5’-3’) Amplificat and 
Sequence  
Cloning strategy 
51-KpnI-Start-
FK2-fwd 
 
ACCAGGTACCATGTTT
GAAGATGGAGGCATT
ATCCG 
Human FKBP51 
ΔFK1 
(NM_004117) aa 
141-457+FLAG 
tag 
 
Amplification from 
pcDNA3 FKBP51FLAG 
and introduction in 
pcDNA3 with KpnI and 
EcoRI → 
pcDNA3FKBP51 
ΔFK1FLAG 
FLAG-Stop-
EcoRI-rev 
TTTTTTGAATTCTCACT
TGTCATCGTCGTCCTT
GTAGTC 
KpnI-FKBP51-
fwd 
GGCCGGTACCATGAC
TACTGATGAAGGTGC
CAAG Human FKBP51 FK1 
(NM_004117) aa 
1-140+FLAG tag 
Amplification from 
pcDNA3 FKBP51FLAG 
and introduction in 
pcDNA3 with KpnI and 
EcoRI → pcDNA3 
FKBP51FK1FLAG 
FK1-FLAG-
Stop-EcoRI-
rev 
TTTTTGAATTCTCACTT
GTCATCGTCGTCCTTG
TAGTCCTCTCCTTTGA
AATCAAGGAGC
Kpn-51-Start-
TPR-fwd 
CCGAGGTACCATGGA
TACCAAAGAAAAATT
GGAGCAG 
Human FKBP51 
ΔFK1FK2 
(NM_004117) aa 
259-457+FLAG 
tag 
Amplification from 
pcDNA3 FKBP51FLAG 
and introduction in 
pcDNA3 with KpnI and 
EcoRI →pcDNA3 
FKBP51ΔFK1FK2FLAG 
Flag-Stop-
EcoRI-rev 
TTTTTTGAATTCTCACT
TGTCATCGTCGTCCTT
GTAGTC 
EcoRI-
FKBP51-fwd 
CCCGGAATTC 
ACCATGACTACTGATG
AAGGTGCCAA 
Human FKBP51 
FK1 
(NM_004117) aa 
1-140+FLAG tag 
 
 
Amplification from prk5 
FKBP51FLAG and intro-
duction in pRK5 with 
EcoRI and 
BamH1→pRK5FKBP51 
FK1FLAG 
FK1-FLAG-
Stop-BamH1-
rev 
TTTTTGGATCCTCACT
TGTCATCGTCGTCCTT
GTAGTCCTCTCCTTTG
AAATCAAGGAGC 
Table 3.1: Oligonucleotide primers and cloning strategies used for generation of FKBP plasmids 
The restriction sites are underlined, coding sequences are bold, tags are italic. 
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The following primers were used for introduction of Akt1 point mutations:  
 
name Sequence (5’-3’) Cloning strategy 
 
Akt1 T450A-fwd 
 
CCAGATGATCACCATCGCACCACCTGAC
CAAGA 
 
Base exchange to 
pCMV5HA_Akt1T450A 
 
Akt1 T450A-rev 
TCTTGGTCAGGTGGTGCGATGGTGATCA
TCTGG 
Akt1 T450D-fwd 
GGCCCAGATGATCACCATCGATCCACCT
GACCAAGATGACA 
 
Base exchange to 
pCMV5HA_Akt1T450D 
Akt1 T450D-rev 
TGTCATCTTGGTCAGGTGGATCGATGGT
GATCATCTGGGCC 
PKBα T308A 
sense 
GGTGCCACCATGAAGGCCTTTTGCGGC
ACAC 
 
Base exchange to 
pCMV5HA_Akt1T308A PKBα T308A an-
tisense 
GTGTGCCGCAAAAGGCCTTCATGGTGG
CACC 
PKBα T308D 
sense 
CGGTGCCACCATGAAGGACTTTTGCGG
CACACCT 
 
Base exchange to 
pCMV5HA_Akt1T308D PKBα T308D 
antisense 
AGGTGTGCCGCAAAAGTCCTTCATGGTG
GCACCG 
PKBa S473A 
sense 
CTTCCCCCAGTTCGCCTACTCGGCCAG 
 
Base exchange to 
pCMV5HA_Akt1S473A PKBa S473A 
antisense 
CTGGCCGGAGTAGGCGAACTGGGGGAA
G 
PKBa S473D 
sense 
CACTTCCCCCAGTTCGACTACTCGGCCA
GCAG 
 
Base exchange to 
pCMV5HA_Akt1S473D PKBa S473D 
antisense 
CTGCTGGCCGAGTAGTCGAACTGGGGG
AAGTG 
Table 3.2: Oligonucleotide primers to generate Akt1 point mutations 
The tripletts coding for the changed aminoacids are underlined, the changed bases are shown in bold. 
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3.2 Expression vectors 
Table 3.3: Plasmids used for protein expression in bacteria I 
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Table 3.3: Plasmids used for protein expression in bacteria II 
S
tra
te
gy
/p
ro
vi
de
r 
V
. K
up
fe
r, 
(M
P
I o
f P
sy
-
ch
ia
try
, M
un
ic
h)
 
V
. K
up
fe
r ,
 (M
P
I o
f 
P
sy
ch
ia
try
, M
un
ic
h)
 
 V
. K
up
fe
r ,
 (M
P
I o
f 
P
sy
ch
ia
try
, M
un
ic
h)
 
V
. K
up
fe
r ,
 (M
P
I o
f 
P
sy
ch
ia
try
, M
un
ic
h)
 
V
. K
up
fe
r ,
 (M
P
I o
f 
P
sy
ch
ia
try
, M
un
ic
h)
 
V
. K
up
fe
r ,
 (M
P
I o
f 
P
sy
ch
ia
try
, M
un
ic
h)
 
V
. K
up
fe
r ,
 (M
P
I o
f 
P
sy
ch
ia
try
, M
un
ic
h)
 
V
. K
up
fe
r ,
 (M
P
I o
f 
P
sy
ch
ia
try
, M
un
ic
h)
 
V
. K
up
fe
r ,
 (M
P
I o
f 
P
sy
ch
ia
try
, M
un
ic
h)
 
V
. K
up
fe
r ,
 (M
P
I o
f 
P
sy
ch
ia
try
, M
un
ic
h)
 
E
xp
re
ss
io
n 
FK
B
P
51
TP
R
  w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g 
(a
a2
57
-4
57
) 
FK
B
P
FK
1 
 w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g(
aa
 
1-
14
0)
 a
nd
 p
oi
nt
 m
ut
at
io
n 
F6
7L
 
FK
B
P
FK
1 
 w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g(
aa
 
1-
14
0)
 a
nd
 p
oi
nt
 m
ut
at
io
n 
F6
7I
 
FK
B
P
FK
1 
 w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g(
aa
 
1-
14
0)
 a
nd
 p
oi
nt
 m
ut
at
io
n 
F6
7M
 
FK
B
P
FK
1 
 w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g(
aa
 
1-
14
0)
 a
nd
 p
oi
nt
 m
ut
at
io
n 
F6
7A
 
FK
B
P
FK
1 
 w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g(
aa
 
1-
14
0)
 a
nd
 p
oi
nt
 m
ut
at
io
n 
F6
7G
 
FK
B
P
FK
1 
 w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g(
aa
 
1-
14
0)
 a
nd
 p
oi
nt
 m
ut
at
io
n 
F6
7S
 
FK
B
P
FK
1 
 w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g(
aa
 
1-
14
0)
 a
nd
 p
oi
nt
 m
ut
at
io
n 
F6
7T
 
FK
B
P
FK
1 
 w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g(
aa
 
1-
14
0)
 a
nd
 p
oi
nt
 m
ut
at
io
n 
I1
22
V
 
FK
B
P
FK
1 
 w
ith
 N
-te
rm
in
al
 h
ex
ah
is
tid
in
 ta
g(
aa
 
1-
14
0)
 a
nd
 p
oi
nt
 m
ut
at
io
n 
F1
30
Y
 
re
si
st
an
ce
 
A
m
pi
ci
lli
n 
A
m
pi
ci
lli
n 
A
m
pi
ci
lli
n 
A
m
pi
ci
lli
n 
A
m
pi
ci
lli
n 
A
m
pi
ci
lli
n 
A
m
pi
ci
lli
n 
A
m
pi
ci
lli
n 
A
m
pi
ci
lli
n 
A
m
pi
ci
lli
n 
na
m
e 
pP
ro
E
x-
H
ta
_F
K
B
P
51
TP
R
  
(p
P
ro
E
x-
H
ta
_F
K
B
P
51
Δ
FK
Δ
FK
2)
 
pP
ro
E
x-
H
ta
 _
FK
B
P
51
FK
1F
67
L 
  
pP
ro
E
x-
H
ta
 _
FK
B
P
51
FK
1F
67
I  
pP
ro
E
x-
H
ta
_ 
FK
B
P
51
FK
1F
67
M
 
pP
ro
E
x-
H
ta
 _
FK
B
P
51
FK
1F
67
A
   
pP
ro
E
x-
H
ta
 _
FK
B
P
51
FK
1F
67
G
  
pP
ro
E
x-
H
ta
 _
FK
B
P
51
FK
1F
67
S
  
pP
ro
E
x-
H
ta
_ 
FK
B
P
51
FK
1F
67
T  
pP
ro
E
x-
H
ta
 _
FK
B
P
51
FK
1I
12
2V
 
pP
ro
E
x-
H
ta
_ 
FK
B
P
51
FK
1F
13
0Y
   
Materials 
__________________________________________________________________________ 
29 
 
Table 3.3: Plasmids used for protein expression in bacteria III 
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 Table 3.4: Plasmids used for protein expression in eukaryotic cells I 
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 Table 3.4: Plasmids used for protein expression in eukaryotic cells II 
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 Table 3.4: Plasmids used for protein expression in eukaryotic cells III 
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 Table 3.4:Plasmids used for protein expression in eukaryotic cells IV 
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3.3 Antibodies 
3.3.1 Primary antibodies 
For protein detection in immunoblotting experiments, the following primary antibodies were 
diluted in buffered protein solution (BSA or milk powder): 
Antibody Antigen Species 
Dilution factor 
and used solu-
tion 
Manufacturer, 
cat# 
αActin 
C-terminual se-
quence of human 
Actin  
IgG, polyclo-
nal, from goat 
1:3000 in 5% 
(w/v)milk pow-
der in TBS-T 
BSA 
Santa Cruz Bio-
technology (San-
ta Cruz, CA, 
USA) 
αAkt kinase 
(pan) 
C-terminal se-
quence of mouse 
Akt 
IgG, monoclo-
nal, from rab-
bit 
1:1000 in 5% 
(w/v) milk pow-
der in TBS-T 
Cell Signaling 
(Danvers, MA, 
USA) 
#4685 
αAkt (phospho 
S473) 
Peptide around 
phospho S473 
IgG, monoclo-
nal, from rab-
bit 
1:1000 in 5% 
(w/v) BSA in 
TBS-T 
Cell Signaling 
(Danvers, MA, 
USA) 
#4058 
αCyclophilin 
40  
(Cyclophilin D) 
epitope corre-
sponding to ami-
no acids 186-370 
mapping at the C-
terminus of Cy-
clophilin D of hu-
man origin 
IgG, polyclo-
nal, from rab-
bit 
1:1000 in 5% 
(w/v) milk pow-
der in TBS-T 
Santa Cruz Bio-
technology (San-
ta Cruz, CA, 
USA) 
#H-185 
αFFI FK1 domain of FKBP51 
IgG, polyclo-
nal, from 
mouse 
1:2000 in 5% 
(w/v) milk pow-
der in TBS-T 
[81] 
αFKBP12 aa 1-13 of human FKBP12 
IgG, polyclo-
nal, from rab-
bit 
1:1000 in 5% 
(w/v) milk pow-
der in TBS-T 
Abcam (Cam-
bridge, UK) # 
ab2918 
αFKBP12.6 aa 1-81 FKBP12.6 
IgG1, mono-
clonal, from 
mouse 
1:500 in 5% 
(w/v) milk pow-
der in TBS-T 
Abcam (Cam-
bridge, UK) 
#ab58075 
αFKBP25 Peptide from aa1-100 
IgG, polyclo-
nal, from rab-
bit 
1:1000 in 5% 
(w/v) milk pow-
der in TBS-T 
Abcam (Cam-
bridge, UK) 
#ab16654 
αFKBP51 Peptide from aa 407-457 
IgG, polyclo-
nal, from rab-
bit 
1:5000 in 5% 
(w/v) milk pow-
der in TBS-T 
Bethyl Laborato-
ries (Montgom-
ery, TX, 
USA)#A301-430 
Table 3.5: Primary antibodies used in immunoblotting and their properties I 
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Table 3.5: Primary antibodies used in immunoblotting and their properties II 
Antibody Antigene Species 
Dilution factor 
and used 
solution 
Manufacturer,  
cat# 
αFKBP52 Peptide from aa 400-440 
IgG, polyclo-
nal, from rab-
bit 
1:5000 in 5% 
(w/v) milk 
powder in 
TBS-T 
Bethyl Laborato-
ries (Montgomery, 
TX, USA)#A301-
427A 
αFLAG-HRP DYKDDDDK 
IgG, monoclo-
nal, from 
mouse 
1:10000  in 
5% (w/v) milk 
powder in 
TBS-T 
Sigma-Aldrich 
(Saint Louis, MO, 
USA) 
#A8592 
αFLAG DYKDDDDK 
IgG, polyclo-
nal, from rab-
bit 
1:5000 in 5% 
(w/v) milk 
powder in 
TBS-T 
Abcam (Cam-
bridge, UK) 
#ab1162 
αFoxO1 
corresponding 
to carboxy-
terminal resi-
dues of human 
FoxO1 
IgG, monoclo-
nal, from rab-
bit 
1:1000 in 
5% (w/v) BSA 
in TBS-T 
Cell Signaling 
(Danvers, MA, 
USA) 
#2880 
αFoxO1 (phos-
phoS256) 
residues around 
Ser256 
of human FoxO1 
IgG, polyclonal 
from rabbit 
1:1000 in 
5% (w/v) BSA 
in TBS-T 
Cell Signaling 
(Danvers, MA, 
USA) 
#9461 
αGSK-3β Not specified 
IgG1, mono-
clonal from 
rabbit 
1:1000 in 
5% (w/v) BSA 
in TBS-T 
Cell Signaling 
(Danvers, MA, 
USA) 
#9336 
αGSK-3β 
(phosphoS9) 
residues around 
Ser9 of human 
GSK3ß 
IgG1, polyclo-
nal from  rab-
bit 
1:1000 in 
5% (w/v) BSA 
in TBS-T 
Cell Signaling 
(Danvers, MA, 
USA) 
#9315 
αGST schistosomal  GST 
IgG, polyclonal 
from goat 
1:5000 in  5% 
(w/v) milk 
powder in 
TBS-T 
1:2000 
GE Healthcare 
(Chalfont St Giles, 
GB) 
αHA-HRP YPYDVPDYA IgG1, mono-clonal, from rat
1:5000 in 5% 
(w/v) milk 
powder in 
TBS-T 
Roche Diagnostics 
(Mannheim) 
#12013819001 
αHA YPYDVPDYA 
IgG1, mono-
clonal, from 
mouse 
1:1000 in 5% 
(w/v) milk 
powder in 
TBS-T 
Roche Diagnostics 
(Mannheim) 
#11583816001 
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Table 3.5: Primary antibodies used in immunoblotting and their properties III 
3.3.2 Secondary antibodies 
The following secondary antibodies were used in immunoblotting experiments: 
Name Conjugation 
IgG subtype 
from species 
Dilution factor and 
used solution 
Manufacturer 
Mouse IgG Horseradish peroxidase 
Polyclonal, IgG, 
H&L, from goat 
1:3500 in 5% (w/v) 
milk powder in TBS 
Abcam (Cam-
bridge, UK) 
#ab6885 
Rabbit IgG Horseradish peroxidase 
Polyclonal, IgG, 
H&L, from goat 
1:3500 in 5% (w/v) 
milk powder in TBS 
Abcam (Cam-
bridge, UK) 
#ab6721 
Goat IgG Horseradish peroxidase 
Polyclonal, IgG, 
H&L, from donkey 
1:3500 in 5% (w/v) 
milk powder in TBS 
Abcam (Cam-
bridge, UK) 
#ab6789 
Table 3.6:  Secondary antibodies used in immunoblotting experiments 
Antibody Antigene Species 
Dilution factor 
and used solu-
tion 
Manufacturer, 
cat# 
αPHLPP1 
region between 
residue 1150 and 
the C-terminus 
(residue 1205) of 
human PHLPP 
IgG, polyclo-
nal, from rab-
bit, 
 
1:1000 in 5% 
(w/v) milk 
powder in 
TBS-T 
Bethyl Laborato-
ries (Montgom-
ery, TX, USA) 
#A300-660A 
αPHLPP2 
Peptide from aa 
1275-1323 of 
human PHLPP2 
IgG, polyclo-
nal, from rab-
bit, 
 
1:1000 in 5% 
(w/v) milk 
powder in 
TBS-T 
Bethyl Laborato-
ries (Montgom-
ery, TX, USA) 
#A300-661A 
αSGK1 
Peptide from aa 
300 - 400 of hu-
man SGK1 
IgG, polyclo-
nal, from rab-
bit 
 
1:1000 in 5% 
(w/v) milk 
powder in 
TBS-T 
Abcam (Cam-
bridge, UK) 
 # ab43606 
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3.4 Bacterial strains 
While Escherichia coli strain DH5α was used especially for cloning of PCR products and for 
preparation of plasmid DNA, the strain BL21(DE3) is suitable for heterologous protein ex-
pression. The strains were purchased from Invitrogen (Karlsruhe) and display the following 
genotypes: 
 
 
Strain Genotype 
 
DH5α 
 
F' Phi80dlacZ ΔM15 Δ(lacZYA-argF)U169 deoR recA1 endA1 
hsdR17(rK-mK+)phoA supE44 lambda- thi-1 
BL21(DE3)pLysS F–, ompT, hsdSB (rB–, mB–), dcm, gal, λ(DE3), pLysS, Cmr. 
Table 3.7: Bacterial strains used for cloning and expression experiments 
 
3.5 Mammalian cell lines 
The following mammalian cell lines were used: 
Name Description Origin Provided by ATCC No. 
HeLa cervix adenocarcinoma cells H. sapiens 
Dr. T. Rein 
(MPI of Psy-
chiatry, Mu-
nich) 
CCL-2 
HEK293 embryonic kidney cells H. sapiens 
Dr. T. Rein 
(MPI of Psy-
chiatry, Mu-
nich) 
 
CRL-1573 
HEK293-T 
embryonic kidney cells, 
transfected with SV40 T-
antigen 
H. sapiens 
Dr. T. Rein 
(MPI of Psy-
chiatry, Mu-
nich) 
 
CRL-11268 
MEF embryonic fibroblast cells M. muscu-lus 
Marc Cox (Uni-
versity of Texas, 
TX, USA) 
CRL-2991 
Table 3.8: Mammalian cell lines used for different experiments I 
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Name Description Origin Provided by ATCC No. 
MEF51-/- embryonic fibroblast cells, FKBP51 deficient 
M. muscu-
lus 
Marc Cox (Uni-
versity of Texas, 
TX, USA) 
- 
MEF52-/- 
embryonic fibroblast cells, 
FKBP52 deficient 
M. muscu-
lus 
Marc Cox Uni-
versity of Texas, 
TX, USA) 
- 
SU.86.86 ductal carcinoma (pancreas) H.sapiens Kong Bo (TU 
Munich, Munich) 
CRL-1837 
SH-SY5Y neuroblastoma cells H. sapiens 
Dr. M. Gerard 
(University of 
Leuven, Leuven, 
BE) 
CRL-2266 
SH-SY5Y-
shFKBP12 
(SH-SY5Y-
12KD) 
neuroblastoma cells, 
FKBP12 knock down 
H. sapiens 
Dr. M. Gerard 
(University of 
Leuven, Leuven, 
BE) [20] 
- 
Table 3.8: Mammalian cell lines used for different experiments II 
 
3.6 Media and additives for cell culture 
The following media and additives were used to maintain mammalian cell culture: 
Name Contains: Used for Manufacturer 
Ampuwa sterile water   Fresenius-Kabi (Bad Homburg) 
Dulbecco’s Modified 
Eagle Medium 
4.5 g/l glucose,               
L-glutamine, sodium 
pyruvate, phenol red 
HeLa, HEK, 
SU.86.86 
Gibco-Invitrogen 
(Karlsruhe) 
Dulbecco’s Modified 
Eagle Medium 
4.5 g/l glucose,               
L-glutamine, sodium 
pyruvate 
MEF, MEF51-/-, 
MEF52-/- 
Gibco-Invitrogen 
(Karlsruhe) 
Dulbecco’s Modified 
Eagle Medi-
um+GLUTAMAX 
4.5 g/l glucose,               
L-alanyl-L-glutamine, 
phenol red 
SH-SY5Y 
SH-SY5Y-
shFKBP12 
Gibco-Invitrogen 
(Karlsruhe) 
Dulbecco’s Phosphate 
Buffered Saline  all cell lines 
Gibco-Invitrogen 
(Karlsruhe) 
Heat Inactivated Fetal 
Calf Serum (FCS)  all cell lines 
Gibco-Invitrogen 
(Karlsruhe) 
Table 3.9: Media and additives used for cell culture experiments I 
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Name Contains: Used for Manufacturer 
Opti_MEM  
Transfection with 
Lipofectamine 
LTX 
Gibco-Invitrogen 
(Karlsruhe) 
Sodium pyruvate 100x SH-SY5Y Gibco-Invitrogen (Karlsruhe) 
Penicillin/ Strepomy-
cin  
5000 U/ml Penicillin, 
5000 U/ml streptomycin 
all cell lines, ex-
cept SH-SY5Y, 
SH-SY5Y-
shFKBP12 
Gibco-Invitrogen 
(Karlsruhe) 
Poly-D-Lysine 1 mg/ml 
for homogeneous 
time resolved 
FRET assays 
Merck-Millipore (Bil-
lerica, MA, USA) 
Hygromycin 50 mg/ml 
SH-SY5Y-
shFKBP12 
 
Gibco-Invitrogen 
(Karlsruhe) 
Gentamicin 10 mg/ml 
SH-SY5Y, 
SH-SY5Y-
shFKBP12 
 
PAA Laboratories 
GmbH (Cölbe) 
MEM non-essential 
amino acid solution 
100 x 
 
SH-SY5Y, 
SH-SY5Y-
shFKBP12 
 
Gibco-Invitrogen 
(Karlsruhe) 
0.25% Trypsin-EDTA  all cell lines Gibco-Invitrogen (Karlsruhe) 
Table 3.9: Media and additives used for cell culture experiments II 
 
3.7 Chemicals 
The chemicals used for this work are listed below and were purchased from the indicated 
companies: 
 
Acetic Acid Roth (Karlsruhe) 
Acrylamid/Bisacrylamid-Solution (29:1) Serva (Heidelberg) 
Adenosine 5´-Triphosphat  Roth (Karlsruhe) 
Agarose SeaKem  Biozym (Oldendorf) 
Agar-Agar Roth (Karlsruhe) 
Akt Inhibitor VIII  Calbiochem (San Diego, CA, USA) 
Ammonium peroxodisulfate  Roth (Karlsruhe) 
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Ampicillin  Roth (Karlsruhe) 
AMP-PNP (Adenylyl-imidodiphosphate) Sigma-Aldrich (St. Louis, MO, USA) 
Antascomicin B Stephen Ley (Cambridge University, UK) 
[141] 
Anti-FLAG M2 Magnetic beads Sigma-Aldrich (St. Louis, MO, USA) 
Anti-FLAG M2 affinity resin Sigma-Aldrich (St. Louis, MO, USA) 
AT7867 SelleckChem (Houston, TX, USA) 
Biricodar Dr. S. Gaali, (MPI of Psychiatry, Munich) 
Boric acid Calbiochem (San Diego, CA, USA) 
Brilliant Blue R250 Roth (Karlsruhe) 
Bovine Serum Albumine (BSA) Roth (Karlsruhe) 
Bromophenol Blue Merck (Darmstadt) 
Calciumchloride Roth (Karlsruhe) 
p-Coumaric acid Sigma-Aldrich (St. Louis, MO, USA) 
cmpd44=GR591 Dr. R. Gopalakrishnan, [148] 
Desoxynucleotide mix NEB (Frankfurt am Main) 
Dimethyl sulfoxide (DMSO)  Roth (Karlsruhe) 
1,4-Dithiotreitole  Roth (Karlsruhe) 
EDTA (Titriplex III) Merck (Darmstadt)  
Ethidium bromide  Roth (Karlsruhe) 
EZview Red Anti-HA Affinity Gel  Sigma-Aldrich (St.Louis, MO, USA)) 
FK1706 Astellas Pharma Inc. (Tokyo, Japan) 
FK506 (Tacrolimus)  Sigma-Aldrich (St. Louis, MO, USA))  
FLAG peptide Sigma-Aldrich (St. Louis, MO, USA)) 
GC-buffer NEB (Frankfurt am Main) 
Gemcitabine hydrochloride Molekula (Nienburg/Weser) 
Glutathion Pro Catch Sepharose Miltenyi Biotech (Bergisch Gladbach) 
Glycine Roth (Karlsruhe) 
Glycerine (86-88% (v/v)) Roth (Karlsruhe) 
Glycerophosphate Roth (Karlsruhe) 
HA peptide Sigma-Aldrich (St. Louis, MO, USA)) 
Hepes Biomol (Hamburg) 
Immobilon Western   
Chemiluminescent HRP Substrate (ECL) Merck-Millipore (Billerica, MA, USA) 
Imidazole Roth (Karlsruhe) 
Inhibitor VIII Merck (Darmstadt)  
Isopropyl-beta-D-thiogalactopyranoside (IPTG) Roth (Karlsruhe) 
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LB medium (Luria/Miller) Roth (Karlsruhe) 
Lipofectamine 2000 Invitrogen (Karlsruhe) 
Lipofectamine LTX Invitrogen (Karlsruhe) 
Luminol Roth (Karlsruhe) 
Magnesium chloride Merck (Darmstadt) 
2-Mercaptoethanol Merck (Darmstadt) 
Milk powder Roth (Karlsruhe) 
Ni-NTA agarose Qiagen (Hilden) 
Phenylmethylsulfonyl fluoride (PMSF) Molekula (Nienburg/Weser) 
Ponceau S  Roth (Karlsruhe) 
Protease inhibitor cocktail  Sigma-Aldrich (St. Louis, MO, USA)) 
Protein A resin GenScript (Piscataway, USA) 
Rapamycin (Lot #R020) Cfm (Marktredwitz) 
SG537 Dr. S. Gaali (MPI of Psychiatry, Munich) 
Sodium chloride (NaCl) Roth (Karlsruhe) 
Sodium desoxycholate Roth (Karlsruhe) 
Sodium dihydrogenphosphat Roth (Karlsruhe) 
Sodium dodecylsulfat (SDS)  Merck-Millipore (Billerica, MA, USA) 
Sodium flouride Roth(Karlsruhe) 
Sodium dihydrogen orthovanadate Fluka Sigma-Aldrich (St.Louis, MO, USA) 
Sodium pyrophosphate dibasic Fluka Sigma-Aldrich (St.Louis, MO, USA) 
N,N,N',N'-Tetramethylethylenediamine (TEMED)  Roth (Karlsruhe) 
Torin-1 provided by D. Sabatini  
Tris(hydroxymethyl)-aminomethane  Merck (Darmstadt) 
Triton X-100  Roth (Karlsruhe) 
Tween 20 Bio-Rad (München) 
Wortmannin Merck (Darmstadt) 
YW644  Dr. Y. Wang (MPI of Psychiatry, Munich) 
YW648 Dr. Y. Wang (MPI of Psychiatry, Munich)  
YW649 Dr. Y. Wang (MPI of Psychiatry, Munich) 
YW703  Dr. Y. Wang (MPI of Psychiatry, Munich) 
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3.8 Enzymes and Proteins 
The enzyms that were used for different assays are listed below:  
 
Akt1/PKBα (inactive) #14-279 Merck-Millipore (Billerica, MA, USA) 
Akt1/PKBα (active) #14-276 Merck-Millipore (Billerica, MA, USA) 
Antarctic Phosphatase  NEB (Frankfurt am Main) 
GST protein #SCM-G52-30U Biozol (Eching) 
Insulin solution, human Sigma-Aldrich (St. Louis, MO, USA) 
Lysozyme Roth (Karlsruhe) 
Phusion High Fidelity Taq Polymerase NEB (Frankfurt am Main)  
Restriction endonucleases  NEB (Frankfurt am Main)  
T4-DNA Ligase  NEB (Frankfurt am Main) 
Taq Polymerase NEB (Frankfurt am Main) 
 
3.9 Kits 
The following kits were used for DNA purification and FRET assays according to the manu-
facturer’s recommendations: 
 
BCA Protein Assay Thermo Fisher Scientific (Schwerte) 
CellTiter-Fluor Cell Viability Assay Promega (Mannheim) 
High Yield PCR Clean-up/Gel Extraction Kit SLG (Gauting) 
High Yield Plasmid Mini Kit  SLG (Gauting) 
HTRF Phospho Akt (S473) Cisbio (Codolet, France) 
HTRF Phospho Akt (T308) Cisbio (Codolet, France)  
HTRF Phospho mTOR (S2448) Cisbio (Codolet, France) 
Qiagen Plasmid Midi Kit Qiagen (Hilden) 
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3.10 Markers 
For size quantification of protein and DNA samples, the following standards were used:  
 
1 kb DNA Ladder NEB (Frankfurt am Main) 
Fermentas Page Ruler Plus  Thermo Fisher Scientific (Schwerte) 
Prestained Protein Ladder Merck-Millipore (Billerica, MA, USA) 
 
3.11 Equipment 
The following machines and lab items were utilized:  
 
Centrifuge 6K15 Sigma (Osterode) 
Centrifuge Megafuge 1.OR  Thermo Fisher Scientific (Schwerte) 
Centrifuge Avanti J-25, Rotor JA-20  Beckman (Krefeld) 
Centrifuge Biofuge pico  Heraeus (Mannheim) 
Centrifuge Universal 30 F Hettich (Tuttlingen) 
ChemiDoc MP Bio Rad (München) 
CO2 incubator HeraCell Fischer Thermo Scientific (Schwerte) 
Developer machine 3M (Neuss) 
Electrophoresis power supply Pharmacia/GE Healthcare (München) 
Gel electrophoresis chambers  PeqLab GmbH (Erlangen) 
Gel electrophoresis system XCell SureLock Invitrogen (Karlsruhe)  
Ice machine ZBE 150-MT  Ziegra (Isernhagen) 
Incubation shaker Innova 4000 New Brunswick (Edison, NJ, USA) 
Magnet stirer R1000 Carl Roth (Karlsruhe) 
Magnetight Separation Stand Merck Millipore (Billerica, MA, USA) 
MicroCal iTC200 GE Healthcare (Chalfont St Giles, GB) 
Microscope DM IL Leica (Wetzlar) 
Mixer Reax 2 Heidolph Instruments (Schwalbach) 
Multichannel Pipette Research Pro Eppendorf (Hamburg) 
Forma Orbital shaker Thermo Fisher Scientific (Schwerte) 
PCR cycler Gene Amp 9700 Applied Biosystems (Darmstadt) 
pH meter WTW 538  WTW (Weilheim) 
PIPETMAN Pipetten Gilson (Middleton, WI, USA) 
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Pipettor Pipetus akku Hirschmann Laborgeräte (Eberstadt) 
Power Supply Power Pac 3000 Bio Rad (München) 
Precisa 40SM-200A Precisa (Dietikon, Switzerland) 
Precision scalesMaster Pro LP4200S Sartorius (Göttingen) 
Reader Tecan GENios Pro Tecan (Crailsheim) 
Refrigerator Liebherr (Biberach) 
Shaking table SM25A Edmund Bühler (Hechingen) 
Thermomixer comfort  Eppendorf (Hamburg) 
Ultrapure water dispenser PureLab ultra  Elga Lab Water (Celle) 
Ultrasound Sonifier 450 Branson (Dietzenbach-Steinberg) 
UV transilluminator Faust (Meckenheim) 
UV/VIS spectrophotometer DU 530 Beckman (Krefeld) 
Vortexer Mini-Shaker MS2  IKA Labortechnik (Staufen) 
Water bath GfL 1002 GfL (Burgwedel) 
Work bench LaminAir HB2448 Heraeus (Mannheim) 
 
3.12 Consumables 
384-well plates, white Corning (Kaiserslautern), #3572 
384-well plates, low binding surface, black Corning (Kaiserslautern), #3575 
96-well plates, low binding surface, white Corning (Kaiserslautern), #3605 
96-well plates, transparent Carl Roth (Karlsruhe), #9291.1 
96-well plates, transparent Carl Roth (Karlsruhe), #9293.1 
Cell scraper 25 cm Sarstedt (Nümbrecht) 
Cellstar serological pipettes Greiner Bio-One (Kremsmünster, AT) 
Chromatography column 5 ml Bio Rad (München) 
Falcon 6-well plates BectonDickinson (Franklin Lakes,USA) 
96 well plates (cell culture) Corning (Kaiserslautern) #3879 
Falcon 10 cm dish BectonDickinson (Franklin Lakes,USA) 
Tissue culture flasks BectonDickinson (Franklin Lakes,USA) 
Medical X-Ray film Super RX Fujifilm Corporation (Düsseldorf) 
Millex Stringe Filter 0.22 µm Merck-Millipore (Billerica, MA, USA) 
Nucleobond AX2000 Machery-Nagel (Düren) 
Nunclon Surface cell culture dishes Nunc A/S (Roskilde, DK) 
Pipette tips Corning (Kaiserslautern)  
Protran BA 83 Nitrocellulose Whatman (Dassel) 
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Rotilabo Blotting paper Carl Roth (Karlsruhe) 
SDS Mini gel cassettes Invitrogen (Karlsruhe) 
Slide-A-Lyzer Dialysis units Pierce/Fisher Thermo Scientific (Bonn) 
Test tubes Sarstedt (Nürnbrecht)  
Test tubes (low binding) Eppendorf (Hamburg) 
 
3.13 Software and databases 
For data collection and analysis, the following PC programs were used 
 
Endscript 1.1 Laboratoire de BioChristallographie, Insti-
tut de Biologie et Chimie des Protéines; 
(Lyon, France) 
Endnote X5 Thomson Reuters (New York, NY, USA) 
Gimp 2.6      Spencer Kimball, Peter Mattis 
Human protein reference database (hrpd)  http://www.hprd.org 
ImageLab 4.1      Bio-Rad (München) 
Multialin Interface     [268] 
RCSB Protein Data Bank (PDB)   http://www.rcsb.org 
PyMol 0.99      DeLano Scientific  
SigmaPlot 11      Systat Software (Erkrath) 
SPSS 19      IBM (Ehningen) 
PRALINE      [269] 
Protein Calculator v3.3 Scripps Research Institute (La Jolla, CA, 
USA) 
ORIGIN 7.0      Microcal (Northhampton, MA, USA) 
Word, Excel 2010     Microsoft (München) 
Materials 
__________________________________________________________________________ 
46 
Methods  
__________________________________________________________________________ 
47 
4. Methods 
4.1 Molecular biological methods 
4.1.1 Preparation of competent E. coli 
To prepare transformation-competent E. coli cells, 50 ml of sterile LB medium were inocu-
lated with a small amount of glycerol stock and incubated over night at 37°C on a shaking 
platform (200 rpm). 25 ml of this over-night culture were used to inoculate 500 ml of sterile 
LB medium. This culture was grown at 37°C until an OD600 of 0.3 was reached. 
Cells were harvested by centrifugation for 15 min at 5000 x g and 4°C. The pellet was re-
suspended slowly and gently in 125 ml of a cold, sterile 100 mM MgCl2 solution. After anoth-
er centrifugation step (5000 x g, 4°C, 15 min), the bacteria were resuspended in                   
25 ml of a sterile 100 mM CaCl2 solution before another 200 ml of a 100 mM CaCl2 solution 
were added. The mixture was incubated on ice for 20 min. The cells were harvested again 
(4000 x g, 4°C, 10 min) and resuspended in 10 ml of a 100 mM CaCl2 solution with 10% 
glycerin (w/w). Finally, 100µl aliquots of the cell suspension were shock-frozen in liquid ni-
trogen and stored at -80°C until usage. 
4.1.2 Transformation 
50 µl of competent E. coli were thawed on ice and 1-5 ng or 50 ng (for ligation) plasmid DNA 
was added and mixed carefully. After 30 min incubation on ice they were exposed to heat 
shock of 42°C for 45 s. After 2 min incubation on ice 900 µl LB medium were added and the 
transformation mixture was grown at 37°C for 30 min on a shaking platform. Finally, the cells 
were harvested by brief centrifugation, plated on LB agar plates containing antibiotics (100 
µg/ml of ampicillin) and incubated over night at 37°C. The next day single colonies were 
picked and further analyzed. 
4.1.3 Bacterial culture 
The required amount of sterile LB medium containing the selection antibiotics was inoculat-
ed with a single colony from an LB agar plate or glycerol culture and cultivated with agitation 
over night at 37°C. For preparation of the glycerol stocks 1 ml of the overnight culture was 
added to 500 µl of sterile 45 % glycerol solution, mixed carefully and kept at -80°C. 
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4.1.4 DNA preparation and quantification 
DNA was prepared and purified with either High Yield Plasmid Mini Kit, Nucleobond AX 
Mega columns or Qiagen Plasmid Midi Kit according to manufacturer’s protocols. DNA con-
centration was estimated by measuring the extinction at 260nm after dilution to the linear 
range (0.1-1) in a quartz cuvette (d=1 cm). 
 
According to Lambert-Beers Law absorption is proportional to DNA concentration: 
 
A= ε*c*d A=absorption 
 ε=molar extinction coefficient [L mol-1 cm-1] 
 d=path length of the cuvette [1cm] 
 
Using this law an optical density (OD=1) at 260 nm corresponds to 50 µg/ml double stranded 
DNA at a pH 7.0. 
In addition to the concentration of the DNA measured at 260 nm, the ratio A260/A280 was cal-
culated as a measurement for protein contamination and should ideally range from 1.8-2.0. 
4.1.5 Standard polymerase chain reaction (PCR) 
PCR is used to amplify defined DNA-fragments and to insert new restriction sites at 5’ or 3’-
ends by using specific primers [270, 271]. Additionally it is possible to test if bacteria carry a 
certain DNA sequence, as with the “colony PCR”. For a standard PCR reaction the following 
components were combined in a 0.2 ml PCR tube and a total volume of 50 µl: 
 
 250 µM dNTP mix (stock: 25 mM) 
100 nM primer forward (Sigma-Aldrich (St. Louis, MO, USA)) 
 100 nM primer reverse  
 100 ng  plasmid DNA template  
 1 U  Phusion “High Fidelity” Taq polymerase  
5 µl   10x Phusion High-Fidelity buffer  
   
The polymerase chain reaction was performed in a thermo cycler following a defined time 
and temperature profile. Per 1 kb of polymerization, 1 minute elongation time was scheduled. 
Annealing temperature was chosen according to primer melting temperature. 
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step temperature duration purpose 
1 94°C 5 min initial denaturation of DNA 
2 94°C 60 s denaturation of DNA 
3 50-65°C 60 s annealing of primers 
4 72°C  90 s elongation 
5 72°C  10 min final elongation 
6 4°C hold protection from degradation 
 
The chosen annealing temperature was 5-10 °C lower than the melting temperature of the 
primer. Between step 2 and 4 a loop was programmed, which was repeated 30 times. 
4.1.6 Analysis and purification of PCR products: 
4.1.6.1 Agarose gel electrophoresis 
TBE buffer: 90 mM boric acid; 2.5mM EDTA; 90 mM Tris/HCl, pH 8.3 
DNA sample buffer: 40% (w/v) saccharose; 0.25% (w/v) bromophenol blue 
 20 mM EDTA, pH 8.0 
 
To prepare an agarose gel, an appropriate amount of agarose (normally: 0.5 to 1.5 grams to 
yield 0.5 – 1.5% gels) was mixed with 100 ml TBE buffer and boiled in a microwave oven 
until it had dissolved completely. After the solution had cooled down to 60°C, 3 µl of ethidium 
bromide solution were added and mixed thoroughly. Then, the solution was poured into a gel 
tray. Air bubbles were removed, and the comb was put in place. After 30 min, the gel had 
solidified and was transferred to a gel chamber containing TBE buffer. The DNA samples 
(normally: 5 µl of a 100 ng/µl solution) were mixed with an equal amount of DNA sample 
buffer and were filled into the gel wells. Separation of DNA was performed by applying a cur-
rent of 200 mA for 30 min (or until desired separation was achieved). 
4.1.6.2 Isolation of DNA fragments from agarose gels 
The PCR products were visualized using an UV transilluminator and documented photo-
graphically, before the bands were excised with a scalpel. The „High Yield PCR and Gel Ex-
traction Kit“ was used according to the manufacturer’s recommendations to isolate DNA from 
the gel slices. Usually concentrations of 30 – 50 µg DNA / ml were obtained, determined by 
standard UV measurement.  
30 repeats  
of step 2-4 
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4.1.6.3 DNA restriction 
For restriction of vector DNA and PCR products, the following components were combined:  
 
 1 µg  vector DNA (100 µg/ml)   
 2 U  restriction enzyme 1 (20 U/ml)  
 2 U restriction enzyme 2 (20 U/ml) 
 2 µl BSA solution (10 x Stock) if needed 
 2 µl 10x restriction buffer   
bidest. H2O      ad 20 µl   
 
Alternatively: 
 
1 µg   PCR product (50 µg/ml)   
 4 U  restriction enzyme 1 (20 U/ml)  
4 U  restriction enzyme 2 (20 U/ml)  
 2 µl BSA solution (10 x Stock) if needed 
 4 µl 10x restriction buffer   
  bidest. H2O      ad 40 µl 
 
For the enzyme combination EcoRI/BamHI, the buffer NEB buffer III was used. For 
KpNI/EcoRI NEB buffer I was utilized. The restriction mixtures of PCR products were incu-
bated for 3 h at 37°C.  
To avoid re-ligation of single-cut vector, the vector restriction mixtures were supplemented 
with 1 µl of Antarctic Phosphatase (1 U/µl) and 2 µl of the corresponding 10x AP buffer. After 
30 min of incubation at 37°C the samples were subjected to DNA purification using the „Gel 
Extraction Kit“. DNA concentrations of approximately 25 µg/ml were obtained. 
5 µl of the purified DNA samples were separated by gel electrophoresis (1.0% agarose gel) 
to check for contamination and yield. 
4.1.6.4 DNA ligation: 
For ligation, the digested vector DNA and the digested PCR product were combined in a 1:6 
ratio. A typical ligation mixture contained the following components:  
 
50-200 ng    vector DNA (25 µg/ml)   
 250 ng-1 µg   PCR product (25 µg/ml)   
1 U    T4 DNA ligase (20 U/µl) 
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1 mM  ATP  
 1 µl  10x ligation buffer 
bidest. H2O    ad 10 µl  
 
The mixture was incubated over night at 16°C. If an optimization of the reaction was neces-
sary, a higher amount of PCR product was used. Alternatively, the concentration of ligase 
and/or the incubation time was increased. 
Ligation was further processed as described in 4.1.2. 
4.1.6.5 Restriction control 
To verify successful cloning, plasmid DNA was subjected to enzymatic restriction. During 
this control assay the same restriction enzymes are used as for cloning; therefore the insert 
is cut out of the vector. 
The digestion mixtures contained the following components: 
 
 1 µg   plasmid DNA (100 µg/ml)   
 2 U  restriction enzyme 1 (20 U/µl)  
 2 U restriction enzyme 2 (20 U/µl) 
2 µl BSA solution (10 x Stock) if needed 
  2 µl 10x restriction buffer   
bidest. H2O               ad 20 µl 
 
The restriction mixtures were incubated at 37°C for 60 min and analyzed on a 1.5% agarose 
gel. Preparations of plasmid DNA with insert were saved while plasmids without inserts were 
discarded.  
4.1.6.6 DNA sequencing 
For final approval of positive clones the plasmid DNA was sequenced using the chain termi-
nation sequencing technique and standard vector-specific primers. This service was provided 
by the “Microchemistry Core Facility” at the MPI of Biochemistry in Martinsried. The obtained 
sequences were compared to corresponding references in order to exclude base pair dele-
tions and point mutations.  
4.1.6.7 Site directed mutagenesis by PCR 
Site directed mutagenesis allows inserting point mutations in plasmids. First a PCR with pri-
mers containing the mutation was performed (see section 3.1) 
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500 µM dNTP mix (stock: 25 mM) 
 100 nM           primer forward Sigma-Aldrich (St. Louis, MO, USA) 
 100 nM primer reverse  
 100 ng  plasmid DNA template  
 1 U  Phusion “High Fidelity” Taq polymerase  
    2mM  MgCl2 
     5 µl   5x GC buffer (NEB) 
 
The polymerase chain reaction was performed in a thermo cycler with the following time and 
temperature profile: 
 
step temperature duration purpose 
 
1 
 
98°C 
 
30 s 
 
initial denaturation of DNA 
2 98°C 30 s denaturation of DNA 
3 55°C 60 s annealing of primers 
4 72°C  8.5 min elongation 
5 72°C  10 min final elongation 
6 4°C hold protection from degradation 
 
Between step 2 and 4 a loop was programmed, which was repeated 18 times. 
 
After PCR the newly synthesized plasmids contain the mutation. The host plasmids, which 
originated from methylation competent bacteria needed to be digested. Digestion was per-
formed with the methylation-dependent restriction endonuclease DpnI. Every PCR product 
was treated with 1 µl DpnI for 1h at 37°C, followed by heat inactivation for 10 min at 80°C. 
Finally the mutated plasmids were transformed into competent E. coli and plated on LB agar 
as described in section 4.1.2 and incubated at 37°C overnight. The next day colonies were 
picked, the plasmids were isolated (section 4.1.3 and 4.1.4) and sequenced (section 4.1.6.6) 
18 repeats  
of step 2-4 
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4.2 Protein biochemical methods 
4.2.1 Expression and purification of proteins with a hexahistidin tag 
4.2.1.1 Induction of E. coli with IPTG 
Plasmid DNA encoding a specific hexahistidin tagged protein was transformed into the ex-
pression strain E. coli BL21 (section 3.4). 3 l of sterile LB medium, supplemented with the 
appropriate antibiotics, were inoculated with an overnight culture (maximal OD600: 0.1) and 
incubated at 37°C on a shaking platform. As soon as an optical density of 0.5 was reached, 
protein expression was induced by addition of 1.8 ml 1 M IPTG (final concentration: 600 µM). 
After 3 h of additional incubation, the bacteria were harvested by centrifugation in a Sigma 
centrifuge at 4400 x g and 4°C for 15 min.  
4.2.1.2 Cell lysis 
 
Lysis buffer: 50 mM Hepes; pH 8.0; 300 mM NaCl; 40 mM imidazole; 1 mM 
PMSF; 1 mg/ml lysozyme 
 
All further purification steps were carried out at 4°C or on ice. 
The bacteria pellet was resuspended in 50 ml lysis buffer and rotated for 30 minute at 4°C. 
Treatment with an ultrasound sonifier was performed to complete cell lysis (15 cycles:                
12 s ultrasound impulses, 18 s break; intensity 4 (output control 80%). To remove insoluble 
material, the lysate was centrifuged for 40 min at 4°C and 15000 x g in a Beckman centri-
fuge. 
4.2.1.3 Purification on Ni-NTA sepharose 
 
Washing buffer: 20 mM Hepes, pH 8.0; 300 mM NaCl; 40 mM imidazole; 5% glycerin 
(v/v) 
Elution buffer:  20 mM Hepes, pH 8.0; 20 mM NaCl; 300 mM imidazole;  
  5% glycerin (v/v) 
 
5 ml Ni-NTA resin were resuspended in 50 ml water and pelleted again by 5 min of centrifu-
gation at 700 x g. Washing was repeated twice with each 50 ml lysis buffer. 
The cleared lysate was added to the resin and incubated for 2 h with agitation at 4°C. After-
wards, the beads were pelleted by centrifugation (700 x g, 4°C), and the supernatant was 
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discarded. The resin was resuspended in 50 ml washing buffer, incubated shortly and pel-
leted by centrifugation. This washing step was repeated twice. 
Next, the resin was resuspended in 5 ml washing buffer and transferred into a 5-ml chroma-
tography column. As soon as the washing buffer had drained, 5 ml elution buffer were add-
ed. The elution was collected in 0.5 ml fractions and controlled for protein content by BCA 
assay (section 4.2.4.2). Clean elutions with the highest protein concentrations were pooled, 
aliquoted and stored at -80°C. For FKBP51, analysis of elution fractions revealed an insuffi-
cient purity of the preparation. Therefore additional purification steps were needed. Depend-
ent on the amount and concentration of FKBP51 needed, in our lab either ion-exchange 
chromatography followed by size-exclusion chromatography or affinity chromatography by a 
FLAG tag is used. 
4.2.1.4 Purification by anti-FLAG affinity resin 
 
TBS:                          50 mM Tris; 150 mM NaCl; pH 7.5  
Elution buffer:             100 µg/ml FLAG peptide in TBS 
 
FKBP51 used throughout this work was purified taking advantage of the C-terminally fused 
FLAG peptide. This peptide (sequence: DYKDDDDK) binds with high affinity to FLAG anti-
bodies which are covalently bound to a sepharose matrix. 
1 ml of resuspended “anti-FLAG immuno-affinity resin” was transferred to a 5-ml plastic col-
umn and washed with 10 ml TBS. Then the pooled protein-containing fractions of the Ni-
NTA purification were loaded onto the column (in a 1/10 dilution with TBS). After the flow 
through was completed, the resin material was washed with TBS until no protein could be 
detected any more in the washing buffer by BCA assay. By addition of elution buffer the 
FKBP51_FLAG protein was released from the resin and collected in different fractions. 
Once again, protein content was quantified by a BCA assay, and protein-containing fractions 
were pooled and stored at -80°C. 
4.2.1.5 Dialysis of purified proteins 
In case it was necessary proteins were dialyzed into the needed buffer overnight under gen-
tle stirring, using the Slide-A-Lyzer device. The next morning the buffer was changed and 
the procedure was repeated. 
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4.2.2 Expression of GST fusion proteins 
GST_Akt1 and GST_SGK fusion proteins (expressed and purified from HEK cells) were 
provided by Dr. Sonja Neimanis (University hospital, Frankfurt (Main)). 
4.2.3 Analysis of purified proteins by SDS gel electrophoresis 
4.2.3.1 Casting SDS gels 
SDS running buffer:  25 mM Tris/HCl, pH 8.3; 250 mM glycine; 0.1% (w/v) SDS 
SDS sample buffer 2x: 125 mM Tris/HCl; 10% (v/v) 2-mercaptoethanol;“Lämmli buffer” 
[272]: 4% (w/v) SDS; 0.004% (w/v) bromophenol Blue 
Resolving gel:  380 mM Tris/HCl, pH 8.8; 0.1% (w/v) sodium dodecylsulfate; 
  10-16% (w/v) acryl amid; 0.2 – 0.3% (w/v) bisacryl amid; 
  0.12% (v/v) TEMED; 0.06% (w/v) ammonium peroxydisulfate 
Stacking gel: 375 mM Tris/HCl, pH 6.8; 0.1% (w/v) sodium dodeclysulfate 
  5% (w/v) acryl amid; 0.2 – 0.3% (w/v) bisacryl amid 
 0.2% (v/v) TEMED; 0,06% (w/v) ammonium peroxydisulfate  
 
For two mini gels of the indicated acryl amid concentration, following components were 
combined: 
 
final concen-
tration 
acryl amid 
mix 
H2O 
bidest. 
TEMED 
1 M Tris, 
pH 8.8 
10%  (w/v) 
SDS 
10 % (w/v) 
APS 
10% 4.7 ml 3.9 ml 17 µl 5.4 ml 140 µl 85 µl 
12%  5.7 ml 3.0 ml 17 µl 5.4 ml 140 µl 85 µl 
16% 7.6 ml 1 ml 17 µl 5.4 ml 140 µl 85 µl 
Table 4.1: Components and necessary amounts for 2 “mini” SDS gels 
 
Ammonium peroxodisulfate and TEMED were added last because they induce radical for-
mation and start the polymerization. The gel solution was filled into a commercially available 
mini gel cassette and was covered carefully with water. After the polymerization was com-
pleted, water was removed, and the gel cassettes were filled with stacking gel solution. Fi-
nally, 12 or 15-well combs were inserted. 
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4.2.3.2 Preparation of samples and gel run 
 
Coomassie staining solution: 40% (v/v) ethanol, 10% (v/v) acetic acid, 0.01% (w/v)  
  coomassie brilliant blue  
 
Coomassie destaining solution:  40% (v/v) ethanol, 10% (v/v) acetic acid 
 
Samples of the protein-containing fractions were diluted in SDS sample buffer and incubat-
ed at 95°C for 5 min to achieve denaturation. The samples were then loaded into the gel 
wells and separated using a current of 25 mA in the “XCell SureLock Gel System” for ap-
proximately 60 min. Protein patterns were visualized by treatment with Coomassie staining 
solution for 30 min, followed by destaining in Coomassie destaining solution under mild agi-
tation.  
The gel was put on a sheet of blotting paper and was conserved using a gel dryer. Finally, it 
was digitalized on a flatbed scanner. 
Alternatively, the gel was subjected to immunoblotting procedure (section 4.3.7). 
4.2.4 Determination of protein concentration 
4.2.4.1 UV absorption 
Because of the presence of aromatic amino acids (tyrosine, phenylalanine, tryptophan) protein 
solutions display absorption of ultra-violet light. The maximum of absorption is usually at   280 
nm. The Law of Lambert-Beer provides a connection between protein concentration and its 
UV absorption value: 
 
A = ε*c*d A=absorption 
 ε=molar extinction coefficient [L mol-1 cm-1] 
 d=path length of the cuvette [1cm] 
  
The absorption coefficient of a protein can be deduced from its amino acid sequence as it 
depends mainly on the number of aromatic amino acids. The values for purified proteins can 
be found in the appendix. Values were calculated using Protein calculator v3.3. provided by 
Scripps Research institute (CA, USA) with the amino acid sequence as input. 
Determination of UV absorption was performed in a Beckman photometer. For calibration the 
quartz cuvette was filled with 100 µl of elution buffer, and a blank value was recorded. After-
wards, the protein samples were measured in the same manner. If necessary the samples 
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were diluted in elution buffer to give A280 values between 0.1 and 1.0. Protein concentration 
can be calculated using the formula   c = A / (ε*d), being d = 1 cm.  
4.2.4.2 BCA assay  
In order to determine protein concentrations, the colorimetry based bicinchoninic acid assay 
(BCA assay) was used routinely. Peptide bonds in proteins reduce Cu2+ ions from the cupric 
sulfate to Cu+ (a temperature dependent reaction). The amount of Cu2+ reduced is proportion-
al to the amount of protein present in the solution. Next, two molecules of bicinchoninic acid 
chelate with each Cu2+ ion, forming a purple-colored product, which strongly absorbs light at a 
wavelength of 562 nm. 
The assay was performed in transparent 96-well plates (flat bottom). Each well was filled with 
200 µl of BCA working solution as described by the manufacturer. For a reference array 10 µl 
BSA standard solutions from 2000 µg/ml–0 µg/ml were added and mixed thoroughly. The ac-
tual protein samples were diluted 1:10 or 1: 100 in water. 10 µl of the dilution were added to 
each well and mixed thoroughly. 
After 30 min of incubation at 37°C all wells were read out in a Tecan GENios Pro reader with 
standard settings:  
 Measurement mode: Absorbance, endpoint 
 Wavelength: 595 nm  
 Number of reads: 10 reads 
 3 s of orbital shaking before measurement. 
 
The optical density at 595 nm was plotted against the known protein concentration of the ref-
erences, and a trend line was fitted. Using the linear equation of this trend line in Excel, the 
concentrations of the protein samples could be determined taking the corresponding dilution 
factors into account.  
4.2.4.3 Determination of active FKBP protein by the Fluorescence 
polarization assay (FP assay) 
 
Assay buffer:      20 mM Hepes, pH 8; 0.01% (v/v) Triton X-100 
 
As determination of protein concentration by UV/VIS spectroscopy and colorimetric based 
methods includes misfolded proteins and protein contaminations, “active site titration” leads to 
the portion of active protein in a protein solution. Therefore the fluorescein coupled FKBP lig-
and CK97 (derivate of rapamycin, [264]) was titrated in different concentrations against FKBP 
protein. As free tracer molecules possess a smaller molecular weight it can tumble more easi-
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ly compared to tracer molecule bound to an FKBP. This restriction of tumbling leads to a 
weaker depolarization of polarized monochromatic light, which can be detected by measuring 
the emission intensities.  
 
 
 
Because one CK97 binds with nanomolar affinity (Kd=0.11+0.03 nM) to exact one FK1 do-
main of FKBP51, one can state a 1:1 ratio of CK97 tracer molecule binding to FKBPs [264]. 
By adding a known concentration of CK97 to proteins of a dilution series which contains a 
correctly folded FK1 domain, the concentration of the protein solution can be estimated.  
 
The assay was performed as following: In a 96-well low-binding Corning plate 16 wells in two 
rows were filled with each 50 µl of assay buffer. Another well contained 100 µl of a 20 µM dilu-
tion of the respective FKBP protein in assay buffer. From this well, 50 µl were transferred to 
the first well containing 50 µl of buffer and mixed well. Again, 50 µl were transferred to the 
next well. This transfer was repeated until the 1:1 dilution series of the protein was completed. 
The last well contained pure buffer. 
Afterwards 25 µl of these dilutions were pipetted into a 384-well low-binding plate before 25 µl 
of a CK97 dilution (dependent of the FKBP51 usually between 1-200nM final concentration) in 
assay buffer were added (double final concentration). After 30 min of incubation at room tem-
perature, a Tecan GENios Pro reader was used to determine fluorescence polarization val-
ues. The following settings were used:  
 
 Mode: Fluorescence Polarization, end point 
 Wavelengths: Excitation: 485 nm; Emission: 535 nm 
 Number of reads: 10; Integration time: 100 µs 
 T: 25°C 
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The depolarization (P) of linear polarized light was measured by the emission intensities (I) of 
parallel (par) and perpendicular (per) light in µsec range after excitation: 
 
P = (( I parallel – I perpendicular) / ( I parallel + I perpendicular))x100 
 
A plot of mP units against the protein concentration created a dose-response curve that could 
be analyzed by “Four-Parameter-logistic-curve” fitting in SigmaPlot. This analysis also re-
vealed EC50 values that represent a protein concentration at which half of the protein is bound 
to ligand. The formula is depicted as follows: 
 
 
 
 
The concentration of FKBPs was determined by either multiplication of the calculated EC50 
value with the concentration of 50% of the CK97 tracer molecule in nM or, which is exacter, 
by generation of several curves as exemplified in section 8.2 for FKBP52. 
Table 4.2 summarizes used FKBP proteins and their concentrations. Where indicated pro-
teins were purified and characterized by Christian Kozany*, Veronika Kupfer**, Andreas 
März# or Alexander Kirschner~. 
min  = minimum mP value 
max = maximum mP value 
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Protein concentration (µM) determined by 
FKBP12* 600 active site titration 
FKBP12.6# 100 active site titration 
FKBP13# 20 active site titration 
FKBP25# 20 active site titration 
FKBP51_FLAG  15.2  active site titration 
FKBP52_FLAG  116 active site titration 
Cyp40_FLAG*  60 active site titration 
FKBP51FK1** 
FKBP51FK1 (ITC experiments) 
583 
848 
active site titration 
active site titration 
FKBP51ΔFK1_FLAG  19.7 UV spectroscopy 
FKBP51TPR# 
(FKBP51ΔFK1FK2) 
- 
inactive, as determined 
by active site titration 
FKBP51FK1F67V** 150 active site titration 
FKBP51FK1F67I** 292 active site titration 
FKBP51FK1F67L** 176 active site titration 
FKBP51FK1F67M** 442 active site titration 
FKBP51FK1F67A** 189 active site titration 
FKBP51FK1F67G** 135 active site titration 
FKBP51FK1F67S** 136 active site titration 
FKBP51FK1F67T** 148.3 active site titration 
FKBP51FK1F130Y** 79 active site titration 
FKBP51FK1F122V** 302 active site titration 
FKBP51F67V_FLAG* 167 active site titration 
FKBP51FD67DV_FLAG* 
 
9.9 active site titration 
smFKBP51_FLAG~ 4.9 active site titration 
Table 4.2 Table of purified proteins used in different assays 
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4.2.5 Determination of protein-protein interactions in vitro 
4.2.5.1 GST pulldown assay 
Pulldown assays are in vitro methods used to determine a physical interaction between two or 
more proteins. For this procedure a tagged protein can be captured on resin material, forming 
a complex that allows simple fishing of interacting proteins. The assays were performed in 500 
µl final volume in NETN buffer + 1 mM DTT. 
 
NETN buffer :  20 mM Tris-HCl [pH 8.0], 100 mM NaCl, 1 mM EDTA, 0.5% igepal, 
50mM glycerophosphate and 10 mM NaF, 0.5 mM sodium dihydrogen 
orthovanadate 
 
20 µl resin solution (50%) were incubated and thereby saturated with 22 µM GST tagged pro-
tein. Afterwards the resin was washed 3 times with NETN buffer + 1mM DTT. 15.2 µM FKBP 
were added followed by 3 h of incubation at 4°C under rotation. 
Finally the resin was collected by centrifugation, washed 5 times with each 1 ml NETN buffer 
+ 1mM DTT and boiled in 20 µl SDS sample buffer. The supernatant was subjected to SDS 
gel electrophoresis and immunoblotting. 
4.2.5.2 FLAG pulldown assay 
In principle the FLAG pulldown assay was performed as the GST pulldown assay. 20 µl 
FLAG M2 magnetic column (50%) saturated with FKBP_FLAG proteins were incubated with 
50 nM Akt protein (active or inactive) in 500 µl NETN buffer + 1mM DTT at 4°C. The next day 
the resin was collected, washed 5 times with NETN buffer + 1mM DTT and eluted with FLAG 
peptide according to manufacturer’s instruction. The elution was subjected to SDS-PAGE 
and immunoblotting. 
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4.3 Cell biological methods and cell based assays 
4.3.1 Cell lines and growth conditions 
All human or mouse cell-lines were generally cultured at 37°C and 5% CO2 in a humidified 
incubator. Cell growth occurred as adherent culture in standard 125 cm2 cell culture bottles. 
For HeLa, HEK293T, SU.86.86 standard DMEM containing phenol red was supplemented 
with 10% fetal calf serum and 1% penicillin/streptomycin solution. For MEF, MEF51-/- and 
MEF52-/- cells standard DMEM without phenol red was supplemented as described.  As for 
SH-SY5Y cells DMEM+GLUTAMAX was supplemented with 10% FCS, 1% non-essential 
aminoacids and 50 µg/ml gentamycin. For selection of SH-SY5Y-shFKBP12 100 µg/ ml hy-
gromycin was added. 
4.3.2 Maintenance of cells 
When cell density at the bottom of the cell culture bottles was too high for further cell division, 
the cell culture was split.  
During this procedure, DMEM medium was removed, and the cells were washed with ap-
proximately 10 ml of PBS under mild agitation. After the PBS was removed, 500 µl of tryp-
sin/EDTA dilution was added and distributed evenly. Cells were incubated for 5 min at 37°C 
(or until all cells detached from the plastic surface), resuspended in 10 ml DMEM medium 
and singularized by pipetting up and down. To get rid of residual trypsin, the suspension was 
centrifuged for 5 min at 1000 g, and the cell pellet was resuspended in fresh supplemented 
DMEM. The cell suspension was then distributed into several bottles, culture dishes or 6-well 
plates. Finally, the original volume was re-established by filling up with supplemented DMEM.  
4.3.3 Cell transfection 
4.3.3.1 Transfection with Lipofectamine 2000 reagent 
For transient protein expression in eukaryotic cells, lipofection is widely used as a convenient 
method to insert a plasmid. An advantage compared to transfection with Calcium phosphate 
is the higher transfection efficiency. 
Transfections were performed as recommended by the manufacturer. Most transfections 
were performed in a 6-well plate format. Cells were transfected as soon as they reached 80 
% confluency. Plasmid DNA and Lipofectamine 2000 for 1 well were prepared as following: 
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2.5 µg plasmid DNA (Midi-Prep or Mega Prep) in 250 µl DMEM medium 
10 µl Lipofectamine 2000 in 250 µl DMEM medium 
 
After 5 min of incubation at room temperature, the two components were combined and 
mixed thoroughly. During the following 20 min of incubation time, formation of DNA lipid vesi-
cles occurred. 
The cells were prepared for transfection by washing them with PBS and supplying them with 
7 ml DMEM/ 10 % FCS. 500 µl of the transfection mixture were added drop wise and careful-
ly to the cells. The dishes were swayed mildly and incubated at 37°C and 5% CO2 in the in-
cubator. After one day the medium was changed and the cells were cultivated for another 24 
h. Thereafter the cells were harvested or treated as indicated. 
4.3.3.2 Transfection with Lipofectamine LTX reagent 
For transfection of SH-SY5Y-shFKBP12 cells with pcDNA3_FLAG_FKBP12_mut_siRNA 
Lipofectamine LTX was used due to its lower toxicity compared to Lipofectamine 2000. By 
using Lipofectamine LTX the Plasmid/Lipofectamine complex can incubate for a longer time. 
Medium was not changed for 48 h which lead to higher transfection efficiency. This experi-
ment was performed in a 96-well plate format. For each well the following amounts were 
used: 
 
0.1 µg plasmid DNA (Midi-Prep oder Mega Prep) and 0.1 µl PLUS reagent in 5 µl Opti-MEM  
0.5 µl Lipofectamine 2000                                                                                in 5 µl Opti-MEM 
 
After 10 min of incubation time the solutions were mixed and incubated for another 30 min. 
Finally the mixture was added to the cells supplied with 100 µl DMEM/ 10%FCS. 
4.3.3.3 Transfection using calcium phosphate Ca3(PO4)2 
2xHBS buffer:                0.1 M Hepes, 0.56 M NaCl, 3 mM Na2HPO4, pH 7.0 
 
This is a cheap alternative to transfection with commercially available transfection reagents. 
However one has to be aware that the efficiency is less. Density of the cells should be 60-
70%. For transfection of a 10 cm dish in an reaction tube 20-25 µg plasmid DNA and 74 µl 
sterile 2M CaCl2 solution were filled up to 600 µl total volume with sterile water. While this so-
lution was gently mixed, 600 µl of 2 x HBS were added drop wise. Immediately after, the 
whole mixture was given directly and drop wise to the cells. After an incubation of 24 h at 
37°C and 5% CO2 in an incubator, the medium was removed. The cells were washed with 
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PBS, supplied with DMEM/10% FCS and incubated for another 24 h. Then cells were har-
vested or used in other assays. 
4.3.4 Starvation, stimulation and treatment of cells 
In order to investigate the influence of stimulation of Akt/mTOR pathway by growth factors 
transfected or untreated cells were starved. For this purpose, normal medium was removed, 
cells were washed once with PBS and fed with starvation medium (DMEM with 1% antibiotics) 
for at least 16 h. Afterwards, cells were kept in DMEM with 10% FCS and/or 100nM insulin. 
Simultaneously, compounds were added to the wells when indicated. After the indicated 
amount of incubation time at 37°C and 5% CO2, the cells were washed twice with PBS and 
harvested. As starvation did not influence the FKBP/Akt interaction cells were not starved if 
not otherwise stated but only supplemented with 10% FCS for stimulation. 
4.3.5 Lysis of eukaryotic cells 
NETN Lysis buffer: 20 mM Tris-HCl, pH 8.0; 100 mM NaCl; 1 mM EDTA; 50mM glycerol 
phosphate; 10 mM NaF; 0.5 mM sodium dihydrogen orthovanadat; 
0.5% igepal; 1 % (v/v) protease inhibitor cocktail;  
1 mM PMSF  
and 1mM DTT, always freshly added 
 
Desoxycholate buffer: 20 mM Tris-HCl, pH 8.0; 100 mM NaCl; 1 mM EDTA; 50mM glycerol 
phosphate; 10 mM NaF; 0.5 mM sodium dihydrogen orthovanadat; 
1% (w/v) sodium desoxycholate; 1% (v/v) protease inhibitor cocktail; 
1 mM PMSF  
 
In order to harvest transfected cells, the plate was put on ice and washed three times with 
ice-cold PBS. All liquid was drained as thoroughly as possible before 60 µl of lysis buffer 
were added. The cells were removed from the surface using a cell scraper and the suspen-
sion was transferred to a pre-cooled reaction tube. This lysis mixture was then incubated for 
20 min at 4°C with vigorous shaking (1200 rpm) before it was cleared by 20 min of centrifu-
gation at 13000 g and 4°C in a tabletop centrifuge. The supernatant was transferred to an-
other tube and analyzed for total protein concentration by BCA assay. 
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4.3.6 Co-Immunoprecipitation (Co-IP) with FLAG/HA affinity resin 
IP elution buffer:  150 µg/ml FLAG peptide in TBS 
    100 µg/ml HA in TBS 
 
Co-Immunoprecipitation is a method to investigate physical interaction of proteins. In contrast 
to pulldown assays this interaction can occur directly as well as mediated by a part of a het-
ero-complex. Anti-FLAG/HA affinity resin contains the corresponding antibody covalently 
linked to the resin material. Tagged proteins can be captured easily from lysates. As the 
binding does not depend on quality or quantity of a primary antibody, yields are optimized, 
and handling is much easier. To prepare the material for use, the affinity resin was washed 
two times with TBS. A third washing step was used for equilibration with NETN buffer + 1 mM 
DTT or desoxycholate buffer. 1 mg of total protein in cell lysate were combined with 25 µl of 
50% resin suspension, filled up to a volume of 500 µl and incubated for at least 2 h at 4°C 
under mild agitation. Afterwards the supernatant was removed, the pelleted resin was 
washed carefully up to 6 times with each 1 ml lysis buffer. For elution of bound proteins, the 
resin was resuspended in 30 µl FLAG/HA buffer and incubated for 10 min at 4°C under agita-
tion. The beads were collected by the magnet (Flag beads) or the mixture was shortly centri-
fuged to pellet the beads. The supernatant was supplemented with an equal volume of 
2xSDS sample buffer and incubated at 95°C for 5 min. 20 µl of this mixture were separated 
on a SDS gel. 
4.3.7 Immunoblotting 
Blotting buffer:     20 mM Tris; 150 mM glycine; 0.02% (w/v) SDS; 20% (v/v) methanol  
Ponceau S:  0.5% (w/v) Ponceau S; 3% (v/v) acetic acid  
TBS-T:  TBS; 0.05% (v/v) Tween 20  
5% milk powder:  TBS-T; 5% (w/v) skimmed milk powder  
10% milk powder:  TBS-T; 10% (w/v) skimmed milk powder  
Primary antibody:  2 µg antibody in 2 ml 5% milk powder (1:1000) 
Secondary antibody:  1 µg antibody in 5 ml 10% milk powder (1:5000) 
ECL1:  100 mM Tris/HCl, pH 8.5;  440 mg/l luminol,  
 150 mg/l p-coumaric acid 
ECL2:  100 mM Tris/HCl, pH 8.5; 30% (v/v) H2O2  
 
or commercial ECL solutions (Millipore) 
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The immunoblotting procedure was performed according to recommendations of Invitrogen: 
After protein separation on a SDS gel (section 4.2.3.2) the proteins were transferred to the 
nitrocellulose membrane Protran BA 83 in the blotting chamber “XCell II Blot Module“. The 
chamber was filled with blotting buffer before protein transfer was started by applying a cur-
rent of 400 mA for 60-70 min. 
Afterwards, the membrane was stained in Ponceau S solution for 2 min and then destained 
in water to an appropriate degree. Successful blotting was confirmed by complete transfer of 
all pre-stained molecular marker bands. Well positions were marked before the membrane 
was destained completely in distilled water. 
Membranes were blocked in 5% skimmed milk powder solution for 30 min at room tempera-
ture. After a short washing step with TBS-T, the membrane was kept overnight at 4°C with 
mild agitation in a dilution of the primary antibody. Membranes were washed three times for 5 
min with large volumes of TBS-T. Next, the membrane was incubated in a dilution of the 
secondary antibody for 60 min at room temperature. Finally the blots were washed again (3 
x5 min) with TBS-T. 
The luminescence reaction was started by combining 2 ml ECL1 and 2 ml ECL2, and adding 
the mixture immediately to the membrane. After 1 minute of incubation the blot was devel-
oped with the ChemiDoc MP developing machine. Pictures were taken and the optimal ex-
posure time was saved and analyzed by ImageLab 4.0. Some of the Western blots were de-
veloped using medical X-ray films. 
4.3.8 Cell viability assay 
Cell viability was assessed using the CellTiter-Fluor Cell Viability assay from Promega ac-
cording to manufacturer’s protocol. Briefly, cells were plated into a 96-well plate in Dulbec-
co’s Modified Eagle Medium without phenol red and treated for 48-72 h with the in each sec-
tion indicated compounds. Thereafter, CellTiter-Fluor reagent was added and cells were in-
cubated at 37°C for 30 min. Fluorescence was measured at an excitation of 370 nm and an 
emission of 520 nm using a Tecan GENios Pro reader. DMSO treated cells served as control 
and were correlated with treated cells. 
4.3.9 Cell based phosphorylation assays for Akt and mTOR 
Cells were plated one day before the phosphorylation assay was performed. To prevent cell 
loss during the assay procedure, plates were coated with Poly-D-Lysine (10 µg/cm2) for 1h 
Thereafter, the Poly-D-Lysine was removed and the plate was washed with sterile water. The 
cells were plated in 96-well plates in DMEM containing 10%FCS and cultivated overnight. 
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Phosphorylation at Akt(S473), Akt(T308) and mTOR(S2448) was assessed using a homoge-
neous time-resolved fluorescence assay (Cisbio, Codolet, France) according to the manufac-
turer’s recommendations. Briefly, cells were incubated with 10 µM FKBP ligand or 100 nM 
torin-1 for 60 min. Cells were lysed and the lysates were transferred to a white 384-well 
plate. After addition of d2-labelled anti-Akt or anti-mTOR antibody and K-labeled anti-
phospho-Akt or anti-phospho-mTOR antibody, the mixtures were incubated at room tempera-
ture for 4 h or overnight. FRET efficiency was determined by the emission ratios 
665nm/620nm after excitation at 320 nm using a Tecan GENios Pro reader. The data were 
normalized to the results for Torin-1 (0 %) and DMSO (100%). 
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4.4 Physicochemical methods 
4.4.1 Isothermal Titration Calorimetry (ITC) 
 
Bacterially expressed, affinity purified human HisFKBP51FK1 (aa 1-140) (see section 4.2.1) 
was dialyzed against ITC buffer (20 mM HEPES pH= 8, 150 mM NaCl, 5% DMSO). The ac-
tivity was confirmed by active site titration in an FP assay  (see section 4.2.4.3) The pH of 
protein was determined and ligand solutions were degassed and matched within 0.02 pH 
units. All experiments were conducted at 20°C. Compound YW 703 (1 mM) was measured 
by injection into the measurement cell containing the protein (89 μM). 
Due to the limiting solubility compounds YW644 and YW703 were measured in a reverse 
setup injecting the protein (0.5 mM and 0.16 mM, respectively) into a solution of the ligand 
(40 μM for YW644, 15 μM for YW691). Heats of dilution were measured in blank titrations 
and subtracted from the binding heat values. ORIGIN software (version 7.0 Microcal) was 
used for data collection and analysis.            
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5. Results 
5.1 Interactions with FKBPs 
5.1.1 The FKBP51/Akt/PHLPP complex in HEK293T cells 
To confirm the findings by Pei et al. [75] HEK293T cells were co-transfected with 
FKBP51_FLAG and HA_Akt1. After controlling the input a co-immunoprecipitation was per-
formed. Anti-FLAG M2 beads were used as bait as well as anti-HA agarose. Additionally two 
buffer systems were used to reduce the background signal: 
 
 
     
 
 
 
 
A clear interaction of FKBP51 and Akt1 (lane 1 and 5) could be detected independent of the 
used detergents. The immunoprecipitation was possible with both, the HA tagged Akt1 and 
the FLAG tagged FKBP51 as bait. In order to control for unspecific binding, FLAG or HA 
beads were incubated with lysates containing the prey but not the bait protein.  
Since the obtained co-immunoprecipitation signal was stronger with NETN buffer this buffer 
was used for further experiments, if not otherwise stated. 
As members of the FKBP family are highly homologous to each other we asked if other 
FKBPs are able to bind to Akt1. Therefore, HEK293T cells were co-transfected with different 
FKBP subtypes fused to an N-terminal FLAG tag and HA_Akt1. 
Figure 5.1: FKBP51 and Akt1 can be co-immunoprecipitated.  
HEK293T were transfected with HA_Akt1 and the FKBP51_FLAG. After two days the lysates were co-immunoprecipitated (Co-IP)
and analyzed by Western blotting. 
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Surprisingly, Akt1 also co-immunoprecipitated with FKBP52, FKBP25 and even with the 
smaller FKBP12 and 12.6, which consist only of the FK506-binding domain [22, 43]. 
 
According to Pei et al. [75] the phosphatase PHLPP can also be found in complex with 
FKBP51, which could be generally confirmed. Figure 5.3A shows a clear co-
immunoprecipitation signal when HA_PHLPP1 and FKBP51_FLAG are overexpressed. The 
amount of co-immunoprecipitated PHLPP2 (Figure 5.3B) is not as high, nevertheless the 
signal is still slightly above background intensity. This interaction was repeatedly observed as 
can be seen in Figure 5.5, lane 1 and 2.  
 
      A                                   B 
 
Figure 5.3: FKBP51 can be co-immunoprecipitated with PHLPP1 and PHLPP2 
HEK293T were transfected with HA-tagged PHLPP and FLAG tagged FKBP subtypes. After two days the lysates were co-
immunoprecipitated (Co-IP) and analyzed by Western blotting. 
Figure 5.2: FKBP subtypes can be co-immunoprecipitated with Akt1 
HEK293T were transfected with HA_Akt1 and FLAG tagged FKBP subtypes. After two days the cells were lysed in NETN buffer, co-
immunoprecipitated (Co-IP) and analyzed by Western blotting. 
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The detection level for endogenous Akt was too low, therefore, HEK293T cells were trans-
fected with PHLPP1, Akt2 and FKBP51 and FLAG immunoprecipitation was performed 
(Figure 5.4). PHLPP1 is the specific phosphatase of Akt2 [171]. By immunoprecipitating 
FKBP51_FLAG from the lysate we could also isolate the Akt2/PHLPP1 complex. However 
the overexpression of Akt does not seem to influence Akt2/PHLPP1 interaction (compare 
lanes 1 and 2 with lanes 5 and 6) as similar amounts of PHLPP are co-immunoprecipitated. 
 
 
Figure 5.4: FKBP51, Akt2 and PHLPP1 form a complex 
HEK293T were transfected with HA-tagged PHLPP1, FLAG tagged FKBP51 and HA tagged Akt2. After two days, the lysates 
(NETN-buffer) were FLAG co-immunoprecipitated (FLAG-Co-IP) and analyzed by Western blotting.  
 
 
To explore the potential influence of regulatory regions of PHLPP on the FKBP/PHLPP inter-
action, HEK293T cells were transfected with PHLPP2, PHLPP1 or the deletion mutants 
PHLPP1ΔN (aa127-aa1205) and PHLPP1ΔC (aa1-aa1202) [170]. Western blot analysis re-
vealed that PHLPP1 and all modified PHLPP2 proteins can co-immunoprecipitate with 
FKBP51. At least for FKBP51/PHLPP1 interaction neither the N-terminus nor the very C-
terminus containing a PDZ binding motif are important. 
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Figure 5.5: The PDZ binding motif of PHLPP1 and the N terminus are not important for FKBP51 binding 
HEK293T were transfected with FLAG-tagged FKBP51, HA-tagged PHLPP1, HA-tagged PHLPP2 or two PHLPP1 mutants 
missing either the N-terminus (aa 1-126) or the three last aminoacids (aa 1203- aa 1205). After two days the lysates (NETN 
buffer) were FLAG co-immunoprecipitated (FLAG-Co-IP) and analyzed by Western blotting. 
5.1.2 The interaction between Akt and FKBP is direct 
Direct protein-protein interactions can be tested by pulldown assays. To do so, the proteins 
were incubated together for a certain amount of time in an appropriate assay buffer. After-
wards the proteins are pulled from the solution using antibody-coupled beads. In addition to 
the interaction partner, which binds directly to the antibody coupled beads (for example via a 
FLAG tag) one can find binding partners of the precipitated protein. After elution potential 
interaction partners can be analyzed on a SDS gel. To analyze the interaction of FKBP51 
with Akt1, FKBP51 was purified as described (section 4.2.1.). Protein concentration was 15.2 
µM as determined by active site titration. 
 
                  
 
Figure 5.6: Recombinantly expressed FKBP51 is sufficiently pure  
Each step was loaded to a SDS protein gel. After separation the gel was stained with Coomassie Brilliant Blue. 1: lysed bacteria 
before induction with IPTG, 2: lysed bacteria after IPTG induction, 3: protein solution loaded to the nickel column, 4: flowthrough 
of the nickel column, M: protein marker (in kDa), 5: load of the FLAG column (1:10 diluted), 6: flowthrough of the FLAG column, 
7: elution after the FLAG column=purified protein. 
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As interaction partner commercially available inactive Akt protein was used.  
For estimation of the quantity of Akt protein, which would still be detectable different amounts 
of protein were loaded to a SDS gel and a Western blot analysis was performed. Dependent 
on exposure time 0.4 ng of Akt protein are still detectable, if exposed long enough. 
With this result the appropriate amounts of protein needed for a pulldown assay were deter-
mined (Figure 5.7). 
 
 
 
Figure 5.7: With 30 min exposure time 0.4 ng of inactive Akt are still detectable by western blot analysis  
0.2-100 ng Akt (inactive) were loaded to a SDS gel. After separation the gel was blotted and the bands were analyzed. 
 
 
Finally, a direct interaction of Akt/FKBP51 could be shown by a pulldown assay (Figure 5.8). 
Inactive Akt1 and FKBP51 can be found in complex (lane 2). To control for unspecific signals 
controls were prepared, which miss either of the two proteins. The most critical control is the 
one for unspecific binding to the beads (lane one). Intense washing procedures were neces-
sary to reduce background binding. 
 
  
 
Figure 5.8: In FLAG pulldown assays inactive Ak1 and FKBP51 form a complex 
Purified FLAG-tagged FKBP51 and purified inactive Akt were mixed, subjected to a FLAG pulldown and analyzed by Western 
blotting.  
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5.1.3 Numerous FKBPs can bind directly to Akt 
For further confirmation and to test if other closely related FKBP family members would also 
form a complex with Akt1 a reversed pulldown assay was performed, using purified 
GST_Akt1S473D [267], a GST-tagged constitutively active Akt mutant, as well as purified FKBP 
protein. FKBPs were purified using a protocol established in our lab [264]. Because FKBP13 
is located in the lumen of the endoplasmatic reticulum [27] and thus unable to interact with 
cytoplasmic Akt, we didn’t include it in further analysis. 
 
 
Figure 5.9: Recombinantly expressed FKBPs and a constitutively active Akt1 mutant are pure  
Proteins were loaded to SDS protein gels, separated and the gels were stained with coomassie blue. A FKBP proteins were 
pure and active, as tested in FP assays B GST_AktS473D full length and a mutant missing the PH domain, which attaches Akt to 
the cell membrane for activation, were purified for further assays (courtesy of S. Neimanis) 
 
 
Afterwards the pull down experiment was performed. Indeed all tested FKBPs bound to 
Akt1S473D -loaded beads (Figure 5.10A) but not to empty beads or beads loaded with GST 
alone (B). No interaction was observed with purified Cyp40 [265], a closely related immuno-
philin. 
 
 
 
 
 
 
 
 
A B
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Figure 5.10: Akt1 binds to several FKBPs and this interaction is direct 
A Purified FKBPs and purified GST-tagged Akt1S473D (mimicking an active conformation) were subjected to a GST-pulldown 
followed by Western blotting. Cyclophilin40, which also harbors a TPR domain, but no FK domains, was used as a negative 
control (Ld = load (0,8%), E = elution (100%)). B To test for unspecific GST binding to FKBP51_FLAG a pulldown assay was 
performed: purified GST or GST_Akt1S473D were incubated with purified FKBP51_FLAG. 
 
5.1.4 Squirrel monkey FKBP binds stronger to Akt compared to human 
FKBP51 
Over 30 years ago high circulating cortisol levels were described in squirrel monkeys (Saimiri 
boliviensis), leading to the concept of cortisol resistance of the glucocorticoid receptor (GR) 
in New World primates [51, 52]. Glucocorticoid receptor binding is generally negatively regu-
lated by FKBP51 (compare section 1.1.2), which is overexpressed in Saimiri boliviensis [48, 
55]. Human FKBP51 (hsFKBP51) and squirrel monkey FKBP51 (smFKBP51) are highly ho-
mologous (94% protein sequence homology) but individual amino acids differences that con-
tribute to the altered effect on glucocorticoid receptor (GR) inhibition could not be identified 
[55]. 
Having the importance of smFKBP51 in mind pulldown experiments with smFKBP51 and 
hmFKBP51 were performed. 
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A coomassie stained SDS gel of the purified protein can be seen in Figure 5.14. Figure 5.11. 
shows the interaction between hsFKBP51 and GST_AktS473D_ΔPH and smFKBP51 and 
GST_AktS473D_ΔPH. 
 
 
 
             
 
 
 
Figure 5.11: The interaction between smFKBP51 and Akt is more pronounced than the interaction between hsFKBP51 
and Akt 
GST_Akt1S473D missing the PH domain was coupled to Glutathione-beads and the beads were incubated with either smFKBP51 
or hsFKBP51 in duplicates. Elutions were loaded to SDS gels and Western blot analysis was performed. 
 
smFKBP51 leads to a stronger signal in Western blot analysis indicating a tighter or less 
transient interaction. 
 
5.1.5 FK1 domain mutations do not influence Akt/FKBP interaction in pull-
down assays 
 
The FK1 domain of FKBP51 was shown to be the crucial domains for the inhibitory activity 
on GR, while the PPIase activity was dispensable [55]. To investigate the role of the FK1 
domain or the PPIase activity of FKBP51 on the interaction with Akt we used a panel of iso-
lated FKBP51FK1 mutants and performed pulldown assays with GST_Akt1S473D. The func-
tionality of the FKBP51 proteins (with exception of the FKBP51 ΔFK1 construct) was verified 
by active site titration for the FK506-binding pocket ([264] and section 4.2.4).  
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Figure 5.12: FKBP51FK1 mutants can interact with GST_Akt1S473D 
A Three aminoacids of the endogenous FKBP51FK1 domain (ochre) were mutated (red) to  
smaller aminoacids to enlarge the binding groove or to introduce potentially beneficial H- 
donors (modified after C. Kozany). 
B GSH beads loaded with purified GST-tagged Akt1S473D were incubated with the indicated FLAG-tagged FKBP51FK1 con-
structs for 3 h. After elution a Western blot analysis was performed and detected with an antibody which detects the FK1 do-
main of FKBP51 (αFFI). The independency of the PPIase activity is highlighted (red box).  
 
 
None of the tested FKBP51FK1 mutants showed an altered binding mode to GST_Akt1S473D. 
Importantly the FKBP51FK1 domain alone is able to bind Akt1. 
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5.1.6 Multiple domains of FKBP51 contribute to the binding to Akt1 
We next aimed to further map the domains of FKBP51 that interact with Akt. Figure 5.13. 
shows the different modifications applied to FKBP51. 
 
 
Figure 5.13: Left: Overview of the constructs used to map the FKBP51/Akt interaction.  
Right: Summary of the Akt interactions of FKBP domains investigated in HEK293T cells by immunoprecipitation or by pulldown 
with purified proteins (WT= wildtype, n.d. = not determined). 
 
 
To test the capacity of multiple domains of FKBP51 to interact with Akt we continued with 
pulldown assays using purified proteins. A coomassie stained gel depicting purified FKBP51 
FK1 domains can be seen in Figure 5.12. Figure 5.14 shows additional constructs tested in 
pulldown assays (except FKBP51TPR which is also named FKBP51ΔFK1FK2). The func-
tionality of the FKBP51 proteins (with exception of the FKBP51ΔFK1 construct) was verified 
by active site titration for the FK506-binding pocket ([264] and section 4.2.4.3). 
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Figure 5.14: Recombinantly expressed hsFKBP51, hsFKBP51 containing various mutations and smFKBP51 
Proteins were loaded to SDS protein gels, separated and the gels were stained with coomassie blue.  
 
 
Again, all FKBP51 constructs were retained by Akt1 to a similar extent. Here, especially the 
interaction of GST_Akt1S473D with an FKBP51 mutant lacking the FK1 domain should be 
pointed out. 
                               
Figure 5.15: Pulldown assays demonstrate the contribution of different protein structures to FKBP51/Akt interaction 
 
A GSH beads loaded with purified GST-tagged Akt1S473D were incubated with the indicated purified FLAG-tagged FKBP51 
mutants for 3 h. After elution a Western blot analysis was performed. 
 
 
For verification of these results under more physiological conditions experiments with 
HEK293Tcells were performed. First, mutants with truncated FK506-binding domain (ΔFK1) 
and the FK1-like domain (ΔFK1FK2) were tested. Both deletion constructs co-
immunoprecipitated with overexpressed Akt1 (Figure 5.16A). We also co-expressed Akt1 
with two FKBP51 mutants where the PPIase activity of the FK1 domain or the Hsp90-binding 
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capacity of the TPR domain was abolished. Furthermore a construct lacking the putative C-
terminal calmodulin binding site and the isolated FK506-binding domain (FK1) were tested.  
 
 
 
Figure 5.16: In HEK293T cells multiple domains of FKBP51 contribute to FKBP51/Akt1 interaction 
HEK293T cells were transfected with the indicated constructs. A+B After 48 h lysates were prepared and HA- or FLAG-
immunoprecipitation was performed, followed by Western blotting. 
 
Again, in all cases, Akt1 co-immunoprecipitated with the FKBP51 constructs, although with 
slightly reduced efficiency for the mutants (Figure 5.16B). 
 
 
 
 
 
A  
B 
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5.1.7 FKBP51 can bind to multiple AGC kinases 
It was shown that FKBP51 binds to the highly homologous proteins Akt1 and Akt2 but not to 
Akt3 [75]. Binding to Akt2 could be confirmed after FLAG co-immunoprecipitation from 
HA_Akt1 and FKBP51_FLAG co-transfected HEK293T cells. Cells only transfected with HA-
Akt2 but not with FKBP51_FLAG was used to rule out unspecific binding to the beads. 
 
 
Figure 5.17: FKBP51 can be co-immunoprecipitated in HEK293T cells with overexpressed Akt2  
HEK293T cells were co-transfected with FKBP51_FLAG and HA_Akt2. Cells were harvested after 48 h of growth, the input was 
controlled and co-immunoprecipitation was applied. Finally, the elutions were loaded on a SDS gel, blotted and incubated with 
the indicated antibodies. 
 
 
Akt1 and Akt2 and Akt3 belong to the kinase subgroup containing PKA, PKG and PKC (AGC 
kinases). As depicted in the alignment of representative examples of this kinase group in 
Figure 5.18 the kinase motif (Akt1: aa149-aa408 according to human protein reference data-
base) is highly conserved. The protein sequence identity of the kinase domains of the Akt 
homologs SGK1, p70S6K and PKA-Cbeta calculated by PRALINE [269] was 57%. 
Results by A. März [14] showing p70S6K to co-immunoprecipitate with FKBP51 implicated to 
investigate a possible glucocorticoid kinase (SGK) /FKBP51 complex. Therefore HEK293T 
cells were co-transfected with GST_ΔN SGK_wildtype or GST_ΔN SGKS422D, which harbors 
an activating S422D mutation and FKBP51_FLAG. 
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Figure 5.18: The kinase domain of AGC kinases is highly conserved 
Sequence alignment of the AGC kinases Akt1, Akt2, Akt3, SGK1, p70S6K, PKA-Cbeta: aminoacid sequences were aligned using 
Multialin interface [268]. 
Secondary-structure elements (PDB code: 4EKK) of the kinase domain and numbering for Akt1 are indicated above the se-
quences. Similar residues are shown in red and identical residues are shown in bold lettering on a red background. Frames 
indicate homologous regions. The consensus sequence is shown at the bottom (Endscript 1.1). 
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Figure 5.19 shows that both, wildtype SGK1 and SGK1S422D, clearly co-immunoprecipitate 
with FKBP51 to a similar extent as GST-tagged Akt1. The detected interaction is clearly 
higher than the background seen in the control lanes (lanes 7-12).  
 
 
 
 
Figure 5.19: In HEK293T cells SGK1 and FKBP51 can be found in complex 
HEK293T cells were co-transfected with either GST_ΔN SGK_wildtype or GST_ΔN SGKS422D, which harbors an activating 
S422D mutation and FKBP51_FLAG or the SGK constructs alone. After 48 h the cells were lysed. FLAG beads were used to 
fish for FKBP51. By analyzing the co-immunoprecipitated proteins GST_ΔN SGK or GST_ΔN SGKS422D can be clearly detected. 
 
5.1.8 Influence of the PH domain of Akt and its phosphorylation status on the 
interaction with FKBP51 
 
As wildtype SGK and putative active SGK were found to co-immunoprecipitate with FKBP51 
to the same extend we focused on activation status of Akt. Therefore, pull-down assays with 
full length Akt and with an Akt construct lacking the PH domain were performed. Unspecific 
binding was controlled by incubating GST tagged Akt constructs with empty beads (Figure 
5.20). 
 
 
 
Figure 5.20: For Akt1/FKBP51 interaction the PH domain is not obligatory 
Purified GST-tagged active Akt or a mutant, lacking the PH domain, was incubated with purified FLAG-tagged FKBP51. Lane  
4-6 served as controls. After 3 h, the interaction was tested by GST pulldown and Western blotting. 
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HEK293T cells transfected with GST_Akt1S473D_ΔPH and FKBP51K352A/R356A (TPR_mut) were 
analyzed for the influence of the PH domain. Again, no importance of the PH domain on 
Akt1/FKBP interaction was observed. 
 
 
 
Figure 5.21: In HEK293T cells the PH domain is not mandatory necessary for FKBP51/Akt interaction. 
HEK293T cells were co-transfected with either GST_Akt1 or GST_Akt1_ΔPH and FKBP51TPR_mut (prevents interaction with 
Hsp90). After 48 h the cells were lysed. FLAG beads were used to immunoprecipitate FKBP51. 
 
 
Both constructs interacted identically with FKBP51 indicating that the PH domain is not nec-
essary (lane 1 and 2 and lane 3 and 4). This is consistent with the observed S6K/Akt and 
SGK/Akt interaction, two kinases which are lacking the PH domain. The conformation and 
activity of Akt1 is regulated by phosphorylation at T308 and S473. To investigate the influ-
ence of these important sites immunoprecipitation assays with HEK273T cells co-expressing 
FKBP51 (containing a TPR-mutation to exclude confounding influences of Hsp90) were im-
munoprecipitated together with Akt1 containing a series of phosphorylation-resistant (ala-
nine) or Phospho-mimetic (aspartate) substitutions at T308 and/or S473. In addition, a mu-
tant, where threonine in position 450 (turn motif) was substituted by alanine, was included. 
This mimics a missing phosphorylation of the turn motif which is necessary for Akt stability 
[273]. 
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Figure 5.22: Phosphorylation status is not important for the Akt1/FKBP51 interaction – Mutational analysis of the influ-
ence of phosphorylation sites on FKBP51/Akt interaction 
 
HEK293T cells were transfected with the indicated HA-tagged Akt1 phosphorylation site mutants (alanine mimics the phosphor-
ylation resistant state and aspartate the phosphorylated state) with or without co-transfected FLAG-tagged FKBP51K352A/R356A 
(TPR_mut). After 2 days cells were collected, lysed, immunoprecipitated and analyzed by Western blotting. A Investigation of 
position T308 within the activation loop B Investigation of position S473 within the hydrophobic motif (duplicates were analyzed) 
C Analysis of the influence of pT450 (turn motif)  
 
 
All tested Akt constructs co-immunoprecipitated specifically with FKBP51 but not with the 
mock-transfected controls. The phosphorylation status of T308 in the activation loop of Akt 
and T450 within the turn motif was not important for the interaction with FKBP51 under these 
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cellular conditions whereas the phosphor-resistant mutation S473A (Figure 5.22B) slightly 
increased binding of FKBP51.  
Next the Akt activation status was controlled by stimulating or starving the cells or by inhibi-
tion of the PI3K pathway using wortmannin (Figure 5.23.). 
As expected starvation (lane 2) and wortmannin treatment (lane 4) reduced phosphorylation 
of Akt at S473 and correlated with a slightly reduced binding to FKBP51. The underlying rea-
sons for the discrepancy to the results observed with the S473A mutant remain to be estab-
lished. Contrary to the findings by Pei et al. [75], we observed an increase –not a reduction– 
in Akt S473 phosphorylation upon co-expression of FKBP51. 
 
                         
Figure 5.23: Phosphorylation status is not important for the Akt1/FKBP51 interaction – Pharmacological analysis of the 
influence of import phosphorylation sites on FKBP51/Akt interaction 
 
HEK293T cells were starved for 16 h, stimulated with FCS for 45 min or treated with wortmannin. Controls were incubated in the 
presence of 10% FCS and treated with DMSO. Cells were lysed, immunoprecipitated and analyzed by Western blotting. 
 
5.1.9  The FKBP51/Akt interaction depends on the conformation of Akt  
As demonstrated in section 5.1.8 the Akt1/FKBP51interaction doesn’t seem to be mediated 
by a single site. Therefore the conformation of Akt was sought to be controlled more directly 
using Akt conformation-specific inhibitors (see section 1.5.2). The classical ATP-competitive 
inhibitor AT7867 (Figure 5.24A - lanes 3, 4 and 9,10) binds and stabilizes the activated ‘PH 
out’ conformation of Akt (PDB code 2UW9) [255] and thereby prevents access of phospha-
tases [258]. In contrast the allosteric inhibitor VIII (lanes 1,2 and 7,8) intercalates between 
the PH and the kinase domain of Akt and locks the latter in a closed inactive conformation 
(PDB code 3O96) [261]. These two inhibitors were used to stabilize the conformation of Akt 
in cells. As expected, the ATP-competitive inhibitor (AT7867) led to Akt hyperphosphorylation 
[257, 258] but it did not affect the interaction with FKBP51. Stimulation didn’t seem to have 
an influence at all and the results were identical (compare Figure 5.24A - left and right). This 
was confirmed in vitro by pulldown assays using the non-hydrolysable ATP analog AMP-PNP 
(Figure 5.24B). As described, the allosteric inhibitor completely abolished cellular Akt S473 
phosphorylation [260]. Interestingly, this compound substantially reduced binding of Akt to 
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FKBP51. This suggests that in the conformation stabilized by inhibitor VIII the binding site 
with FKBP51 might be masked. It was not possible to study the AktΔPH, because the allo-
steric inhibitor VIII does not bind to Akt missing the PH domain. 
 
A 
 
B 
 
Figure 5.24: The FKBP51/Akt interaction depends on the conformation of Akt 
A HEK293T cells were transfected with FLAG-tagged FKBP51K352A/R356A (TPR_mut) and HA-tagged Akt1. After 2 days one part 
of the cells was stimulated with insulin for 90 min. Additional cells were treated with 10 µM Inhibitor VIII, AT7867 or DMSO for 
1h. Cell lysates and immunoprecipitated proteins were analyzed in duplicates by Western blotting. B GSH beads loaded with 
purified activated GST_Akt1ΔPH were incubated with FKBP51 with or without AMP-PNP. Elutions were analyzed by Western 
blotting. 
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5.2 Investigation of possible side effects of FKBP inhibitors with regard 
to the Akt/mTOR pathway 
5.2.1 Gemcitabine’s toxic effects on cell viability are not reduced by FKBP in-
hibitor FK1706 
 
Since our group is especially interested in the synthesis of selective FKBP51 inhibitors to 
treat mental disorders, we were curious about the finding that FKBP51 could lead to a sensi-
tization of pancreatic tumors to the nucleoside analogue gemcitabine, which is a clinically 
used chemotherapeutic agent [76]. If we could generally confirm this hypothesis, blocking 
FKBP51 in cancerous tissue would cause resistance to some chemotherapeutic treatments, 
which would not be tolerable.  
 
Therefore the cell viability of SU.86.86 cells was examined by titration of gemcitabine togeth-
er with FK1706 (10 µM), an FKBP inhibitor without immunosuppressive properties (see sec-
tion 1.2.2, [142]). After 72 h gemcitabine dose-dependently reduced cell viability but this was 
not substantially altered by the presence of FK1706 (Figure 5.25A). Importantly, 10 µM of 
FK1706 alone did not affect the cell viability (Figure 5.25B). 
 
A                                        B 
 
 
Figure 5.25: FK1706 does not influence gemcitabine’s toxic effects on cell viability  
A SU.86.86 cells were plated, cultivated for 3 h and afterwards treated with gemcitabine. After 24h FK1706 or DMSO were 
added. After altogether 72 h the cell survival relative to DMSO treated controls was determined. B SU.86.86 cells were plated to 
10000 cells per well. Cells were incubated with increasing FK1706 concentrations after 24 h. After altogether 72 h cell a viability 
assay was performed using the CellTiter-Fluor Cell Viability assay (Promega). 
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5.2.2 Tested FKBP inhibitors do not influence Akt and Akt target phosphoryla-
tion 
 
To further investigate an effect of FKBP inhibition on the Akt/mTOR signaling pathway it was 
tested, whether cellular Akt or mTOR phosphorylation would be affected by FKBP inhibitors 
(see section 1.2). Neither the Akt phosphorylation at T308 nor S473 (mTOR phosphorylation 
site) was affected in HEK293T cells treated with high concentrations of FK1706 (Figure 
5.26A). Under equal conditions Akt phosphorylation at both sites was reduced by the highly 
potent and selective ATP-competitive mTOR inhibitor Torin-1 [274], while phosphorylation 
was enhanced by the ATP-competitive Akt inhibitor AT7867 (see section 1.5.2). This demon-
strates that the assay was able to detect the dynamically regulation of Akt in these cells. Sim-
ilar results were obtained for Akt (pS473) in FK1706- or FK506-treated SH-SY5Y (Figure 
5.26B) and HeLa cells (Figure 5.26C). mTOR (S2448) phosphorylation was not altered after 
treatment in most samples as well. However, with compound FK1706 a significant reduction 
of mTOR phosphorylation was observed in HeLa cells, which could be due to a small sample 
size for this condition. In a similar experiment no effect was observed in FK1706 treated 
HeLa cells (Figure 5.47). Rapamycin, which served as control, showed the expected effects.  
In addition the in-house synthesized FKBP inhibitors YW648, cmpd44 [148] and SG537 were 
tested (Figure 5.26D). Compound YW648 is a small molecule non-specific FKBP inhibtor, 
while the synthetic FKBP ligand cmpd 44 is more selective for FKBP12 compared to larger 
FKBPs. SG537 has an increased selectivity for FKBP51 compared to FKBP52. 
In all experiments no significant influence on Akt phosphorylation at position T308 and S473 
was observed. Furthermore, no changes in the mTOR phosphorylation status were ob-
served.  
These types of experiments were repeated and the results can be found in section 5.4.2. 
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C                                       D 
  
Figure 5.26: No influence of FKBP inhibitors on Akt or mTOR phosphorylation was seen in a homogeneous time re-
solved FRET assay 
A-D HEK293T, SH-SY5Y or HeLa cells were stimulated with FCS for 1 h in the presence of the indicated compounds. After cell 
lysis, cellular Akt- and mTOR phosphorylation was determined using a homogeneous time resolved FRET assay. For all exper-
iments mean values of at least 2-3 data points (+ SD) are shown. Results were normalized to those of dimethyl sulfoxide 
(DMSO)-treated controls (100%) and torin-1 (0%) treated cells.  
The values are presented as mean + SD. Two-way analysis of variance (ANOVA) and a priori testing were used for statistical 
analysis. Compared with DMSO treatment: ** p<.01 
With the exception of FK1706 mTOR phosphorylation in HeLa none of the FKBP ligand altered Akt (pS473), Akt (pT308) or 
mTOR (pS2448) significantly. 
5.2.3 FKBP inhibitors do not disrupt the integrity of the FKBP51/Akt or of the 
FKBP51/PHLPP complex 
 
The ability of several FKBP members to bind to Akt (section 5.1.3) suggested the FK506-
binding pocket common to all of these proteins as an interaction site. Therefore it was tested 
if FKBP ligands blocking the PPIase domain could reduce binding of Akt to FKBP51. First, 
pulldown experiments were performed using purified FKBP51 and purified AktS473D as bait in 
the absence and presence of the high-affinity ligand rapamycin. The amount of FKBP51 that 
was specifically retained by Akt was not affected by an excess of rapamycin (Figure 5.27A).  
 -------------------------------------------- 
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Next, Akt was co-immunoprecipitated with FKBP51 or its TPR-mutant in the presence or ab-
sence of the non-immunosuppressive FK506 analogue FK1706 [142]. Binding of Akt was 
slightly reduced for the TPR-mutant but it was still significantly retained compared to back-
ground (Figure 5.27B). Treatment with FK1706 did not affect HA_Akt1 interaction with nei-
ther of the FKBP51 constructs. Similar results were obtained in cells treated with FK506 or 
rapamycin (Figure 5.27C). 
  
A    B                       
 
 
 
 
 
C  
 
 
 
 
                  
 
 
 
Figure 5.27: FKBP inhibitors do not disrupt FKBP/Akt interaction 
A Purified proteins were mixed and treated with DMSO or Rapamycin (1µM). After 3h a GST-pulldown was performed followed 
by Western blotting. B HEK293T cells were transfected with the indicated constructs. After 48 h 1 µM FK1706 was added for 1 
h. The lysates were immunoprecipitated and a Western blot was performed. C HEK293T transfected with the indicated con-
structs were treated with or without 1 µM FK506 or rapamycin 1 µM for 1 h followed by immunoprecipitation and Western blot-
ting. 
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Since PHLPP is regulating Akt phosphorylation and is proposed to be part of the 
Akt/FKBP51/PHLPP complex [75] it was explored if FKBP inhibitors affected the 
FKBP51/PHLPP complex. As shown in Figure 5.28 FKBP inhibitors had no effect on the in-
tegrity of the complex of FKBP51 with PHLPP1 or PHLPP2. 
 
A         B                 
 
 
Figure 5.28: FKBP51/PHLPP interaction is not impaired by FKBP inhibitors 
A and B HEK293T cells were transfected with FLAG_FKBP51 and HA-tagged PHLPP1 or HA-tagged PHLPP2. After 48 h 
FKBP inhibitors (10 µM) or DMSO were added for 1h. Lysates were immunoprecipitated and analyzed by Western blotting. 
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5.3 A chemical inducer of the FKBP51/Akt complex 
5.3.1 Testing FKBP inhibitors for induction of the FKBP51/Akt complex 
As stated in section 5.2 the tested FKBP inhibitors do not affect FKBP/Akt interaction. This is 
an important observation in order to evaluate possible side effects of these inhibitors. How-
ever, immunoprecipitation experiments with available FKBP inhibitors consistently revealed 
an enhancement of the Akt1/FKBP interaction by the natural product Antascomicin B (see 
section 1.2.2 [141]). For these experiments HEK293T cells were transfected with 
HA_AktS473D and FKBP51TPR_mut_FLAG, in order to exclude confounding influences 
caused by the Hsp90/FKBP interaction. After two days cells were treated for 60 min with 1µM 
of Antascomicin B or of the FKBP ligands FK506 and rapamycin (Figure 5.29). 
After treatment cells were harvested, FLAG immunoprecipitation was performed and the im-
munoprecipitates were analyzed by Western blotting. Addition of Antascomicin B gives a 
unique and interesting result: Antascomicin B is the only compound that increases the 
FKBP51/Akt interaction. None of the other compounds shows a strong enhancement or de-
cline in the FKBP51/Akt interaction. 
 
                       
 
Figure 5.29: Antascomicin B enhances FKBP51/Akt1 interaction 
HEK293T cells were transfected with the indicated constructs. After 48 h they were treated with 1 µM of FK506, Rapamycin, 
Antascomicin B (Anta B) or DMSO for 1h. After cell lysis a FLAG immunoprecipitation was performed, followed by protein sepa-
ration on SDS gel and Western blotting. 
 
5.3.2 Verification of induction of FKBP51/Akt interaction 
To evaluate and further specify the newly discovered property of Antascomicin B a few con-
trol experiments were performed. Theoretically a stronger interaction between FKBP51 and 
Akt1 by Antascomicin B could be due to enhanced unspecific adsorption of Akt or FKBP51 
alone to the beads due to changes in pH, charge or other influences by the compound. To 
Results 
__________________________________________________________________________ 
94 
control for this, HEK293T cells were transfected in duplicates with FKBP51_FLAG and 
HA_Akt1. Before harvesting Antascomicin B was added for 60 min. Thereafter, the lysates 
were FLAG co-immunoprecipitated and analyzed by Western blotting. No Antascomicin B- 
induced signal was observed, neither in cells transfected with FKBP51 (Figure 5.30, lane 3, 
9) or Akt1 (lane 5, 11) alone. The signal intensity was clearly enhanced when both proteins 
were transfected together and Antascomicin was added (compare lane 1 with lane 2 and 
lane 7 with lane 8). 
 
 
Figure 5.30: Induction of FKBP51/Akt1 interaction by Antascomicin B seems to be specific 
HEK239T cells were transfected with FKBP51_FLAG and HA_Akt1. Cells were treated with 1 µM Antascomicin B for 60 min. 
After 48 h cells were harvested and FLAG co-immunoprecipitated. 
 
 
To determine the potency of Antascomicin B for induction of the FKBP51/Akt complex  
HEK293T cells were double transfected with the indicated constructs and treated for 60 min 
with increasing concentrations of Antascomicin B (0 nM, 0,1 nM, 1 nM, 10 nM, 100 nM, 1000 
nM). Duplicates were tested. After FLAG co-immunoprecipitation and Western blotting a 
clear dependency on titrated Antascomicin B could be seen. A concentration of 1 µM leads to 
the most intense effects. Therefore all subsequent experiments were performed with 1 µM 
Antascomicin B if not otherwise stated. 
 
               
Figure 5.31: Antascomicin B mediated enhancement of the Akt1/FKBP51 interaction is concentration dependent 
HEK293T cells were transfected with the indicated constructs. After growth for 48 h cells were treated with increasing concen-
trations of Antascomicin B from 0 nM-1000 nM in duplicate for 60 min. After cell lysis a FLAG immunoprecipitation was per-
formed, followed by protein separation on SDS gel and Western blotting.  
______nM_____ µM 
0   0.1  1 10 100  1 
______nM_____  µM 
0   0.1  1  10 100  1 
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Pulldown assays revealed that the Antascomicin B enhanced FKBP51/Akt1 interaction is 
direct and the presence of only these two proteins is sufficient. 
 
A  
 
 
 
 
 
B 
 
Figure 5.32: In pulldown assays Antascomicin B enhances the Akt1/FKBP51 interaction 
A Purified FLAG-tagged FKBP51 and purified inactive Akt1 were mixed in the presence of DMSO or 1 µM of Antascomicin B, 
subjected to a FLAG pulldown and analyzed by Western blotting. B Purified FLAG-tagged FKBP51 and purified active Akt were 
mixed in the presence of DMSO or 1 µM of Antascomicin B, subjected to a GST pulldown and analyzed by Western blotting. 
Controls were missing the according bait protein. I+II are replicates 
 
5.3.3 Antascomicin B as inducer of FKBP/Akt1 complexes 
In order to get deeper insight in the specificity of the induction of FKBP51/Akt1 interaction our 
FKBP portfolio was tested. To do so we overexpressed HA_Akt1S473A with four FLAG tagged 
FKBP homologs, namely FKBP12, FKBP12.6, FKBP51 and FKBP52, and performed co-
immunoprecipitation experiments. A general interaction of these FKBPs with Akt1 could be 
demonstrated in pulldown assays and Co-IP experiments (compare section 5.1). However, 1 
µM Antascomicin B clearly enhanced Akt interaction compared to DMSO treatment with all 
tested FKBPs, as depicted in Figure 5.33.  
The effect was most pronounced for FKBP12.6, followed by FKBP52 and FKBP51 and 
FKBP12. The latter one shows already a rather strong basal FKBP12/Akt1 interaction, which 
is only slightly enhanced by Antascomicin B. To emphasize the difference between 
Antascomicin B and DMSO treated samples the depicted X-ray film of the Western blot 
showing the co-immunoprecipitated FKBP proteins was exposed for a short time. This ex-
plains the absent bands even when both binding partners were transfected. 
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Figure 5.33: Antascomicin B (Anta B) induces FKBP/Akt1 interaction in double transfected cells 
HEK293T cells were transfected in duplicates with the indicated constructs. After growth for 48 h cells were treated with 1 µM 
Antascomicin B for 60 min. Cells were lysed and a FLAG co-immunoprecipitation was performed, followed by protein separation 
on SDS gel and Western blotting. I+II are replicates, as I+II were treated identically the load was only controlled for I 
 
 
In order to mimic conditions, which might be closer to in vivo conditions than double transfec-
tions we performed an HA-co-immunoprecipitation experiment in HeLa cells containing over-
expressed HA-tagged Akt1 (Figure 5.34). After Antascomicin B administration interaction 
with endogenous FKBP12, FKBP51 and FKBP52 was observed, although for the latter there 
was a high background. 
Of note, reverse co-immunoprecipitation (here the HA-Co-IP) leads to the same 
Antascomicin B induced effects as observed in Flag-IPs (as for example in the double over-
expressing samples in section 5.3.2.). 
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Figure 5.34: Antascomicin B (Anta B) induces FKBP/Akt1 interaction 
HeLa cells were transfected with HA-tagged Akt1. After 48 h cells were treated with 1 µM Antascomicin B for 60 min. Cells were 
lysed and a HA co-immunoprecipitation was performed, followed by protein separation on SDS gel and Western blotting. (*weak 
signal due to edge effect) 
 
5.3.4 Antascomicin B as inducer of FKBP51/AGC kinase complexes  
In order to test if the more intense binding of FKBPs after Antascomicin B treatment is unique 
to Akt1 the property of Antascomicin B to enhance FKBP51 interaction with other AGC ki-
nases was investigated. For this purpose HEK293T cells were transfected with 
FKBP51TPR_mut_FLAG and HA-tagged Akt1, Akt2, S6K or GST-tagged SGK. All tested 
AGC kinases displayed stronger binding to FKBP51 after Antascomicin B administration 
(compare also section 5.1.7). In principle the strongest increase of FKBP51/AGC kinase in-
teraction after Antascomicin B treatment was observed for Akt2. As for Akt1, S6K and SGK 
the Antascomicin B mediated increase was similar. For better clarity the X-ray films showing 
the co-immunoprecipitated AGC kinases were exposed for a shorter time compared to the 
Western blots in section 5.1.7. The results are shown in Figure 5.35.  
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Figure 5.35: Antascomicin B induces FKBP51/AGC kinase interaction 
HEK293T cells were transfected in duplicates (I+II) with the indicated constructs. After growth for 48 h cells were treated with 1 
µM Antascomicin B for 60 min. Cells were lysed and a FLAG co-immunoprecipitation was performed, followed by protein sepa-
ration on SDS gel and Western blotting. 
 
5.3.5 Insight into the mode of induction of the FKBP51/Akt1 interaction by 
Antascomicin B 
 
To dissect the mode of action of Antascomicin B on the Akt1/FKBP51 interaction the 
Antascomicin B was competed with several ligands known to interact with either of the two 
proteins. In the first experiment of these series, double transfected HEK293T cells were 
treated with 1 µM Antascomicin B and 10 µM of the ATP-competing Akt inhibitor AT7867. 
After 60min cells were harvested, FLAG immunoprecipitated and analyzed by Western blot-
ting (Figure 5.36A). The signal intensity of co-immunoprecipitated HA_Akt1 for each condi-
tion is shown in Figure 5.36B. Antascomicin B clearly enhanced interaction of FKBP51 and 
Akt1. AT7867 was not able to disturb this interaction.  
 
A          B 
 
 
 
Figure 5.36: AT7867 does not diminish the Antascomicin B-induced Akt/FKBP51 interaction 
HEK293T cells were transfected in duplicates with FKBP51_FLAG and HA_Akt1. After 48 h cells were treated for 60 min with 
Antascomicin B and 10 µM of the Akt inhibitor AT7867 or Antascomicin B or AT7867 alone. A Cells were lysed and a FLAG 
immunoprecipitation was performed, followed by protein separation on SDS gel and Western blotting. B Signal intensities were 
determined using Biorad image software. Results were normalized to those of dimethyl sulfoxide (DMSO)-treated cells, where 
each DMSO treated sample was set 100% + SD. 
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Next ,10 µM of the allosteric Akt inhibitor VIII [260] were administered (Figure 5.37A). Inhibi-
tor VIII was shown to abolish Akt phosphorylation [260] which we also observed (lane 3 and 
4 and Figure 5.24A). Furthermore, Inhibitor VIII reduced the interaction between Akt and 
FKBP51, similar to previous results but it did not block the capability of Antascomicin B to 
enhance the interaction between FKBP51 and Akt. The Akt phosphorylation in the hydropho-
bic motif (S473) seems to be independent of Antascomicin B treatment (compare Western 
blot showing Akt (pS473), lane 1 and 2 with lane 3 and 4; and lane 4 and 5 with lane 6 and 
7). The amount of co-immunoprecipitated HA_Akt1 is depicted in Figure 5.37B. 
 
A            B 
 
 
 
Figure 5.37: Inhibitor VIII does not diminish the Antascomicin B induced Akt/FKBP51 interaction 
HEK293T cells were transfected in duplicates with FKBP51_FLAG and HA_Akt1. After 48 h cells were treated for 60 min with 
Antascomicin B and 10 µM of the Akt inhibitor VIII or Antascomicin B or inhibitor VIII alone. A Cells were lysed and a FLAG 
immunoprecipitation was performed, followed by protein separation on SDS gel and Western blotting. B Signal intensities were 
determined using  Biorad image software. Results were normalized to those of dimethyl sulfoxide (DMSO)-treated cells, where 
each DMSO treated sample was set 100% + SD.  
 
 
Furthermore, we applied 10 µM of the FKBP inhibitor FK506 (Figure 5.38). Interestingly we 
observed that in the presence of FK506 Antascomicin B did not enhance binding of FKBP51 
to Akt (compare lane 2 and 8 with boxed lanes).  
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Figure 5.38: The FKBP inhibitor FK506 abolishes the stronger interaction of Akt/FKBP51 caused by Antascomicin   
HEK293T cells were transfected in duplicates with FKBP51_FLAG and HA_Akt1. After 48 h cells were treated for 60 min with 
Antascomicin B and 10 µM of the FKBP ligand FK506 or Antascomicin B or FK506 alone (for explanations regarding Akt inhibi-
tor VIII compare Figure 5.37). Cells were lysed and a FLAG immunoprecipitation was performed, followed by protein separation 
on SDS gel and Western blotting.  
 
 
Encouraged by this finding the FKBP inhibitor FK1706 (50 µM) was applied together with 
Antascomicin B (1 µM). Antascomicin B enhanced FKBP51/Akt interaction as expected. Ap-
plication of FK1706 prevented the increase of Antascomicin mediated FKBP51/Akt interac-
tion (compare lane 3 to lane 2, lane 6 to lane 5 and lane 11 to lane 10). 
 
 
 
Figure 5.39: The FKBP inhibitor FK1706 abolishes the stronger interaction of Akt/FKBP51 caused by Antascomicin  
HEK293T cells were transfected in triplicates with FKBP51_FLAG and HA_Akt1. After 48 h cells were treated for 60 min with 
Antascomicin B and 50 µM of the FKBP ligand FK1706 or Antascomicin B or FK1706. Cells were lysed and a FLAG immuno-
precipitation was performed, followed by protein separation on SDS gel and Western blotting. (The missing band (α HA) in lane 
12 could be due to an edge effect) 
 
5.3.6 Influence of Antascomicin B on Akt phosphorylation and downstream 
targets 
 
Having the findings of Pei [75] in mind, where FKBP51 serves as a scaffold protein to bring 
the phosphatase PHLPP and Akt in close proximity for Akt dephosphorylation, one could 
imagine that enhanced binding of Akt and FKBP could lead to less phosphorylated Akt. As 
initially indicated in section 5.3.5 this does not seem to be the case in HEK293T cells. No 
influence on Akt phosphorylation in the position S473 could be observed by Western blot 
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analysis after Antascomicin B treatment for 60 min (Figure 5.37). Treatment of HeLa cells 
with 0-10 mM Antascomicin B for 24 h revealed (Figure 5.40): First, stimulation with FCS 
(10%) or insulin (100 nM) enhanced Akt phosphorylation at S473 or T308 as expected. The 
effects observed after stimulation could also be seen in Antascomicin treated cells. Therefore 
the following experiments were performed in medium containing 10% FCS.  
Second, a slight increase in Akt phosphorylation at both positions (S473 and T308) was ob-
served after treatment with 0.1 and 1 µM Antascomicin B. 
Third, a clear reduction of the Akt phosphorylation signal was caused by 10 µM of 
Antascomicin B. To clarify weather this was due to a loss of viable cells cell viability assays 
were performed, here in SH-SY5Y neuroblastoma cells (Figure 5.40).  
 
A  
 
B 
 
Figure 5.40: Stimulation of cells does not influence the effects of Antascomicin B  
HeLa cells were plated and cultured for 48 h. Cells were incubated with increasing concentrations of Antascomicin B for 24 h. 
Additionally cells were either starved or stimulated with FCS (10%) , insulin (10 nM) or both for 45 min before cell lysis. Cellular 
Akt phosphorylation was determined using a homogeneous time resolved FRET assay. Results are displayed as standard 
deviations from the mean. A Phosphorylation status of Akt (pS473) was determined B Phosphorylation status of Akt (pT308) 
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In SH-SY5Y neuroblastoma cells toxicity of Antascomicin concentrations above 0.1 µM could 
be observed in a cell viability assay (Figure 5.41). 
 
A                  B 
 
Figure 5.41: Antascomicin B long term-treatment becomes toxic in neuroblastoma SH-SY5Y cells 
10000 SH-SY5Y cells per  well (supported with medium + 10% FCS) were plated in a 96 well plate. A After 4 h Antascomicin B 
was added and after 48 h cell viability was analyzed using the CellTiter-Fluor Cell Viability assay Kit (Promega) B After 4h 
Antascomicin B was added for 96 h and cell viability was assessed using the CellTiter-Fluor Cell Viability assay Kit (Promega). 
 
 
Next the influences on Akt (S473) and Akt (T308) phosphorylation were tested in SH-SY5Y 
cells. Because of the toxic effects after 24 h or 48 h or 96 h we continued using a short term 
Antascomicin B treatment for 60 min. Interestingly, as in HeLa cells (Figure 5.40A and Figure 
5.40B) an increased phosphorylation status was observed after Antascomicin B administra-
tion in SH-SY5Y (Figure 5.42). This increased phosphorylation was concentration-
dependent.  
 
 
 
Figure 5.42: Antascomicin B enhances Akt phosphorylation in SH-SY5Y neuroblastoma cells 
SH-SY5Y cells were supplied with FCS and were incubated with Antascomicin B for 60 min. After cell lysis, cellular Akt phos-
phorylation was determined using a homogeneous time resolved FRET assay. 
Results were normalized to those of dimethyl sulfoxide (DMSO)-treated cells (100%) for each phosphorylation site + SD. 
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The phosphorylated and thereby activated Akt enzyme is able to phosphorylate downstream 
targets. Akt target phosphorylation triggers survival, growth, migration, proliferation, polarity, 
metabolism, cell cycle progression, muscle and cardiomyozyte contractility as well as angio-
genesis [275]. To investigate functional consequences of the Antascomicin enhanced 
FKBP51/Akt1 interaction HeLa cells were cultured for 48 h, followed by 1h in the presence of 
Antascomicin B. Here we focused on FoxO1 (pS256) and GSK-3ß (pS9). Additionally, Akt 
activity status was controlled (Akt (pS473)).  
 
A 
 
B 
 
 
Figure 5.43: Antascomicin influences Akt target phosphorylation 
A HeLa cells were cultivated for 48 h. Medium was changed (10% FCS) and 1 µM Antascomicin B was applied for 1 h with or  
without Insulin (10 nM, 45 min). Cells were harvested and Western blot analysis was performed using the indicated antibodies. 
B Band intensity was analyzed and results were normalized to those of dimethyl sulfoxide (DMSO)-treated cells (100%) for each 
protein + SD. Lane 12 was not analyzed due to edge effects. 
 
In these triplicate experiments an influence of Antascomicin B on Akt phosphorylation could 
not be detected. However, FoxO1 and GSK-3β phosphorylation were decreased in the sam-
ples lacking insulin. 
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5.3.7 Antascomicin B enhances the interaction between FKBP51_FLAG and 
HA_PHLPP2 
 
To get a deeper understanding of the involvement of PHLPP in the Akt/FKBP51/PHLPP 
complex it should be investigated if the binding between FKBP51 and PHLPP1 or PHLPP2 is 
also enhanced by Antascomicin B. To do so HEK293T cells were transfected with 
FKBP51_FLAG and HA_PHLPP1 or HA_PHLPP2. Cells were treated for 60 min with 10 µM 
of the indicated compounds. Afterwards cells were lysed, FLAG co-immunoprecipitated and 
Western blot analysis was performed. Antascomicin was the only tested compound able to 
enhance FKBP51/PHLPP interaction. It should be pointed out, that rapamycin is the only 
FKBP inhibitor able to increase Akt phosphorylation at S473. PHLPP overexpression does 
not decrease Akt phosphorylation under these conditions which supports our results de-
scribed in section 5.1.8, but contradicts the findings of Pei [75]. 
 
A 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 5.44: Antascomicin B induces interaction between FKBP51 and PHLPP 
HEK293T cells were transfected with FLAG_FKBP51 and HA-tagged PHLPP1 or HA-tagged PHLPP2. After 47 h FKBP inhibi-
tors (10 µM) or DMSO were added for 1h. Lysates were immunoprecipitated and analyzed by Western blotting. A Antascomicin 
B enhances the interaction between FKBP51 and PHLPP1 B Antascomicin B enhances the interaction between FKBP51 and 
PHLPP2 
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5.3.8 Investigation of toxicity effects of Antascomicin B  
Some cells seem to be more sensitive to Antascomicin B than others. Antascomicin B as an 
inducer of FKBP51/Akt1/PHLPP interaction might act synergistic to the chemotherapeutically 
used compound Gemcitabine, even so FKBP51 effects on Akt S473 phosphorylation could 
not be generally confirmed in our hands. To investigate this further the pancreas cancer cell 
line SU.86.86, which was shown to be sensitive to FKBP51 overexpression [76], was used.  
First, the effects of Antascomicin B on the general cell viability of SU.86.86 cells were tested 
(Figure 5.45A). Concentrations of up to 10 µM Antascomicin B were well tolerated when ad-
minstered for 24 h.  Thereafter SU.86.86 cells were treated with increasing concentrations of 
gemcitabine in the presence of 10 µM of Antascomicin B. After 72h gemcitabine dose-
dependently reduced cell viability, however no synergistic effect of Antascomicin B was ob-
served (Figure 5.45B).  
 
A               B 
 
 
 
 
Figure 5.45: Antascomicin B does not enhance cell toxicity of Gemcitabine 
A To test the effect of Antascomicin without gemcitabine 10000 SU.86.86 cells per well were plated and let attach for 48 h. Cells 
were incubated with increasing Antascomicin B concentrations for 24 h. After altogether 72 h cell a viability assay was per-
formed using the CellTiter-Fluor Cell Viability assay (Promega). B 10000 cells were plated and cells were incubated with in-
creasing Gemcitabine concentrations for 72 h. 24 h before cell viability was assessed Antascomicin B (10 µM) was added. 
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5.4 Contribution of FKBPs to the cellular action of rapamycin 
So far the drug rapamycin, which is FDA-approved for prevention of graft-versus-host dis-
ease and as an anti-cancer agent (see section 1.2.1), is almost exclusively interpreted and 
discussed in the context of a complex with the prototypical FKBP12. However, our group 
could demonstrate, that rapamycin does not exclusively interact with FKBP12 but rather 
binds with high affinity to most members of the F506-binding-protein family [264]. Additional 
data by Andreas März revealed that larger FKBP homologs like FKBP51 contribute substan-
tially in mediating the effects of rapamycin [14]. The following data supports this postulate 
with additional findings. 
5.4.1 Modulation of mTOR (pS2448) by rapamycin is cell type dependent 
The anti-proliferate efficiency of rapamycin has been modest for many cancer cell types 
[276]. Therefore it was essential to select a cell line which would respond to rapamycin in 
order to study the effect of rapamycin and specific FKBP inhibitors in more detail. Rapamycin 
was titrated in several concentrations leading to dose-response curves (Figure 5.46). mTOR 
(pS2448) measured by a time resolved FRET assay was used as a read out. 
 
A       B 
   
  
Figure 5.46: Modulation of mTOR (pS2448) by Rapamycin is cell type dependent 
A HEK, HeLa, SH-SY5Y wildtype , SH-SY5Y-shFKBP12 and SU.86.86 cells were treated with increasing concentrations of 
rapamycin or DMSO for 60 min. mTOR (pS2448) was assessed using a  time resolved FRET assay. Results of rapamycin 
treatment were normalized to the DMSO control of each cell type. Torin-1 (100 nM) was used as positive control B MEF, MEF 
52-/- and MEF 51-/- were treated with increasing concentrations of rapamycin or DMSO for 60 min. mTOR (pS2448) was as-
sessed using a time resolved FRET assay. Results of rapamycin treatment were normalized to the DMSO control of each cell 
type.   
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In HeLa, HEK and SH-SY5Y-WT cells the mTOR phosphorylation at position S2448 started 
to decrease at rapamycin concentrations below 1 nM.  Rapamycin concentration up to 100 
nM could not decrease phosphorylation any further and a plateau was reached in the latter 
ones. In contrast there was no plateau reached in HEK cells with the used concentrations, 
indicating that mTOR phosphorylation could still be decreased with higher rapamycin con-
centrations. The ductal carcinoma cell line SU.86.86 showed a response at concentrations 
below 1 nM but even with high rapamycin concentrations mTOR (pS2248) could not be de-
creased which limits their response to rapamycin. Interestingly a difference between SH-
SY5Y-WT and SH-SY5Y_12KD cells was observed: With decreased FKBP12 expression 
rapamycin reduced mTOR (pS2448) to a much lower extend. Finally MEF WT cells showed 
the fastest response to rapamycin treatment. To decrease phosphorylation of mTOR (S2448) 
in MEF52-/- rapamycin concentrations higher than 0.1 nM were necessary. However, knock-
out of FKBP51 or FKBP52 in MEF cells did not change the reached minimal phosphorylation. 
Taken together FKBP knockout or knockdown alters the response to rapamycin.   
 
Table 5.1 summarizes the dose-response curves. 
 
  Torin-1 Minimum Maximum EC50 [nM] 
HeLa 0.3 0.36+0.50 1.04+0.05 21.2+49.1 
HEK 0.3 0.50+0.02 1.06+0.01 3.8+0.4 
SH-SY5Y_12KD 0.3 0.76+0.17 0.9+0.09 1.3+4.9 
SH-SY5Y 0.3 0.53+0.02 1.06+0.02 2.7+0.6 
SU.86.86 0.4 0.68+0.01 0.92+0.01 2.3+0.3 
MEF 0.8 0.7+0.07 1.09+0.10 0.3+0.4 
MEF52-/- 0.8 0.71+0.02 1.02+0.05 0.9+0.6 
MEF51-/- 0.8 0.70+0.02 1.10+0.04 0.1+0.0 
 
Table 5.1:  Summary of the resulting curves 
In grey are calculated values which can’t be considered as right due to missing plateau in HeLa cells and no typical dose re-
sponse curve in SH-SY5Y_12KD cells. 
 
 
Since HeLa, HEK and SH-SY5Y cells showed maximal response to rapamycin, we decided 
to continue with HeLa or/and SH-SY5Y cells to distinguish between the contribution of 
FKBP12 and other members of the FKBP family to the functional effects of rapamycin in hu-
man cells.  
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5.4.2 FKBP12-selective ligands do not block the cellular effects of rapamycin  
To explore the FKBP-subtype involved in the action of rapamycin a pharmacological ap-
proach in which rapamycin was administered together with non-selective FKBP inhibitors 
(FK1706, FK506, YW649) and FKBP12 selective-inhibitors (Biricodar and cmpd 44) was 
used. As a pre-experiment it was verified that FKBP ligands alone do not affect Akt phos-
phorylation at S473 or mTOR phosphorylation at S2448 (see section 5.2.2  and Figure 5.47). 
 
A    B 
 
      
C                        D           
Figure 5.47: FKBP inhibitors alone do not affect Akt or mTOR phosphorylation in SH-SY5Y neuroblastoma cells and 
HeLa cells 
SH-SY5Y neuroblastoma or HeLa cells were treated with DMSO, 10 µM of FKBP12-selective inhibitors Biricodar (Biri) [145], 
compound 44 [148],  the non-selective FKBP inhibitors FK1706 [142], FK506 [264] or YW649 [144]. After 60 min cellular Akt 
phosphorylation (A and C) and cellular mTOR phosphorylation (B and D) were determined using a homogenous time resolved 
FRET assay.  
For all experiments mean values from at least 3 data points are shown. DMSO control was set to 100% phosphorylation while 
Torin-1 was defined as 0 % phosphorylation. 
The values are presented as mean + SD. Two-way analysis of variance (ANOVA) and a priori testing were used for statistical 
analysis. Compared with DMSO treatment: ** p<.01  
 
 
Except for Biricodar which induced increase in Akt phosphorylation in SH-SY5Y cells, none 
of the FKBP ligands altered Akt (pS473) or mTOR (pS2448) significantly. 
Afterwards the effects of FKBP ligands on rapamycin induced Akt hyperphosphorylation and 
the inhibition of mTOR auto-phosphorylation was determined. In SH-SY5Y neuroblastoma 
cells the rapamycin-induced effects were blocked or significantly reduced by the pan-
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selective FKBP ligand FK506, which potently binds to all cytosolic FKBPs (Figure 5.48). 
FK1706, a non-immunosuppressive analogue of FK506, which tightly binds to FKBP12 as 
well as to FKBP51 (KI=50 nM) and to FKBP52 (KI=20 nM), likewise blocked the effects of 
rapamycin [142, 264]. The same could be observed for the small molecule non-
immunosuppressive unselective FKBP ligand YW649. Biricodar [145] and compound 44 
[148] are two structurally different substances, which bind to FKBP12 almost as tightly as 
FK506 and FK1706 but which more strongly discriminate against the larger FKBP51 and 
FKBP52 (> 500 fold selectivity for FKBP12). In contrast to FK506, FK1706 or YW649 none of 
the FKBP12-specific inhibitors affected the effects of rapamycin on mTOR auto-
phosphorylation or Akt hyperphosphorylation, even at concentrations 3-10-fold higher com-
pared to FK506, FK1706 and YW649.  
 
A          B 
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Figure 5.48: In SH-SY5Y neuroblastoma cells FKBP12 selective ligands do not block the cellular effects of rapamycin 
SH-SY5Y cells were treated with DMSO, rapamycin or Torin-1 (100 nM) in the absence or presence of the FKBP12-selective 
inhibitors Biricodar (Biri) [145] or compound 44 [148] or the non-selective FKBP inhibitors FK1706 [142], FK506 [264] or YW649 
[144] at the indicated concentrations. After 60 min cellular Akt phosphorylation (A) and cellular mTOR phosphorylation (B and 
C) were determined using a homogenous time resolved FRET assay. The pan-selective FKBP inhibitors, but not the FKBP12-
selective inhibitors, blocked the effect of rapamycin.  
For all experiments mean values from at least 3 data points are shown. DMSO control was set to 100% phosphorylation while 
Torin-1 was defined as 0 % phosphorylation. 
The values are presented as mean + SD. Two-way analysis of variance (ANOVA) and a priori testing were used for statistical 
analysis. Compared with DMSO treatment: *** p<.001, ** p<.01, * p<.05; compared with treatment of rapamycin alone:  +++ 
p<.001, ++p<.01, + p<.05 
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Almost identical results were obtained in HeLa cells as shown in Figure 5.49. 
 
A                    B 
 
 
C                                          D 
 
Figure 5.49: In HeLa cells FKBP12 selective ligands do not block the cellular effects of rapamycin  
Hela cells were treated with DMSO, rapamycin or Torin-1 (100 nM) in the absence or presence of the FKBP12-selective inhibi-
tors Biricodar (Biri) [145] or compound 44 [148] or the non-selective FKBP inhibitors FK1706 [142] and FK506 [264] or YW649 
[144] at the indicated concentrations. After 60 min cellular Akt phosphorylation (A and B) and cellular mTOR phosphorylation (C 
and D) were determined using a homogenous time resolved FRET assay. The pan-selective FKBP inhibitors, but not the 
FKBP12-selective inhibitors, blocked the effect of rapamycin.  
For all experiments mean values from at least 3 data points are shown. DMSO control was set to 100% phosphorylation while 
Torin-1 was defined as 0 % phosphorylation. 
The values are presented as mean + SD. Two-way analysis of variance (ANOVA) and a priori testing were used for statistical 
analysis. Compared with DMSO treatment: *** p<.001, ** p<.01, * p<.05; compared with treatment of rapamycin alone:  +++ 
p<.001, ++p<.01, + p<.05 
 
5.4.3 FKBP12 is necessary for rapamycin mediated effects 
 
The neuroblastoma SH-SY5Y and FKBP12-knockdown SH-SY5Y [20] cell lines turned out to 
be appropriate model systems to study rapamycins effects. In wild type SH-SY5Y cells, ra-
pamycin potently and dose-dependently reduced mTOR auto-phosphorylation and induced 
Akt hyperphosphorylation, whereas these effects were blunted in FKBP12-knockdown SH-
SY5Y cells (Figure 5.50A and B). Even very high rapamycin concentrations did not induce 
Akt hyperphosphorylation in the FKBP12-depleted cells (Figure 5.50A).  
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Figure 5.50: FKBP12 is necessary for rapamycin-induced feedback on mTOR phosphorylation and Akt hyperphosphor-
ylation  
SH-SY5Y neuroblastoma cells (wild type and FKBP12-knockdown) in medium supplemented with FCS (10%) were incubated 
for 60 min with 0-100 nM rapamycin or 100 nM Torin-1. Cells were lysed and Akt S473 (A) or mTOR S2448 phosphorylation (B)  
were assessed using a phosphor-antibody based FRET assay. Mean values of four independent samples are shown. Values 
were normalized to 0 % phosphorylation for Torin-1 and 100% phosphorylation for DMSO treated cells. 
5.4.4 FKBP12, but also FKBP51 expression restores rapamycin’s effect on Akt 
phosphorylation but not on mTOR phosphorylation 
 
Re-expression of FKBP12 restored the inducibility of Akt S473 phosphorylation by rapamycin 
in these cells. Importantly, FKBP51 was almost as efficient as FKBP12 to enable the ra-
pamycin-induced Akt S473 hyperphosphorylation, suggesting that FKBP51 can functionally 
replace FKBP12. However rapamycin’s effect on mTOR could not be restored, neither by 
FKBP12 nor by FKBP51. The Western blots at the bottom (Figure 5.51C) confirm overex-
pression of FKBP12 and FKBP51, respectively. 
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Figure 5.51: FKBP12 can be replaced by FKBP51 in mediating the effects of rapamycin 
A+B FKBP12-knockdown SH-SY5Y cells were transfected with FKBP12, FKBP51 or a control plasmid. After 24 h the cells were 
treated with 10 nM rapamycin or 100 nM Torin-1 for 60 min. Cellular Akt (pS473) and mTOR (pS2448) were assessed using a 
homogeneous time resolved FRET assay. Mean values of three independent data points are shown. Results were normalized 
to DMSO-treated controls (100%) for each transfection condition. **p<.002, *p<.05 C Western Blot analysis was used for control 
of expression of FKBP12 and FKBP12 respectively.  
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5.5 Bicyclic FKBP ligands and the energetic characterization of their 
binding 
Based on structure based rational ligand design Y. Wang of our research group synthesized 
FKBP51 ligands with reduced flexibility to improve ligand affinities and efficiencies [144]. He 
was able to improve the ligand efficiency (LE) of FKBP51 ligands. LE is an important metric 
tool as LE values > 0.3 are considered as promising candidates for the development of orally 
available drugs [277-281]. The [4.3.1] scaffold was shown to have higher affinity compared to 
the [3.3.1] or monocyclic scaffold (Table 5.2).  
 
 
Table 5.2: Structures and binding affinities of lead-like monocyclic or conformationally constrained FKBP ligands for 
FKBP51 (courtesy of Y. Wang) 
a) affinities were measured by fluorescence polarization assay using the purified FK506-Binding domain of human FKBP51 (see 
section 4.2.4.3 and [264]) b) Ligand efficiency (LE) is defined as ratio of Gibbs free energy (ΔG) to the number of non-hydrogen 
atoms of the compound: LE = (ΔG/N), where ΔG = -RTlnKi with RT equal to 0,6 and N is the number of non-hydrogen atoms. c) 
Binding affinities as reported before [264] d) for substructures compare section 1.2.1 
 
Classically, higher affinities of rigid scaffolds are attributed to an entropic advantage com-
pared to flexible analogs. To elucidate the origin of the additional binding energy in more 
detail isothermal titration calorimetry measurements (ITC) were performed as depicted in 
Figure 5.52A.  
All three curves were fitted according to a one site binding model (0.8<n<1.2). While the ITC 
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data for compound YW691 is very robust, the data for YW644 and YW703 are less so. In the 
titration curve of compound YW644 and YW703 no plateau was reached which makes exact 
data-analysis difficult. Thermodynamic characteristics are summarized in Figure 5.52B. 
 
A 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.52: A Thermodynamic parameters for binding of YW644, YW703 and YW691 to the FK506 binding domain of FKBP51 
B Overview of thermodynamic signatures of YW644, YW703 and YW691 upon binding to the FK506 binding domain of FKBP51 
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For FKBP51FK1 the [4.3.1]-bicyclization contributed ΔG> 2 kcal/mol to the binding energy.  
The Kd values obtained (3.3 μM, 10.5 μM and 0.36 μM, respectively) were in excellent 
agreement with the fluorescence polarization assay results (Table 5.2). Compound YW644 
and YW703 showed a very similar thermodynamic profile. The binding was driven enthalpi-
cally and entropically. Surprisingly a strong increase in binding enthalpy was observed for the 
[4.3.1] bicycle YW691 compared to YW703 and YW644 (ΔH= -13.6 kcal/mol vs. -3.0 and -4.5 
kcal/mol, respectively). This indicates that the interactions between FKBP51FK1 and YW691 
were even stronger than hypothesized by the affinity data (i.e, ΔG). The enhanced binding 
enthalpy was, however, largely counterbalanced by an opposing negative change in entropy.  
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6. Discussion 
6.1 Akt1 and FKBP51 – only the tip of the iceberg  
6.1.1 Expanding interactions 
The presented data support a robust FKBP51/Akt1 interaction as it was proposed by Pei et 
al. [75]. According to the results presented here, the interaction of Akt with FKBP51 might be 
more complex than previously thought. Importantly, the interaction is direct and not restricted 
to FKBP51 since Akt can bind several FKBPs. Whether different FKBPs can compete for a 
similar binding site on Akt and whether this could be important for the effect of individual 
FKBPs on Akt remains to be established. For example, other FKBPs such as FKBP52, 
FKBP25 or the smaller FKBPs FKBP12 and FKBP12.6 could displace FKBP51 from the 
Akt/PHLPP complex in a way reminiscent of the opposing effects of FKBP51 and FKBP52 on 
steroid hormone receptors [112].  
It is also interesting that squirrel monkey FKBP51 seems to interact more strongly with Akt 
than human FKBP51 as shown in section 5.1.4. The amino acid identity between the squir-
rel monkey FKBP51 and the human FKBP51 protein is 94%. 28 amino acids deviate be-
tween the two species, whereas 15 are within the FK1 domain, five are within the FK2 
domain and eight amino acids differ within the TPR domain (Figure 6.1). More than 50 % 
of the amino acid deviation between human FKBP51 and squirrel monkey FKBP51 are 
consequently located at the FK1 domain. In glucocorticoid signaling the monkey version of 
the protein displays stronger inhibitory effects than human FKBP51. However, this effect 
could not be explained by structural differences so far  [55].  
Chimeric mutants of human FKBP51 and squirrel monkey FKBP51, which were generated in 
our group, could serve as a valuable tool to investigate the reason for the enhanced interac-
tion displayed by squirrel monkey FKBP51.  
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Figure 6.1: Crystal structure of human FKBP51  
Amino acid deviations between the squirrel monkey FKBP51 and human FKBP51 are highlighted as red sticks. Amino acids 
were mapped on the human FKBP51 wildtype sequence (PDB code 1KT0). 
 
 
Additionally our findings support an interaction between closely related AGC kinases and at 
least FKBP51. As FKBPs can compete for their binding partners so might do the highly ho-
mologous AGC kinases Akt, S6K and SGK. The finding that FKBPs can bind to several ki-
nases is consistent with data from previous studies [67, 282] showing an interaction of 
FKBP51 with other kinases such as IKKα, IKKε, TAK1 and MEKK1. It should be mentioned 
that SGK shares downstream targets and upstream effectors of Akt and provides a potential 
parallel pathway to PI3K/Akt signaling. Thereby SGK represents a novel player in PI3K on-
cogenic signaling [283]. Similarly S6K signaling is highly interconnected with Akt and SGK 
signaling. Any effects observed on the PI3K/Akt/mTOR pathway after FKBP51 overexpres-
sion or down regulation are thus not necessarily being mediated via Akt but could be due to 
modulation of any of those kinases. Whether the binding to SGK or S6K is direct or via a 
third partner (e.g. Hsp90) is currently unclear. 
6.1.2 PHLPP – another interaction partner of FKBP51 
The phosphatase PHLPP (PH domain leucine-rich repeat protein phosphatase) dephosphor-
ylates and thereby inactivates Akt (S473) [170] and p70SK [284]. It is likely that the closely 
related SGK and p90S6K, which possess a hydrophobic phosphorylation motif as well are 
substrates of PHLPP. However, experimental evidence is missing so far. 
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Mechanistically FKBP51 was suggested to act as a scaffolding protein thereby helping to 
switch off the Akt pathway [75].  
The presented study supports an interaction between FKBP/Akt and PHLPP (see section 
5.1.1). While the PDZ binding motif consisting of the amino acid sequence DTLP (PHLPP1) 
and DTAL (PHLPP2) of PHLPP was shown to be important for Akt regulation [170]  it is dis-
pensable for PHLPP/FKBP interaction. The FKBP51/Akt interaction is independent of PHLPP 
as demonstrated in several biochemical experiments throughout this thesis as the 
FKBP51/PHLPP interaction is independent of the presence of Akt. The lacking PHLPP1 sig-
nal in lane 11 an12 (Figure 5.5) is due to the PDZ binding motif being the target for the anti-
body against PHLPP1. Therefore in addition the HA signal was detected.  
PHLPP’s N-terminus is not important for AKT/PHLPP/FKBP51 interaction as well. Since 
there were no pulldown assays performed it is not known if the interactions between FKBP51 
and PHLPP are direct. 
 
We were unable to observe enhanced dephosphorylation induced by FKBP51 as Pei et al. 
[75]. In contrast, we detected an even stronger Akt phosphorylation in HEK293T cells upon 
overexpression of FKBP51 (Figure 5.23).  
This might be due to PHLPP not being the rate-limiting phosphatase for Akt in our cells or 
under our cell culture conditions.  
6.1.3 Akt1 binds FKBP51 via the FK domain 
Since the small FKBPs, which only contain the highly conserved FK506-binding domain in-
teract with FKBP51 this domain seems to be sufficient for a direct Akt/FKBP interaction. The 
FK506-binding domain displays its well-characterized PPIase activity but can also mediate 
protein-protein interactions [285]. The finding that all FKBPs, but not Cyp40, bound to Akt 
suggested the common and highly conserved FK506-binding site being the connector to Akt. 
However, binding of FKBP51 to Akt was not affected by several high-affinity ligands, neither 
in purified systems nor in cells (Figure 5.27). Likewise, mutations in the FK506-binding site, 
which abolish the PPIase activity, did not affect binding to Akt (see section 5.1.6). Additional 
mutations within the binding pocket did not alter Akt/FKBP51 interaction as well (Figure 
5.12).  
Since the FK506-binding pocket is not the interaction site for Akt other highly conserved 
parts of the FK506-binding domain must interact with Akt. As depicted in Figure 6.2 several 
residues can be considered. For example the conserved structures within the 50S loop could 
serve as a starting point for mutational analysis (compare also [286]). However, several ami-
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no acid mutations might be necessary in order to abolish the FKBP/Akt interaction complete-
ly. 
 
A                                                               
 
B 
 
 
Figure 6.2: Conserved regions within the FK1 domain 
A PRALINE representation of the multiple sequence alignment [269] of FKBP12 (PDB code 2PPN) with FKBP12.6 (PDB code 
1PBK), and the FK binding domains of FKBP25 (PDB code 3KZ7), FKBP51 (PDB code 3O5E) and FKBP52 (PDB code 1Q1C) 
B Cartoon (left side) and surface representation (right side) of FKBP51FK1 (PDB code 3O5E) colored according to sequence 
conservation,  ranging from (white (variable residues) through yellow to red (conserved residues). Sequence conservation cor-
responds to the PRALINE calculations depicted in A. 
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6.1.4 The conformation of Akt is important for interaction but not necessarily 
the phosphorylation 
 
Mutational analysis of important phosphorylation sites did not substantially affect the 
FKBP51/Akt interaction although Akt1 containing the phosphorylation-resistant (alanine) 
S473 mutation interacted slightly less compared to the wildtype (Figure 5.22).  
In our mapping studies regarding the Akt/FKBP51 interaction we found the PH domain itself 
not being required for the FKBP51/Akt interaction. This is consistent with the finding that 
AGC kinases missing a PH domain can also interact with FKBP51 (e.g. S6K and SGK).  The 
best indication where FKBP51 binds on the Akt surface was obtained using conformation-
specific Akt inhibitors. The structures of Akt in complex with AT7867 and inhibitor VIII show 
that most of the core C- and N-lobes are structurally conserved, indicating that most regions 
of the conserved kinase domain may not provide the key interaction sites with FKBP51.  
The most prominent difference in the conformations of Akt stabilized by AT7867 and by in-
hibitor VIII is the rearrangement of the αC-helix (residues 185-205), which is stabilized in the 
presence of AT7867 allowing the binding of the HM to the PIF-pocket and which is destabi-
lized in complex with inhibitor VIII. In addition, the activation loop (residues 292-313) is com-
pletely occluded by the PH domain in the presence of inhibitor VIII (Figure 6.3). 
 
A                                          B 
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Figure 6.3: The ATP-competitive inhibitor AT7867 stabilizes the αC-helix of Akt 
A Cartoon representation of the Akt2 core structure (grey) complexed with AT7867 (green). Ordered structural domains like the 
αB-helix and the αC-helix are are specified (PDB code 2UW9). B Cartoon representation of the Akt1 core structure (wheat) and 
PH domain (lavender) complexed with inhibitor VIII (pink) (PDB code 3O96) C Overlay of the core structures of Akt complexed 
with AT7867 (grey) or inhibitor VIII (wheat) 
 
Interestingly, the attachment of the PH domain to the catalytic domain of Akt occluding the 
activation loop, as observed in complex with inhibitor VIII, is thought to occur in the inactive 
conformation of Akt [287, 288], to which FKBP51 also binds. Therefore, a key binding site for 
FKBP51 is unlikely to lie within the PH-domain interaction site on the catalytic domain. Ra-
ther, the interaction site may exist at or within the proximity of the actual site where inhibitor 
VIII binds on the catalytic domain or at allosteric sites affected by the interaction with inhibitor 
VIII. Interestingly, the binding of inhibitor VIII to Akt completely disrupts the formation of the 
αC-helix highlighting this region, which appears highly flexible in AGC kinases in solution, as 
the potential common recognition site for kinases by FKBPs.  
 
In contrast the stabilization of the αC-helix is observed with the non-hydrolyzable ATP analog 
AMP-PNP which did not affect the Akt/FKBP51 interaction, similar to the observations made 
with inhibitor AT7867 (Figure 6.4). 
 
 
 
 
 
 
  
C 
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Figure 6.4: AMP-PNP complexed with Akt2 
A Cartoon representation of the Akt2 core structure (green) complexed with AMP-PNP (orange).  
Ordered structures such as the αB-helix and the αC-helix are specified (PDB code 1O6K).  
6.1.5 Introducing Hsp90 – boosting complexity 
Since binding of Akt to FKBP51 is partially affected by Hsp90-disrupting mutations (see Fig-
ure 5.16 and Figure 5.27) we suggest that the Akt/FKBP51 interaction is mediated in part by 
Hsp90. Based on the presented results a model is proposed, in which the Akt/FKBP51 inter-
action is probably bimodal at the biochemical level (Figure 6.5C). 
This is consistent with the domain mapping of FKBP51, where all constructs that contained 
either a functional TPR domain or the FK1 domain (see section 5.1.6) were able to bind to 
Akt. The only exception is the pull-down of purified FKBP51ΔFK1_FLAG, where FKBP51 
lacks the FK1 domain and cannot bind via Hsp90 since the latter is lacking in the purified 
reconstituted system. This may indicate that FKBP51 can bind to Akt also via the FK2 do-
main or it could be due to misfolding of this construct and spurious binding of Akt (FKBP51Δ 
FK1_FLAG was the only construct that could not be checked by active site titration prior to 
the pull-down assays). 
This two-domain interaction model also raises the possibility that FKBP51 might use both 
interaction sites to regulate Akt within a FKBP51/Hsp90/Akt complex, similar to the putative 
regulation of steroid hormone receptors by FKBP51.  
 
 
αC-helix 
αB-helix 
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Figure 6.5: Schematic model of possible Hsp90/Akt/FKBP51 complexes 
A FKBP51 can bind directly to Akt via its FK1 domain, but not with its FK506-binding pocket. Several other FK1-possessing 
FKBP homologs may bind to Akt in a similar mode. B Akt and several other kinases can bind to FKBP51 indirectly via Hsp90. C 
FKBP51 could assist the chaperoning of Akt by binding to Hsp90 via its TPR domain and by interacting with Akt via its FK1 
domain. 
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6.2 Large FKBPs mediate the effects of rapamycin 
The primary effect of rapamycin is its ternary complex formation with FKBP12 and the FRB 
(FKBP12-rapamycin-binding) domain of mTOR, thereby inhibiting mTOR kinase activity. 
Mechanistically, the allosterically restrained access of substrates (e.g. S6K) to the kinase 
active site or interference with the mTOR complex integrity [289] or assembly [254] are dis-
cussed. 
So far the pharmacological effects of rapamycin are almost exclusively interpreted and dis-
cussed in the context of a complex with the prototypical FKBP12, although there is little ex-
perimental evidence for this exclusive role in mammals. In several fungi, knockout of the re-
spective homolog of FKBP12 was shown to abolish sensitivity to rapamycin [290-293]. 
However, the FKBP repertoire in fungi is much smaller than in mammals and fungal FKBP12 
is the only well-established ortholog of human FKBPs [294]. In addition, fungal FKBP12 is 
usually the only cytoplasmatic FKBP expressed, explaining the strict FKBP12 dependence of 
rapamycin in these organisms. Indeed, A. März [14] could demonstrate that overexpression 
of large FKBPs restores rapamycin sensitivity in a FKBP12 deficient yeast strain. 
In mammalian cells FKBP12.6, a highly related homolog to FKBP12 was found to form a ter-
nary complex with rapamycin and FRB-TOR [295]. However, in FKBP12.6 deficient mice it 
was shown that FKBP12.6 can be redundant for the action of rapamycin [296]. Moreover, 
FKBP38 has been proposed as a player in mTOR inhibition, but this effect was largely ra-
pamycin independent and might be indirect [297]. In addition other groups argued against a 
role of FKBP38 in mTORC1 signaling [298, 299]. 
The complex-forming FK506-binding domains are highly homologues and it was shown that 
rapamycin does not exclusively interact with FKBP12 but rather binds with high affinity to 
most members of the FKBP family [264]. Our group therefore set out to investigate, whether 
the pharmacology of rapamycin is indeed restricted to FKBP12.  
In his studies A. März [14] observed downstream effects mediated by complexes of larger 
FKBPs with mTOR/rapamycin. Inhibition of mTOR by larger FKBPs appeared to be even 
more pronounced than those mediated by FKBP12. März argues that FKBP51 might be the 
main mediator of rapamycin action in some tissues in vivo. Despite the rapamycin-dependent 
interaction of small and large FKBPs with mTOR he observed a rapamycin independent 
binding, especially in the case of FKBP51. This was discussed as the mTOR complexes be-
ing multi-protein complexes, where interactions can occur outside of the FRB (FKBP12-
rapamycin-binding) domain of mTOR. These interactions do not have to be necessarily di-
rect, rather adapter proteins (substrate recruiters such as Raptor or Rictor) or even mTOR 
substrates like S6Kinase or Akt could be involved.  
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The data presented herein consolidate the finding that several FKBPs, especially the large 
FKBP51, contribute to the action of rapamycin (see section 5.4). 
Of note, in our cellular experiments the response to short term rapamycin treatment (60 min) 
was clearly cell type dependent (Figure 5.46). The mTOR (S2448) phosphorylation as as-
sessed by a time resolved FRET assay was efficiently reduced in HEK and SH-SY5Y cells 
with an EC50 of 3.8+0.4 nM and 2.7+0.6 nM respectively. In HeLa cells increasing rapamycin 
concentrations also lead to a reduced mTOR phosphorylation, even though higher rapamycin 
concentrations were necessary. Of note, the comparison between the neuroblastoma cell 
line SH-SY5Y and the SH-SY5Y_FKBP12 knockdown version revealed an impaired re-
sponse of SH-SY5Y_FKBP12 knockdown to rapamycin concentrations higher than 1 nM. 
Rapamycin in principle exerts its inhibitory effects in a concentration range below 5 nM as 
found in an in vitro mTOR assay [14]. A small fraction of FKBP12/rapamycin which could still 
be available in FKB12 knockdown cells (a knockdown is never 100%) and/or a substitution 
by other FKBPs could mediate the rapamycin effect at lower rapamycin concentrations in 
these cells.  
Mouse embryo fibroblast (MEF) cells showed a generally lower response to rapamycin. 
However there was not much difference in MEF cells lacking FKBP51 or FKBP52 compared 
to wildtype cells. Here the remaining FKBPs might be sufficient to mediate the effects of ra-
pamycin. The pancreatic ductal carcinoma cell line SU.86.86 partially inhibited mTOR phos-
phorylation with an EC50 of 2.3+0.3 nM but higher concentrations could not further reduce the 
phosphorylation status, indicating an overall reduced response to short term rapamycin 
treatment. 
It is indeed known that the efficiency of rapamycin can be disappointingly modest for several 
cancer cell types. This can be in part attributed to a counterproductive repression of a nega-
tive feedback on Akt that increases the PI3K/Akt pathway. This feedback mechanism can be 
exerted either via Grb10 or S6Kinase (Figure 1.8), the insulin receptor substrates [246, 300] 
or at least in some cells via an enhanced degradation of PHLPP by ubiquitination or reduc-
tion of PHLPP expression [248]. However the cellular factors involved in partial rapamycin 
resistance are not well understood. 
As shown by the above described experiment mTOR phosphorylation measured by a time- 
resolved FRET assay can serve as a valuable readout for the effects of rapamycin, a method 
that was used in our inhibition studies and reconstitution experiments.  
Based on the initial experiments we performed our inhibition studies in SH-SY5Y- and HeLa 
cells. In order to block rapamycin-induced inhibition of mTOR auto-phosphorylation and Akt 
hyperphosphorylation the inhibition of all cytosolic FKBPs by the pan-selective FKBP inhibi-
tors FK1706 and FK506 was necessary (Figure 5.48 and Figure 5.49). 
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The inhibition of FKBP12 by FKBP12-selective FKBP inhibitors (compound 44 or Biricodar) 
alone was insufficient even in concentrations 3-10 x higher than the pan-selective inhibitors. 
The FKBP12-selective inhibitors compound 44 and Biricodar are highly lipophilic substances 
and several close analogs easily permeate cells. The inability of these compounds to block 
the effect of rapamycin is therefore unlikely to be due to insufficient cell penetration. Taken 
together larger FKBP homologs seem to substitute for FKBP12 in mediating the effects of 
rapamycin. 
 
Intriguingly it was repeatedly shown that inhibition of mTOR auto-phosphorylation and the 
hyperphosphorylation of Akt by rapamycin depend on the availability of higher FKBP levels in 
SH-SY5Y cells ([14] and Figure 5.50). It was demonstrated by Tang et al. that rapamycin 
inhibits the late phases of neuronal long-term potentiation (LTP), an adaptive process con-
tributing to synaptic plasticity and memory consolidation [301]. In FKBP12-deficient neurons 
rapamycin induced LTP inhibition was reduced and this was interpreted as FKBP12 being 
necessary for the effects of rapamycin on mTOR [40]. An additional explanation for the func-
tional alteration in neurons lacking FKBP12 could be, based on our result, that low FKBP12 
levels reduce the rapamycin induced activation of the PI3K/Akt pathway per se. 
In order to investigate if FKBP51 could rescue rapamycin induced Akt (S473) phosphoryla-
tion and inhibition of mTOR auto-phosphorylation we used SH-SY5Y_12 knockdown cells 
and reconstituted FKBP12 or FKBP51. We could clearly show that both FKBP12 and the 
larger FKBP51 protein could enable the effect of rapamycin.  
 
The identity of specific FKBP homologs in rapamycin-mTOR complexes will be functionally 
important when they add novel functionalities to the ternary complexes. As mTOR complexes 
have been shown to depend on the Hsp90 machinery [302] and to be sensitive to rapamycin 
only in certain cell types one could imagine that the identity of specific FKBP homolgs in ra-
pamycin-mTOR complexes will be functionally highly important. In this context, FKBP51 or 
FKBP52-rapamycin complexes, both co-chaperones of Hsp90, could be more effective than 
the smaller single-domain homolog FKBP12.  
It is important to note that most FKBP family members bind to rapamycin with comparably 
high affinity [264]. Consequently, a mixture of different FKBP proteins will bind to rapamycin, 
when the compound is administered. At the level of a whole animal/human the action of the 
relevant FKBP homologs will also depend on their tissue distributions. For the cytosolic 
FKBPs, the contributions of each particular FKBP homolog might be largely dictated by their 
relative cellular abundance. Baughman et al. characterized the tissue distribution and cellular 
concentration of FKBP51 and directly compared it to FKBP12 [30]. They found that FKBP51 
was more abundant in 11 of 17 tissues with up to a 12-fold molar excess in the liver. Fur-
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thermore, mRNA quantification suggests that FKBP51 is highly over-expressed especially in 
adipocytes and in skeletal muscle cells, compared to median expression [303]. These tissues 
are extremely important for the metabolic (side)-effects of rapamycin and FKBP51 might be 
the most relevant FKBP subtype for the inhibition of mTOR by rapamycin in these tissues. 
 
Besides immunomodulation, rapamycin treatment has been suggested for several other indi-
cations including type II diabetes, neurodegenerative diseases [127], or even life span exten-
sion [132, 304], but the prolonged systemic use of rapamycin is hampered by unacceptable 
side effects [305]. For these indications, a tissue-selective mTOR inhibition would be very 
advantageous. Our results suggest a mechanistic rationale how tissue or cell type-biased 
mTOR inhibition might be realized, namely by engaging specific FKBP homologs dominating 
the FKBP pool in the desired cell types. This could be accomplished by blocking undesired 
FKBPs with non-immunosuppressive, FKBP-subselective FKBP ligands such as Biricodar or 
cmpd44, which leave other FKBPs like FKBP51 or FKBP52 as the mediators of rapamycin’s 
action. A more direct way would be tailoring rapalogs for the desired FKBP homologs. Such 
FKBP subtype-selective rapamycin analogs can be expected to be active primarily in those 
cells where their cognate FKBP is highly expressed, e.g. liver, skeletal muscle or adipocytes 
in the case of FKBP51 [30, 303]. Conversely, rapalogs devoid of FKBP51 binding might be 
less active in these compared to other tissues.  
 
Taken together, the presented results call for expanding the customary focus on FKBP12-
rapamycin and for considering additional FKBP/rapamycin/mTOR complexes to comprehen-
sively understand and optimally exploit the action of rapamycin. 
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6.3 Antascomicin B – mediation of a new functional ternary complex? 
In search for novel materials that might elicit similar biological effects to rapamycin and 
FK506 Sandoz discovered the novel Antascomicin family, which was isolated from a Mi-
cromonospora strain from a soil sample collected in china [140]. The most abundant deriva-
tive Antascomicin B potently binds to FKBP12 with an IC50 of 0.7 nM [140], which is in the 
same range as rapamycin and FK506. However, Antascomicin B lacks their immunosup-
pressive properties as the effector region is structurally different (Figure 1.4). 
Several groups engaged in the total synthesis of Antascomicin B and in 2005 the Ley group 
reported the completed total synthesis [141]. However, to our knowledge nothing is known 
about biological effects of Antascomicin B. Here we unambitiously show that Antascomicin B 
can enhance protein-protein interactions leading to new biological effects. 
 
We discovered that Antascomicin B is the only tested FKBP ligand exclusively able to en-
hance the interaction between FKBP51 and Akt1 (Figure 5.29 and Figure 5.34). This en-
hancement of the interaction between FKBP51/Akt by Antascomicin B seems to be direct, as 
it was confirmed in pulldown experiments (Figure 5.32).  
Of note by titrating Antascomicin B in HEK293T cells the strongest interaction of Akt1 with 
FKBP51TPR_mut was observed with concentrations above 1 µM. The FKBP51TPR mutant 
was used to prevent confounding influences of interaction with Hsp90 (see section 6.1.5). 
This concentration is at least 200 times higher than the binding affinity of Antascomicin B to 
FKBP51 as obtained in a fluorescence polarization assay (see section 4.2.4.3) (unpublished 
results by A. März, labbook IV, p. 16/17, 17.2.2009). Therefore we conclude that FKBP51 
first binds to Antascomicin. This complex then binds to Akt, whether allosteric or otherwise, 
leading to a weak interaction. We suggest a scenario where the other FKBPs have to be sat-
urated before FKBP51/Akt gets sufficiently accumulated. Indeed, A. März obtained for 
FKBP/Antascomicin B interaction IC50 values FKBP12<FKBP52<FKBP51<FKBP25, with 0.03 
nM, 0.5 nM, 2.2 nM and 4 nM, respectively (unpublished results by A. März, labbook IV, p. 
16 ff., 02/2009). Our co-immunoprecipitation experiments in HEK293T cells showed the 
strongest increase of Akt interaction for FKBP12.6/Anta B, followed by FKBP52/Anta B and 
FKBP51/Anta B while for FKBP12/Anta B the enhancement of interaction was very little in 
comparison with samples lacking Antascomicin B. Different H-bonds or electrostatic interac-
tions might be responsible for these differences together with possible multiple complex for-
mations which could favor or discriminate an enhancement of interaction. For quantitative 
analysis of co-immunoprecipitated protein it is important to compare staining with the same 
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antibody (e.g. α-FLAG), therefore only qualitative conclusions can be obtained from Figure 
5.34.  
All formed FKBP/Antascomicin B complexes will then compete for Akt, SGK or S6K as we 
found an enhancement of the interaction between AGC kinases and at least 
FKBP51TPR_mut. Here, Akt2 seems to be favored, followed by Akt1, S6K and SGK, indicat-
ing some degree of selectivity. The preference for certain FKBPs or certain AGC kinases 
could be further analyzed in competition experiments.  
 
Our competition experiments performed in HEK293T cells (section 5.3.5) revealed that the 
ATP competitive Akt- (IC50 = 32 nM for Akt1) [255] and p70S6K- (IC50 = 85 nM) [256] inhibitor 
AT7867 is unable to abolish the stronger interaction of FKBP51 with Akt even in concentra-
tions 20 times higher than the one of Antascomicin B. Therefore additional interactions which 
contribute to the enhanced binding of FKBP51 and Akt are unlikely to be mediated by amino 
acids within the ATP binding domain. Inhibitor VIII (IC50 = 58 nM for Akt1) [259] did not abol-
ish the enhancement of Antascomicin B (Figure 5.37) but it did reduce the overall binding 
(Figure 5.24 and Figure 5.37) suggesting an impairment of the FKBP51/Akt interaction by 
inhibitor VIII, which is stabilized again by Antascomicin B. 
In contrast FKBP inhibitors such as FK506 and FK1706 counteracted the Antascomicin B 
mediated effect pointing to a clear structural dependency on the FK506-binding domain of 
FKBP51 (Figure 5.38 and Figure 5.39). 
 
Recently Pei et al. [75] found FKBP51 acting as a scaffold protein mediating the 
dephosphorylation of Akt by PHLPP. According to this mechanism an enhancer of the 
FKBP51/Akt interaction as Antascomicin B would theoretically reduce Akt phosphorylation. 
However, instead we found a slight increase, not a decrease, in Akt phosphorylation at both 
position T308 and S473 in HeLa cells by Antascomicin B treatment after 24 h (Figure 5.40). 
This supports our initial finding in HEK293T cells where FKBP51 overexpression induced Akt 
phosphorylation (Figure 5.23). Activation of Akt is not necessary for Antascomicin B-
enhanced Akt1/FKBP51 interaction as Akt (S473A), an inactivating mutant of Akt, can also 
serve as an interaction partner in the ternary complex formation (Figure 5.31 and Figure 
5.33).The clear reduction of phosphorylation caused by Antascomicin B concentration higher 
than 1-10 µM after 24 h can simply be explained by reduced cell viability (Figure 5.41). 
As long term treatment of concentration higher than 1 µM impaired cell viability we set out to 
focus more on short term effects. Therefore we controlled for the Antascomicin B phosphory-
lation in SH-SY5Y neuroblastoma cells. Here we could repeatedly observe a slight increase 
in Akt phosphorylation at both positions (T308 and S473) after administration of increasing 
Antascomicin B concentrations. One possible explanation for this could be that Antascomicin 
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B in complex with FKBP51 and Akt favors and stabilizes the active conformation of Akt, simi-
lar to AT7867, which then blocks the access of phosphatases. Furthermore one could imag-
ine an enhanced phosphorylation by mTORC2 due to feedback mechanisms other than 
p70S6K since this is blocked by AT7867 as well. A third possibility is based on alternative 
FKBP51/Antascomicin B/Akt complexes which block the enhancement of dephosphorylation 
by PHLPP mediated by uncomplexed FKBP51. 
 
An increased Akt phosphorylation is indicative of more active Akt kinase and should lead to 
effects on at least some targets of Akt. We focused on GSK-3β and FoxO1 phosphorylation 
(see section 1.3.2.). Surprisingly, we observed a decreased phosphorylation upon short term 
Antascomicin B treatment in HeLa cells (Figure 5.43). Therefore we propose an inhibiting 
effect of FKBP51/Antascomicin B on the Akt downstream targets GSK-3β and FoxO1. 
However, since the above results are cell based the decreased phosphorylation of GSK-3β 
and FoxO1 might be indirect. Therefore these data of downstream effects should be consoli-
dated with biochemical and in vitro analysis and evaluated carefully due to complexity and 
involvement of possible feedback mechanisms.  
 
Antascomicin B is not only able to enhance the interaction between AGC kinases and FKBPs 
but also between FKBP51 and the Akt phosphatase PHLPP (Figure 5.44). However, as this 
was only tested in a cell based assay this could be indirect, for example via Akt. Future ex-
periments will elucidate the biological relevance of this finding. 
 
Wang and colleagues found FKBP51 to enhance the response to chemotherapeutics, such 
as Gemcitabine in pancreatic and breast cancer cell lines [75, 76]. Mechanistically, the latter 
effect was attributed to the scaffolding function of FKBP51, which could promote 
dephosphorylation of Akt by the phosphatase PHLPP. However, in a cell viability assay the 
toxic effects of Gemcitabine on the pancreatic cancer cell line SU.86.86 were observed as 
expected but there was no prominent effect of Antascomicin B when given in combination 
with Gemcitabine. For us there was no indication of a possible role of FKBP51 being a tumor 
suppressor in these cells. 
 
Taken together the experiments of this section point towards the discovery of a new “gain-of-
function” ternary complex. Such complexes are very rare in pharmacologic intervention strat-
egies since it is more straightforward to design ligands for inhibition of biological processes. 
The most prominent examples of gain-of-function formation complexes necessary for phar-
macological actions are the inhibition of mTOR by rapamycin and the inhibition of calcineurin 
by FK506 and Cyclosporine A [112] (Figure 6.6).  
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Figure 6.6: Antascomicin B forms functional ternary complexes 
A The ternary complex formed by mTOR/rapamycin/FKBPs: schematic (left side), crystal structure of mTOR 
FRB/rapamycin/FKBP51 (PDB code 4DRI) (right side) 
B The ternary complex formed by Calcineurin/FK506/FKBP12: schematic (left side), crystal structure of the calcineurin A frag-
ment, calcineurin B/FK506/FKBP12 (PDB code 1TCO) (right side)  
C schematic model of a ternary complex possibly formed by AGC kinases/Antascomicin B/FKBPs and/or PHLPP (left side) 
Model of Antascomicin B (green) in the FK506 binding pocket (wheat) together with FK506 (blue) or Rapamycin (yellow) 
A 
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The differences of the structure of C16-C25 of Antascomicin B compared to rapamycin is most 
likely to be responsible for the observed exclusive effects of Antascomicin B as the modelling 
of Antascomicin B into the FK506-binding pocket of FKBP12 reveales. In contrast the addi-
tional OH-group at the top group (cyclohexan) is unlikely to contribute to interactions due to 
missing H-donors in close proximity. 
 
The exploration of FKBP/Antascomicin/AGC kinases or FKBP/Antascomicin B/PHLPP com-
plexes could bear a completely new therapeutic strategy. Therefore it is important to clarify if 
the observed dephosphorylation caused by Antascomicin B is a direct effect, for example in 
in vitro kinase assays. Competition experiments with FK506 or rapamycin where the effects 
caused by Antascomicin B are rescued in vitro and in cell based systems could further speci-
fy its action. Furthermore the different Akt inhibitors might be able to compete with 
Antascomicin B providing additional insights in structural requirements. It will be interesting to 
examine the effects of Antascomicin on FKBPs of other species, such as squirrel monkey.  
It is important to understand the reason for the reduced cell viability of Antascomicin B after 
long term treatment in some cell types. Reduced cell viability might be based on reduced cell 
growth, e.g. caused by the observed reduction of the phosphorylation status of GSK-3β, 
which in principle could lead to a reduced transcription activity of pro-survival proteins. On 
the other hand cells could be lost by apoptosis. With the observed decreased FoxO1 phos-
phorylation one would expect enhanced transcription of pro-apoptotic proteins. These predic-
tions need to be tested experimentally and it should be elucidated which of these effects is 
more pronounced in which cell types. 
 
Additional direct or indirect downstream effects of Antascomicin B might be seen in antibody 
phospho proteomic screens (for example PhosphoScan™ Kit from Cell Signaling Technolo-
gy). By the approach used so far differential expression patterns after Antascomicin B treat-
ment might be missed even though they are likely due to the observed changes in phosphor-
ylation of FoxO1 or GSK-3β. Microarrays and SILAC based methods could serve as a start-
ing point to elucidate the biological meaning of the FKBP/AGC kinase complexes, which are 
enhanced by Antascomicin B and its enigmatic pharmacological applications.  
Since Antascomicin B enhances FKBP51/Akt interaction it could further serve as a tool to 
solve the crystal structure of the complex in order to locate residues important for interaction. 
Thus Antascomicin B serves as an innovative lead structure to manipulate the FKBP/AGC 
kinase or the FKBP/AGC kinase/PHLPP complex formation.  
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6.4 Towards selective FKBP inhibitors 
6.4.1 FKBP selective inhibitors against psychiatric disorders 
An imbalanced stress hormone system, the deregulation of the hypothalamus pituitary ad-
renal (HPA) axis (see  Figure 6.7), is correlated with the risk and course of psychiatric dis-
eases such as major depression, bipolar disorder, post-traumatic stress disorder (PTSD), 
schizophrenia and anxiety disorders [90]. A crucial characteristic of the HPA axis is a nega-
tive feedback exerted by cortisol via the glucocorticoid receptor (GR), thus keeping the stress 
reaction in balance, a process found to be impaired in depressed patients [58]. 
 
 
 
Figure 6.7: FKBP51 decreases HPA axis reactivity after stress or a glucocorticoid challenge [90]. 
Upon perception of stress, CRH (corticocotropin-releasing-hormone) is released from the hypothalamus, thus promoting synthe-
sis and release of ACTH from the pituitary. ACTH in turn increases release of cortisol from the adrenal glands. In a negative 
feedback loop, glucocorticoids down-regulate the HPA axis. Decreased sensitivity of this feedback loop and glucocorticoid 
hyposensitivity were repeatedly observed in depressed patients. 
 
The expression of FKBP51 is strongly increased by corticosteroids [56] indicating that 
FKBP51 attenuates cortisol responses in hormone-conditioned tissues as part of the men-
tioned feedback mechanism [53, 57]. High circulating FKBP51 levels lead to reduced hor-
mone binding affinity as observed in squirrel monkeys [48-50]. Results from animal studies 
show a protective effect of FKBP51 knockout or knockdown on stress endocrinology and 
stress-coping behavior [62-64]. Finally, human genetic studies correlate polymorphisms with-
in the FKBP51 encoding gene FKBP5, with increased recurrence of depressive episodes and 
improvement of patient’s response to antidepressive treatment [59-61]. All this culminates in 
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an important role of FKBP51 in HPA axis deregulation. Pharmacological targeting of this pro-
tein by FKBP51 inhibitors might be beneficial for treatment of patients suffering from depres-
sion and anxiety disorders.  
As FKBP52 has an opposite function on the GR and as the FKBPs are highly homologues in 
structure but different in function, which could lead to severe side effects (for example con-
cerning the reproductive system), there is a high need for selective FKBP51 inhibitors.  
 
As current pharmacotherapeutic options for mood disorders leave substantial unmet medical 
needs, tailoring selective FKBP51 inhibitors is an innovative strategy to correct disturbances 
of the HPA axis and a main aim pursued in our group.  
6.4.2 Improving the ligand efficiency for FKBP51 
All known FKBP51 ligands, including the natural products rapamycin and FK506, suffer from 
a very low ligand efficiency (<0.18) [145, 148]. 
Increasing ligand efficiency, here defined as ligand free binding energy normalized to the 
number of non-hydrogen atoms [306], is an attractive conceptual framework for guiding drug 
discovery as it balances the potency of  ligands against undesired properties such as in-
creasing molecular weight [278, 280, 307-310]. Ligand efficiency has been firmly linked to 
the quality of lead compounds but also to the druggability of the individual protein target clas-
ses [278, 279, 308, 310-312]. Notably, shallow binding sites such as those mediating protein-
protein interactions have an intrinsically limited contact surface and these targets are notori-
ously difficult for the development of efficient ligands or drugs [313]. 
Flexible ligands are thought to suffer an entropic penalty upon binding due to the freezing of 
rotatable bonds [314, 315]. In turn, reducing ligand flexibility  is an appealing concept to im-
prove potency [316-319]. It is also well known that flexible ligands often adopt higher energy 
conformations upon binding to fine-tune ligand-protein interactions [320-323]. Thus, in princi-
ple, additional binding energy could be gained by pre-organizing or stabilizing these high-
energy active conformations. 
 
A higher affinity of rigid ligands such as compounds YW703 and YW691 (see Table 5.2, sec-
tion 5.5) is commonly attributed to entropic advantages. In our isothermal calorimetric exper-
iments (section 5.5) the opposite was observed when comparing YW691 to YW644. While 
we cannot exclude that the rigidification in ligand YW691 was entropically advantageous per 
se – e.g. compared to a hypothetical unconstrained analog of equal binding enthalpy – this 
was masked compared to YW644 by a dominating enthalpy-entropy compensation, a com-
mon phenomenon in ligand-protein interactions [324], which was also observed for FKBP12 
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and the high affinity ligands FK506 and rapamycin [325]. Negative changes in binding entro-
py upon ligand rigidification have recently been observed by several groups [326-330]. In one 
case, the counterproductive entropic change was shown to be caused by a stronger ordering 
of the protein by the more rigid ligands [329].  
The differences between the monocycle YW644 and the more rigid bicycles YW691 and 
YW703 could be explained, first by better hydrogen bond acceptor properties of the C1-
amide compared to the C1-ester and second by stabilization of the conformation of O1-C1-C2-
N7. In addition the C8-methylene could mediate additional van-der-Waals contacts. The en-
hanced binding enthalpy of YW691 (ΔH=-13.6 kcal/mole) is surprising, given the minimal 
differences in the binding mode compared to YW703 (ΔH=-3 kcal/mole). The direct compari-
son reveals the strong orientation dependence of the hydrogen bond and dipolar contact 
network around the C1=O carbonyl which could account for a substantial amount of the addi-
tional binding entropy of YW691.  
 
The binding affinities of YW644, YW703 and YW691 measured by ITC (3.3 μM, 10.5 μM and 
0.36 μM, respectively) were in excellent agreement with the fluorescence polarization assay 
results (Table 5.2). 
 
It should be noted that 5% DMSO, as used for solubility reasons throughout the measure-
ments is a high amount and even careful preparation of controls that contain  the same 
amount of DMSO can’t fully exclude mistakes by buffer mismatches. Therefore it is recom-
mended either to use smaller fractions of DMSO or prepare the ligand and the protein solu-
tion from the same diluted DMSO stock solutions. 
 
Altogether the bicyclic [4.3.1] aza-amide scaffold was identified as a privileged substructure 
for FK506-binding proteins (FKBPs) and serves as a valuable starting point for the synthesis 
of efficient FKBP51 ligands [144]. 
6.4.3 Selective FKBP inhibitors – will they be safe? 
The multitude of functions known for FKBP51 (co-chaperone, involvement in glucocorticoid 
receptor- , NF-κB- signaling, PPIase – see section 1.1.2) carries the inherent danger of side 
effects when blocking FKBP51. 
However, no target specific side effects became apparent from studies on FKBP51 knockout 
mice [62-64]. A phase I clinical trial with the pan-specific FKBP ligand FK1706 suggested 
that the blockage of FKBPs (including FKBP51 and FKBP52) are tolerated in humans for 
prolonged times [143]. 
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In contrast Hou et al. [76] found that the down regulation of FKBP51 in shFKBP51 xenograft 
mice promotes tumor growth and resistance to gemcitabine, a phenomenon consistent with 
their previous findings in pancreatic cell lines [75]. This raises the possibility that the block-
age of FKBP51 might promote cell growth in cancerous tissue or at least promotes re-
sistance to certain therapies in some types of cancer. This was attributed to increased Akt 
hyperphosphorylation and activation caused by a reduction of FKBP51-facilitated action of 
the phosphatase PHLPP. Using the pancreatic cancer cell line SU.86.86, which was also 
used in the above publication we could demonstrate that the pan-specific FKBP inhibitor 
FK1706 did not alter cell viability alone (Figure 5.25B). When administered together with the 
nucleoside analog gemcitabine, gemcitabine’s ability to reduce cell viability was not impaired 
even by 10 µM of FK1706 (Figure 5.25A). 
Consistent with this finding FKBP51 ligands did not disrupt the FKBP51/Akt interaction (Fig-
ure 5.27) or FKBP51/PHLPP interaction (Figure 5.28) suggesting that the clinically used 
FKBP ligands are unlikely to affect the regulation of Akt by FKBP51. This coincides with the 
lack of an effect of the high-affinity ligands FK506 or FK1706 and YW648 but also the FKBP-
subgroup specific inhibitors cmpd 44 (FKBP12-selective) and SG537 (FKBP51 selective) on 
the Akt/mTOR pathway in several studied cell types (Figure 5.26).  
However, FK1706 showed a significant reduction on mTOR phosphorylation in HeLa cells in 
one experiment (Figure 5.26). In general this study can only serve as a starting point since 
statistical analysis with such a small sample size (2-3 samples) is very critical.  
At the biochemical level, however, parts of the FK1 domain, which must be in the vicinity of 
the FK506-binding site, seem to be important for the interaction with Akt. This raises the pos-
sibility to develop ligands for the FK506-binding site that might be able to allosterically modu-
late the FKBP51/Akt interaction. The feasibility of this hypothesis will require a better under-
standing of the parts of FKBP51 that bind to Akt. Here the further exploration of the en-
hancement of Akt1/FKBP51 interaction by Antascomicin B could provide a first starting point 
(see section 6.3). 
 
Moreover, the safety of future medication has to be discussed not only from the pharmaco-
dynamic point of view but also pharmacokinetic properties have to be taken into account. For 
example FK506 was shown to inhibit the drug efflux pump Pgp1, leading to increased gluco-
corticoid levels [331]. The inhibition of drug efflux pumps also has to be considered when 
additional medication occurs since it can strengthen toxic side effects. 
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6.5 The possible role of FKBP51 in cancer aethology 
The kinase Akt is a key signaling node which is essential for many adaptive processes (e.g. 
neuroregeneration [332]), but detrimental when overactive like in many cancers. In turn, the 
activity of Akt is tightly regulated under normal conditions. Recently, FKBP51 emerged as a 
new regulator of Akt. FKBP51 is a target of the clinically used immunosuppressants or anti-
cancer-drugs FK506 and rapamycin. While the role of protein kinases in cancer development 
is well established, the influence of FKBP51 on malignancy is contradictory. Several studies 
have shown that FKBP51 is up-regulated in several cancers and that it can promote the pro-
liferation of many cancer cell lines [69, 72, 74, 77, 333]. Interestingly A. März [14] found a 
rapamycin dependent increase of Akt (S473) phosphorylation up to 30% upon overexpres-
sion of FKBP51 compared to mock transfected cells.  
In contrast, Wang and colleagues found FKBP51 to enhance the response to chemothera-
peutics, such as Gemcitabine in pancreatic and breast cancer cell lines [75, 76]. Mechanisti-
cally, the latter effect was attributed to a scaffolding function of FKBP51, which could pro-
mote dephosphorylation of Akt by the phosphatase PHLPP. The presented results support a 
role of FKBP51 in Akt phosphorylation, however we observed an increase not a decrease in 
Akt phosphorylation. A reason for this discrepancy could be that PHLPP is not the limiting 
phosphatase in HEK293T cells or under our cell culture conditions. Recently deficiency of 
diacylglycerol kinase δ (DGK δ) was found to be connected to an activation of protein kinase 
C α (PKCα) which via reduced epidermal growth factor led to the dephosphorylation of Akt. 
Since depletion of PHLPP2 exclusively rescued Akt phosphorylation in DGK δ deficient cells 
it was argued that β-arrestin 1 might function as a scaffolding protein which mediates specific 
interaction of PHLPP2 with Akt [334]. It is likely that the regulation, composition and interplay 
of scaffolding proteins contribute to the outcome of signalling pathways. 
 
We believe in a connection of FKBP51 expression levels and the promotion of cancer. Since 
the effects of FKBP expression seem to be highly context and cell type dependent immuno-
histochemical expression studies in human malignancies will help to understand the role of 
FKBP51 levels in abnormal cell growth of cancers, and this could be considered as a promis-
ing new marker of tumor progression and response to radio/chemotherapy [77, 335]. 
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6.6 Possible effects of Akt/FKBP51 interaction on other pathways 
A cell is immersed in an ocean of growth factors and signaling molecules integrate these 
multiple cues. The integration of signaling pathways is only marginally understood. Feedfor-
ward and feedback loops embracing interacting pathways make the input-output response of 
one pathway dependent of the activity of another. Therefore, by focussing on just one path-
way like the Akt/mTOR pathway it is difficult to understand the effects of a newly found inter-
action such as FKBP51 and Akt. The following table summarizes important pathways that 
could be affected by Akt/FKBP51 interaction (Table 6.1).  
 
 
Protein involved Pathway/mechanism 
Involved signaling 
nodes 
literature 
Akt 
Ras/MAPK 
 
PI3K, GRB2, E3-
ubiquitin ligase, 
p70S6K, TSC2 etc. 
 
[336, 337] 
 
 
glycolysis 
 
AMPK, glucose 
transporter, 
hexokinase. 
PFK 
 
[201] 
autophagy AMPK, mTORC1 [165] 
Pentose phosphate 
pathway 
Prolipogenic factor 
SREBP1 
[338] 
lipogenesis 
DEPTOR, 
Prolipogenic factor 
SREBP1 
[218, 339] 
JAK/STAT PI3K [340] 
IKK/NF-κB mTOR [341] 
angiogenesis HIF1α [342] 
Wnt signaling GSK3 [343] 
Cytoskeletal organi-
zation 
mTORC2 [165] 
Hsp90 mTORC1 [302] 
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Protein involved Pathway/mechanism 
Involved signaling 
nodes 
literature 
FKBP51 
Hsp90/glucocorticoid 
receptor signaling 
Hsp90 [344] 
apoptosis Calcineurin, NFAT [66] 
NF-κB  [67, 345]  
Hsp90 mTOR [302] 
Akt/PHLPP scaffolding protein [75] 
 
Table 6.1: Akt and FKBP51 can be involved and are interconnected in several pathways 
 
 
Furthermore, if other AGC kinases such as SGK or S6K could substitute for Akt in some 
point and certain FKBPs could take over the role of others the complexity will even raise. 
Indeed it was shown, that tumor cells, which are resistant to Akt inhibitors exhibit higher lev-
els of SGK [D. Alessi, personal communication]. One has to consider that these pathways 
are highly cell- and context dependent [218]. 
 
Due to detection purposes and protein stability we decided to overexpress Akt, FKBP and/or 
PHLPP. We are aware that is at the same time a limitation. When overexpressed we ob-
served a stable interaction of Akt1 and FKBP51 and influences on downstream targets. Nev-
ertheless, it must be considered that the plasmid-based overexpression of proteins may alter 
protein compositions which might change the outcome of experiments. In addition one sig-
naling pathway cannot be favored against others; thus most probably one observes a combi-
nation of different effects on several pathways. Some of them may amplify each other, some 
of them may extinguish each other. In addition compensatory signaling can be involved. In 
order to study single pathways others could be blocked by inhibitors or mutations as for ex-
ample achieved by the FKBP51TPR_mut, which rules out effects of the Hsp90 pathway. In 
addition expression levels of recombinant proteins were only moderately higher than endog-
enous proteins. 
 
Altogether overexpression of proteins serves as a valuable tool when protein-protein interac-
tions are very weak or intermediate. In order to observe maturation processes or transition 
states one could apply pulse-chase techniques to monitor protein-protein interactions. 
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7. Summary 
The immunosuppressant and anti-cancer drug rapamycin works by a ternary gain-of-function 
mechanism that enables cytosolic proteins to inhibit the kinase mTOR. The obligatory acces-
sory partner of rapamycin was thought to be FKBP12. Here it is demonstrated that the pan-
selective FKBP inhibitors but not FKBP12-specific inhibitors can block the effects of rapamy-
cin. In addition, we show that at least the large Hsp90 co-chaperone FKBP51 can reconsti-
tute the effects of FKBP12 in FKBP12-knockdown cells. Our findings call for a broader inter-
pretation of the actions of rapamycin. Moreover, they provide a rationale for FKBP subtype-
selective rapamycin analogs, which could specifically target tissues that express a certain 
FKBP subtype. 
 
FKBP51 was shown to be involved in several cancers, both as an oncogenic- or tumor sup-
pressing protein. Here we clearly demonstrate that FKBP51 directly interacts with the kinase 
Akt. This kinase constitutes an important signaling node as it plays a crucial role in several 
pathways, which are frequently deregulated in a wide variety of cancers. In addition to Akt we 
found other AGC kinases to form complexes with FKBP51. In turn, paralogs and orthologs of 
FKBP51 were involved in complex formation with Akt. Our mapping studies revealed that 
FKBP51 interacts with Akt via multiple domains independent of their activation or phosphory-
lation status. We present a model where FKBP51 binds directly to Akt as well as via Hsp90.  
 
The FKBP51/Akt1 interaction was not affected by FK506 analogs or Akt active site inhibitors, 
but was diminished by the allosteric Akt inhibitor VIII. None of the FKBP51 inhibitors affected 
Akt (S473) or Akt (T308) phosphorylation or downstream targets of Akt. The FKBP51/Akt 
interaction is sensitive to the conformation of Akt1, but does not depend on the FK506-
binding pocket of FKBP51. Thus we found FKBP inhibitors unlikely to inhibit the 
Akt/FKBP/PHLPP network.  
 
In the search for modulators of the Akt/FKBP51 complex we serendipitously identified 
Antascomicin B, which forms a ternary complex with FKBP51/Akt and FKBP51/PHLPP re-
spectively. The FKBP51/Antascomicin B/Akt complex does not depend on additional proteins 
as shown in our pulldown experiments. Furthermore, several AGC kinases and different 
FKBP homologs can substitute each other in an enhanced interaction mediated by 
Antascomicin B. We further observed downstream effects on Akt phosphorylation and down-
stream targets such as GSK3β and FoxO1, providing for the first time experimental data for 
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biological effects of Antascomicin B. Antascomicin B constitutes a valuable tool for the inves-
tigation of FKBP51/Akt interaction and more importantly a starting point for chemical dimeriz-
ers of FKBPs and AGC kinases.  
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8. Appendix 
8.1 Extinction coefficients for purified proteins  
The protein concentrations were determined using extinction coefficients which were calcu-
lated based on the protein sequence. A web-based application was used: 
Proteincalculator v3.3: http://www.scripps.edu/~cdputnam/protcalc.html 
 
Protein Molecular weight 
[kDa] 
Molar extinction co-
efficient 
[L*mol-1*cm-1] 
Specific extinction 
coefficient 
[L*g-1*cm-1] 
 
HisFKBP51_FLAG 
 
55.5 
 
46200 
 
0.8317 
HisFKBP52_FLAG 56.1 51800 0.9227 
HisFKBP51ΔFK1 36.8 28000 0.7862 
HisFKBP51FK1 18.7 16800 0.9007 
 
Table 8.1: Extinction coefficients used to calculate protein concentrations 
 
8.2 Active site titration of FKBP52 
As the purification process can diminish the functionality of expressed purified proteins, the 
activity was checked before proceed with the functional assays. Therefore “active site” titra-
tions with the synthetic fluorescein-labeled FKBP ligand CK97 (“tracer”) were carried out 
[264]. “Active site titrations” offer valuable clues if the concentration, determined by UV 
measurement corresponds to the concentration of active protein. Where indicated in Table 
4.2 (see section 4.2.4.3) this procedure was used. As an example FKBP52 titration curves 
are depicted in Figure 8.1. Here, FKBP52 is titrated against a fixed concentration of labeled 
ligand. The experiment was performed several times with different concentrations of constant 
CK97 (Figure 8.1A). For each binding curve the EC50 values were extracted and plotted 
against the corresponding ligand concentration (Figure 8.1B). By linear curve fitting and ex-
trapolation the intersection with the y-axis is determined which leads to a Kd like value. This 
value was examined by [264] to be 1.4+0.1 nM and found throughout this experiment to be 
3.4 (bold letters in the regression formula). The value herein measured is also in the low na-
nomolar range and the slight difference could be based on pipetting or technical differences. 
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A 
 
B 
 
 
Figure 8.1: Determination of the concentration of FKBP52 by active site titration 
A Binding curved of the titration of FKBP52 against 3-48 nM CK97, half-logarithmic plot 
B Plot of calculated EC50 values against the actual tracer concentration, the linear equation is depicted and the intersection with 
the y-axis is printed in bold 
 
The slope value shows the portion of active FKBP52 being underestimated. The correction 
factor which should be used for correction of the UV values determined can be calculated by 
forming the quotient of 0.5 and the slope value. Multiplication of the concentration deter-
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mined by UV measurement multiplied with the factor leads to the correct value as exempli-
fied here for FKBP52 (Table 8.2). 
 
Protein Slope Correction 
Faktor 
Kd Protein con-
centration, UV 
determined 
(µM) 
Protein con-
centration 
corrected 
(µM) 
 
FKBP52 
 
0.354 
 
1.4 
 
3.4 
 
83 
 
116 
Table 8.2: Protein concentrations must be corrected corresponding to results of active site titration 
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8.3 Abbreviations 
 
AP           Alkaline Phosphatase  
APS     ammonium peroxodisulfate 
aa     amino acid  
AGC kinases cAMP-dependent, cGMP-dependent and PKC (protein 
kinase C) kinase 
Anta B Antascomicin B 
ATP           adenosine-5’-triphosphate   
bp     base pair(s) 
BCA      bicinchoninic acid 
BSA          bovine serum albumin  
CIP          calf intestine phosphatase 
CV        column volume  
d     day 
Da           Dalton  
bidest. H2O       double distilled water  
DMSO         dimethyl sulfoxide  
DNA        deoxyribonucleic acid  
dNTP     2’-deoxynucleoside 5’-triphosphate  
dsDNA    double strand DNA  
E. coli     Escherichia coli  
EDTA          ethylendiamine-tetraacetic acid  
EMA     European Medicines Agency 
EtOH          ethanol  
FCS           fetal calf serum  
FDA     Food and Drug Administration 
g     gram(s)  
GSK-3     glycogen synthase kinase 3 
h     hour(s)  
Hepes        4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HRP     horseradish peroxidase 
Hs     Homo sapiens 
IP     Immunoprecipitation 
IPTG           Isopropyl-β-D-1-thiogalactopyranoside  
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IRS     insulin receptor substrate  
ITC     isothermal titration calorimetry 
kb     kilo base pair(s)  
kDa     kilo Dalton  
l     litre  
LB Medium        lysogeny broth 
M           molar (mol/l)  
m     metre(s) 
mA     milliAmpere(s) 
MAPK     mitogen-activated protein kinase 
min     minute(s)  
ml     millilitre(s)  
mM     millimolar  
MW          molecular weight  
nM     nanomolar 
NF-AT     nuclear factor of activated T cells 
OD          optical density 
ORF          open reading frame 
PCR        polymerase chain reaction  
PFK     phospho-fructokinase 
pM     picomolar 
RNase  A    Ribonuclease A 
rpm     round(s) per minute 
Rap     Rapamycin 
RT           room temperature 
S6K                                                   ribosomal S6 kinase 
SD     standard deviation 
SDS        sodium dodecyl sulfate 
SGK     serum/glucocorticoid-inducible kinase  
SHR     steroid hormone receptor 
s     second(s)  
sm     squirrel monkey 
ssDNA     single strand DNA 
Tris           tris(hydroxymethyl)aminomethane 
Triton X-100       polyethylene glycol p-(tetramethylbutyl)-phenyl ether 
U      enzymatic unit(s) 
UV        ultraviolet  
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V     Volt  
v/v      volume per volume 
w/v     weight per volume  
wt     wild type 
μl        microlitre(s) 
μM        micromolar  
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